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Magnetic nanoparticles (MNP) are attracting interest for a range of biomedical 
applications being used either alone or as part of cell-based therapies. An area of 
particular interest is magnetic nanoparticle-mediated hyperthermia (MNHT), when 
MNP absorb energy from alternating magnetic fields (AMF) and transform this energy 
into heat which results in cancer cell death. While promising, the use of MNP for 
diagnosis and therapy has been limited by their rapid removal from the blood and 
biological barriers at the tissue and cellular levels. Moreover, MNP may have adverse 
side effects when used clinically. 
To overcome these problems there is increasing interest in the development of cell-
based strategies to deliver MNP. Current strategies include combining commercially 
available MNP with mesenchymal stem cells (MSC), as these cells can migrate to sites 
of tissue injury and tumor growth. However, problems with MNP cytotoxicity have 
hindered progress in this area and need to be overcome. Therefore, the ultimate aim of 
this PhD project was to find an alternative way to develop MSC that contain MNP 
using a genetic engineering approach by which the cells can be induced to stably 
produce biogenic MNP and to establish whether such an approach could be of value 
for MNHT for cancer treatment.  
To achieve this goal, the experiments conducted in this PhD project involved 
transfection of adipose-derived mesenchymal stem cells (AD-MSC) to introduce a 
synthetic magnetic gene, mms6, into the cells. The gene is originally derived from 
Magnetospirillum magneticum AMB-1, a genus of magnetotactic bacteria (MTB), 
which has unique intracellular structures called magnetosomes. The magnetosomes 
contain iron-rich magnetic nanoparticles that are enclosed within a lipid bilayer 
membrane. During the formation of magnetosome, mms6 has been known for its key 
role in the formation of uniform isomorphic magnetite nano-crystals and helps regulate 
the crystal morphology of magnetite. Due to the unique feature of this gene, therefore 
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the novelty of this study was in introducing codon-optimised mms6 into AD-MSC, 
enabling the cells to produce biogenic nanoparticles. 
In this study, mms6 mRNA expression in AD-MSC, following transfection, was 
demonstrated by reverse transcription polymerase chain reaction (RT-PCR). The His-
GFP tag Mms6 protein expression was demonstrated by Flow cytometry, Western blot 
and GFP imaging analysis revealing the expression of Mms6 protein in AD-MSC. 
Furthermore, for stable mms6 expression, a lentiviral transduction approach was used. 
AD-MSC stably expressing mms6 were then used in in vitro MNHT studies. 
The effect of mms6 stable expression on MSC markers of stemness and differentiation 
ability of AD-MSC were also investigated. The cellular ultrastructure of AD-MSC 
expressing mms6 was demonstrated by transmission electron microscopy (TEM), 
revealing the presence of nanoparticles. The magnetism of AD-MSC expressing mms6 
was proved by superconducting quantum interference device (SQUID). Furthermore, 
as a comparison study, Ferucarbotran, chemically synthesized superparamagnetic 
nanoparticles, were also used to magnetize AD-MSC. Both AD-MSC expressing 
mms6 and Ferucarbotran-loaded AD-MSC were used in in vitro MH and magnetic 
resonance (MR) imaging studies. 
In vitro studies of MNHT were undertaken to investigate whether AD-MSC expressing 
mms6 and Ferucarbotran-loaded AD-MSC could have a MNHT effect when exposed 
to an AMF. Cell viability, cell apoptosis and HSP70 expression were assessed to 
investigate the MNHT effect. The results did not indicate that the AMF application on 
AD-MSC expressing mms6 have a MNHT effect, showing no observable difference in 
cell viability, cell apoptosis and HSP70 expression. In vitro MRI experiments were 
conducted to test whether mms6 can function as a MR reporter gene for molecular 
imaging. The result revealed AD-MSC expressing mms6 produced a detectable 
magnetic signal, revealing a promising potential of mms6 as a reporter gene for MR 
imaging.  
Overall, the results indicate that an MTB gene, mms6, can be expressed in AD-MSC 
without an adverse effect on important cell functions. Moreover, these results also 
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indicate that no appreciable cell necrosis or cell apoptosis was found when AD-MSC 
expressing mms6 were exposed under AMF. However, this study has helped our 













































Magnetic nanoparticles are at the core of today's nanomedicine: they serve as 
diagnostic imaging agents, thermal anti-cancer agents, drug targeting agents, and 
tissue engineering agents. These tiny structures have shown promise for cancer therapy 
as they can be injected directly into the cancerous growth and activated by an external 
alternating magnetic field (AMF) to produce local increases in which causes the cancer 
cells to die, without affecting the healthy tissue surround the tumours. This approach 
is called magnetic hyperthermia (MNHT). 
The challenge for delivering MNHT to the clinic application is identifying optimal 
nanoparticles which are biocompatible, less toxic and when administered systemically 
in clinically appropriate doses, accumulate in the tumour well enough to allow the 
AMF to heat and kill cancer cells. To overcome this challenge, a cellular approach 
using mesenchymal stem cells (MSC) as carriers of MNP has been proposed as these 
cells can home to sites of tissue injury and tumor growth. However, progress in this 
field has been hindered by variable toxicity of available magnetic nanoparticles. As 
such it has been proposed that inducing adiposed-derived mesenchymal stem cells 
(AD-MSC) to synthesize MNP directly may overcome at least some of these problems. 
A genetic engineering approach has been developed by introducing a ‘magnetic 
gene’ derived from magnetotactic bacteria (MTB) into MSC with the aim to induce 
production of biogenic MNP. MTB have tiny nanoscale organelles called 
magnetosomes which consist of a chain of membrane-enclosed nanoparticles that act 
like a compass needle helping the bacteria navigate to nutrient-rich locations in aquatic 
environments, their natural habitats, by using the Earth's magnetic field. 
Magnetosomes contain magnetite nanocrystals (Fe3O4), uniform nanoparticles that 
have desirable magnetic properties. MTB use proteins to form crystalline particles 
about 50 nanometres in size, and one protein, Mms6, has been known to bind iron to 
initiate and regulate the nanoparticle formation. Therefore, a major goal of this study 
was to investigate whether it was possible to modify MSC with the mms6 gene so they 
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would be able to self-produce MNP, thus allowing their use for MNHT applications 
and cancer treatment. 
In this study, I was able to perform mms6 gene transfection and demonstrate that mms6 
can be expressed in AD-MSC, allowing them to self-produce MNP, something that 
would not be achieved without the gene. Importantly, experiments revealed that the 
expression of mms6 on AD-MSC did not have adverse effects on the function of these 
cells. 
Overall, experiments conducted in this study demonstrated that AD-MSC expressing 
mms6 produce a detectable magnetic signal, suggesting a promising potential of mms6 
as a reporter gene for magnetic resonance imaging (MRI). However, the in vitro 
MNHT experiments conducted in this study did not indicate that the AMF application 
on AD-MSC expressing mms6 have a MNHT effect, showing no cell killing effect 
detected after the AMF exposure. Therefore, the MNP produced by AD-MSC 
expressing mms6 does not appear to be adequate to generate heat in order to trigger 
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FC  Field-cooled 
GFP  Green Fluorescent Protein  
HCELL  Haematopoietic cell E-/L-selectin ligand  
HEK293T  Human Embryonic Kidney 293T 
HGF  Hepatocyte growing factor  
HSPs  Heat shock proteins  
HT  Hyperthermia therapy 
IF   Immunofluorescence  
IGF-1  Insulin-like growing factor 1 (IGF-1) 
ILP  Intrinsic loss power  
MAG MAGISTER gene 
MAI Magnetosome island  
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MHC  Major histocompatability complex  
MM  Magnetosome membrane  
MNHT  Magnetic nanoparticle-mediated hyperthermia  
MNP  Magnetic Nanoparticle 
MRI  Magnetic Resonance Imaging  
MSC  Mesenchymal stem cells  
MTB  Magnetotactic bacteria 
NH  northern hemispheres 
NK  Natural killer 
NP  Nanoparticles 
OATZ  Oxic-anoxic transition zone  
PBS  Phosphate buffered saline  
PTX  Paclitaxel  
P/S  Penicillin/Streptomycin  
RES  Reticuloendothelial system  
RNA   Ribonucleic Acid  
ROS  Reactive oxygen species  
RT-PCR  Reverse transcription polymerase chain reaction  
SAR   Specific absorption rate  
SH  Southern hemispheres 
SLP  Specific loss power  
SPION  superparamagnetic iron oxide nanoparticles 
SQUID  Superconducting quantum interference device 
TALENS  transcription activator-like effector nucleases   
TEM  Transmission Electron Microscopy  
TNF  Tumour necrosis factor  
TRAIL  TNF-related apoptosis-inducing ligand  
TUNEL  Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling 
UC  Umbilical cord  
ZFC  Zero-field-cooled  
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 LITERATURE REVIEW 
1.1 INTRODUCTION  
Due to their small size and high surface-to-volume ratio, magnetic nanoparticles 
(MNP) have attracted great interest for their potential biomedical applications either 
alone or through cell-based therapies (Cole et al., 2011).  One of the most promising 
approaches is magnetic nanoparticle-mediated hyperthermia (MNHT) for cancer 
treatment, where magnetic nanoparticles (MNP) absorb energy from alternating 
magnetic fields (AMF) and transform this energy into heat. While they are promising, 
the major drawback has been the difficulty of delivering MNP to the tumour site due 
to their rapid removal from blood and biological barriers at tissue and cellular level 
(Gao et al., 2013; Huang and Hainfeld, 2013).  
To overcome these problems, the use of MNP-labelled mesenchymal stem cells (MSC) 
has been proposed due to their inherent tumour-tropic and migratory properties, thus 
enabling cell-based MNP vehicle for the targeted delivery into tumour (Roger et al., 
2010; Duchi et al., 2013; Gao et al., 2013; Huang and Hainfeld, 2013). However, 
problems with MNP cytotoxicity have hindered progress in this area and need to be 
overcome. Therefore, the main goal of this project was to develop MSC able to self-
express MNP by genetically modifying them with the mms6 gene, a specific 
magnetosome gene derived from magnetotatic bacteria (MTB) 
 
1.2 MAGNETIC NANOPARTICLE 
1.2.1 Overview 
Nanotechnology is an emerging and promising field for research and development in 
the 21st century. The growing interest in nanotechnology and materials at nanoscale, 
including magnetic nanoparticles (MNP), has provided invaluable sources for 
healthcare and biomedical application. Considerable efforts have been made in 
engineering the MNP, leading to significant advances in medical areas such as 
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hyperthermia, drug delivery, tissue engineering, and theranostics (Shubayev et al., 
2009; Mohammed et al., 2017)  
MNP, which are amorphous or semi-crystalline structures, have gained great 
popularity because of their important properties such as non-toxicity, biocompatibility, 
size uniformity, and the ability to control their accumulation in the target tissue or 
organ (Corchero and Villaverde, 2009). Their increasing use includes a range 
applications include magnetic-based separation or selection, magnetic relaxometry, 
magnetic resonance imaging (MRI) and therapeutic applications such as drug delivery 
and magnetic hyperthermia (Hedayatnasab et al., 2017). 
 
1.2.2 Biomedical application of magnetic nanoparticles 
Due to their nanoscale size with at least one dimension up to 100 nm and their ability 
to be functionalized, MNP exhibit the ability to operate on cellular and molecular 
levels to attain specific performance based on required biomedical applications. In 
general, the use of MNP depend on the physicochemical properties of MNP, which are 
mainly affected by the particle structure, particle size, synthesis methods, and 
interaction among MNP. Therefore, precise control over the method of MNP synthesis 
is required in order to effectively tune the magnetic properties which are suitable for 
its biomedical purposes (Reddy et al., 2012; Hedayatnasab et al., 2017)  
MNP can be classified as metal, alloys or oxides, and commonly consist of magnetic 
elements of iron, nickel and cobalt or manganese. However, iron based-nanoparticles 
are the most widely studied due to their biocompatibility (Conde et al., 2014). An iron 
oxide core material, such as superparamagnetic iron oxide nanoparticle (SPIONs) are 
the most widely used MNP for biomedical application. SPIONs are composed of either 
magnetite or maghemite nanocrystals, and mainly coated with organic materials such 
as fatty acids, polysaccharides or polymers. These coating materials are specifically 
designed to improve biocompatibility, colloidal stability and to prevent separation into 
particles and carrier medium (Tietze et al., 2015). Due to those advantages, these MNP 
have already been tested in clinical trials for various cancer types, such as brain and 
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prostate cancers (Johannsen et al., 2010; Mazur et al., 2018).  MNP have also been 
used as contrast agents for MRI to detect liver metastases, metastatic lymph nodes, 
inflammatory and degenerative diseases at early stages (Gobbo et al., 2015). 
Moreover, the magnetic properties of MNP also allow the remote control of their 
accumulation into specific tissue which are directed by an external magnetic field. This 
application provides an improved strategy for magnetic targeting of drugs as well as 
magnetic hyperthermia therapy which is the main focus of this study (Silva et al., 
2011). 
 
1.2.3 The potential use of magnetic nanoparticle in cancer therapy 
Cancer management remains one of the major challenges facing health services around 
the world. Indeed cancer is now the second major cause of death in developing 
countries (Jemal et al., 2016). The fact that the available cancer treatment options are 
limited and, in many situations, the timely diagnosis and prognosis are difficult makes 
the effort more challenging. Facing this, much effort has been set on finding state of 
the art approaches for its diagnosis and therapy, which can be combined in cancer 
theranostics (Lima-Tenório et al., 2015) 
Theranostics can be defined as the fusion of therapeutic and diagnostic approaches 
with the main aims to personalize and advance medicine (Shubayev et al., 2009). In 
cancer theranostic, the main objective is not merely improving the diagnosis and 
increasing the efficacy of the treatment of cancers but also minimizing the systemic 
toxicity associated with this treatment. Thus, the critical feature of this approach is 
directing therapeutic agents that can be precisely concentrated on the target sites in the 
body. In this scenario, MNP are promising as theranostic agents, in which, they 
represent a particularly appropriate tool based on their ability to be simultaneously 
functionalized and controlled by an external magnetic field. With this ability, the MNP 
can be directed toward certain area of the body allowing MRI detection and releasing 
a therapeutic drugs with limited side effects as shown in  
Figure 1-1 (Gobbo et al., 2015)  
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The fundamental aspect behind this theranostic capability of MNP is the surface design 
of MNP which consist of multi-layered structure as shown in Figure 1-2. Through this 
multi-layered functionalization, MNP could have various properties with 
multifunctional purposes. For this, SPIONs formed by three main functional layer: (1) 
an iron oxide core functioning as MRI contrast agent, (2) a biocompatible coating and 




Figure 1-1: Example of magnetic nanoparticle for theranostic applications. 
Image taken from Gobbo et al (2015). 
In cancer diagnostic, the high magnetic susceptibility of MNP cores provides strong 
enhancement of transverse (T2 and T2*) relaxivity in tissue regions where 
nanoparticles have localized. Strong relaxivity is manifested on T2-weighted MR 
images as pronounced negative contrast (Cole et al., 2011). For example, the approved 
drugs Feridex IV and Resovist have been used as contrast agents for hepatic imaging. 
These polymer-coated MNP agents were polydisperse (size heterogeneous) 
superparamagnetic iron oxides that were rapidly cleared from the blood by 
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macrophages of the reticuloendothelial system (RES), thus leading to significant 
deposition in the liver and spleen. Consequently, these MNP darken normal liver tissue 
preferentially over cancerous lesions in T2 weighted images, allowing detection of 
primary or metastatic hepatic tumours (Abraham Lee, 2006).  
 
Figure 1-2: Schematic of a multilayered SPION with personalized medicine 
application. The figure represents the three main components formed by “layering” an iron 
oxide nanoparticle: (1) MNP core, (2) biocompatible coating and (3) therapeutic 
coating/targeting ligand. Image taken from Gobbo et al (2015). 
In 2010, Liu et al reported a study developing a theranostic system combining MRI 
and therapeutic MNP conjugated with the anticancer drug epirubicin for delivery and 
image tracking functions in a C6 tumour-bearing rat model (Liu et al., 2010). The 
study was also focused on using ultrasound to disrupt the blood - brain barrier (BBB) 
at the tumour site to improve nanoparticle accumulation. The result showed MNP 
distribution and enhancement of drug delivery then can be monitored by MRI in real 
time in vivo. A 2.6 fold increase in relaxation rate with MRI was observed in animals 
injected with the nanoparticles following the focused ultrasound/magnetic targeting 
treatment compared to the non-treated groups. This study provides a promising 
potential of multifunctional MNP to deliver therapeutic doses locally and 
simultaneously reduce the problem of systemic toxicity common to i.v.-administered 
therapeutic agents. Furthermore, the study also provides an integrated nanoplatform to 
monitor and quantify the drug delivery in real time in vivo. 
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Another area of interest in cancer theranostics is synergistic cancer diagnostic and 
treatment by combining three important elements: the improved ability of the magnetic 
nanoparticles as contrast agents for MRI, the unique drug delivery targeting cancer 
cell, and the unique heat generation property of magnetic nanoparticles in an 
alternating magnetic field (AMF) to induce hyperthermia. In 2016, Ramachandra 
Kurup Sasikala et al. reported a study developing a multifunctional nanocomposite 
consisting of Graphene Oxide–Iron Oxide-Doxorubicin (GO-IO-DOX) as a 
theranostic cancer platform which acts both as a hyperthermic agent that delivers heat 
when an alternating magnetic field is applied and a chemotherapeutic agent in a cancer 
environment by providing a pH-dependent drug release to administer a synergistic 
anticancer treatment with an enhanced T2 contrast for MRI (Ramachandra Kurup 
Sasikala et al., 2016). The study showed that periodic hyperthermia for three cycles 
resulted in a moderate cell cytotoxicity of 26% due to the mild hyperthermia at a 
temperature of ~40 °C in the GO-IO-MH group, whereas GO-IO-DOX-MH group 
exhibited an enhanced cell cytotoxicity of 82% due to both hyperthermia and drug 
activity. Therefore, the synergistic enhancement in the combined scenario can be 
explained to be a result of an increase in drug cytotoxicity due to the mild hyperthermia 
that was concurrently delivered.  
 
1.3 MAGNETOTACTIC BACTERIA 
1.3.1 The discovery of magnetotactic bacteria 
Magnetotactic Bacteria (MTB) are a diverse group of Gram-negative microorganisms 
that passively align and actively swim along the geomagnetic field and other fields 
(Lower and Bazylinski, 2013). This unique ability is dependent on its specific 
intracellular organelles, the magnetosomes, which are composed of a nanometer size 
magnetic crystal, either magnetite (Fe3O4) or greigite (Fe3S4) surrounded by a lipid 
bilayer membrane known as the magnetosome membrane as shown in Figure 1-3 
(Balkwill et al., 1980; Bazylinski and Frankel, 2004). 
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The discovery of MTB was first reported by Salvatore Bellini in 1963 when he 
microscopically observed a certain group of bacteria that moved toward the Earth’s 
North Pole, thus these group of bacteria named “magnetosensitive bacteria” (Jogler 
and Schuler, 2009). However, eleven years later, it was Blakemore who independently 
used the terms “magnetotaxis” for the phenomenon and MTB for the bacteria after he 
discovered aquatic bacteria from Woods Hole, Massachusetts. He noticed that the 
swimming direction of these bacteria was always the same, independently from the 
external stimulus given, as they migrated northward in water drops along magnetic 
field lines. In his landmark paper, he also discovered that the cells were roughly 
coccoid with two bundles of seven flagella each on one side of the cell by using 
Transmission Electron Microscope (Blakemore, 1975). The study also demonstrated 
that MTB cells contained chains of elongated, electron-dense, iron-rich crystals, 
comprise of magnetite. These chains of nanocrystal were enclosed within 
intracytoplasmic vesicles arranged next to the cytoplasmic membrane in the cell. It 
was speculated that magnetotaxis movement of MTB recovered from aquatic 
sediments in Woods Hole probably has correlation to the chains of crystals within 
MTB (Richard B. Frankel et al., 2006). 
Phylogenetically, MTB belong to the domain Bacteria and are associated with different 
subgroups of the Proteobacteria and the Nitrospira phylum. They represent a diverse 
group of microorganisms with respect to morphology and physiology (Bazylinski and 
Frankel, 2004). Based on its morphology, MTB have a cell wall structure which is a 
distinctive feature of Gram-negative bacteria (Bazylinski and Frankel, 2004). 
Structurally, they also have flagella as their motility organelle which varies between 
species/strains and can be either polarly monotrichous, bipolar, or in tufts 
(lophotrichous). This structure allows MTB to propel through the water actively by 
rotating their helical flagella, but passively orient along the geomagnetic field 




Figure 1-3: Transmission electron microscopy image of a cell of a 
magnetotactic bacterium. (Left) Transmission electron microscopy image of a cell MTB 
collected from the Olentangy River, Columbus, Ohio, USA. The MTB contains chain of 
electron-dense magnetosomes containing cuboctahedral crystals of magnetite running along 
the long axis of the cell and the single polar long flagellum (at arrow). (Right). Transmission 
electron microscopy image of a chain of purified magnetosomes from M. marinus. Arrows 
denote magnetosome membrane. Image taken from Lower and Bazylinski (2013). 
 
1.3.2 The ecology and behavior of MTB 
MTB are generally distributed in water columns or sediments with vertical chemical 
stratification (Bazylinski and Williams, 2006). MTB are a great example of gradient-
loving organisms due to their preference to live in the oxic-anoxic transition zone 
(OATZ) which is a particular zone created by two opposite gradients, one formed by 
the oxygen coming from the surface and another created by the sulphide produced by 
the sediments of the bottom. OATZ provides low level of oxygen, which is a preferable 
environment for MTB. In general, MTB located in environments with higher than 
optimal oxygen concentration will move toward the OATZ by rotating their flagella 
counter clockwise, whereas bacteria located in environments having lower than 
optimal oxygen concentration will rotate their flagella clockwise and move toward the 
OATZ. This typical MTB orientation of moving toward OATZ, exploiting magnetic 
field through their magnetosomes, is called "magneto-aerotaxis" and can be seen in 
Figure 1-4 (Frankel et al., 1997; Bazylinski and Frankel, 2004). However, despite their 
major preference towards OATZ, several different species of MTB are dependent on 
9 
 
specific chemical/redox conditions, hence can be found at different positions within 
the gradients. A greigite-producing MTB, for example, are found below the OATZ 
when the anoxic zone is sulfidic (Moskowitz et al., 2008). 
In 1997, Frankel et al hypothesized MTB has two forms of magneto-aerotaxis, which 
are polar magneto-aerotaxis and axial-aerotaxis (Frankel et al., 1997). In polar 
magneto-aerotaxis, MTB have a polar preference in their swimming direction under 
oxic conditions. Some MTB strains, mainly the magnetotactic cocci, are polar 
magneto-aerotactic that swim persistently in one direction along the magnetic field. 
For example, north-seeking MTB in the northern hemisphere have north polarity, 
which means that they swim toward geomagnetic north into anoxic sediments or 
waters in a vertical chemical gradient when they exposed to higher than optimal 
oxygen levels. For the same reason, south-seeking MTB swim toward geomagnetic 
south. In contrast to polar-aerotaxis MTB, axial magneto-aerotaxis MTB use the 
magnetic field as an axis while swimming under oxic conditions in both directions 
along magnetic field lines without polar preference. The earth geomagnetic field 
provides both an axis and a direction of motility for polar magneto-aerotactic bacteria, 
whereas it only provides an axis of motility for axial types of bacteria (Frankel et al., 





Figure 1-4: Schematic representation of Magneto-aerotaxis in the northern (NH) 
and southern (SH) hemispheres. MTB exploit magnetic field to find their optimal oxygen 
concentration at the microaerobic oxic–anoxic transition zone (OATZ). To move across 
different stratifications, in both the hemispheres, MTB on the oxic side of OATZ swim down 
geomagnetic field lines, whereas those on the anoxic side swim up along the magnetic lines. 
The MTB on oxic side of OATZ rotate their flagella counterclockwise (CCW), whereas the 
ones on the anoxic side rotate their flagella clockwise (CW). MTB showing north or south-
seeking behaviour show also different magnetic polarity, indicated by arrows. Image taken 
from Uebe and Schüler (2016). 
 
Conflicting reports to the polar magneto-aerotaxis, however, were reported by 
Simmons and his coworkers (2006). They found that populations of polar MTB in the 
northern hemisphere respond to high oxygen levels by swimming toward geomagnetic 
south, in contrast to all previous studies on MTB magneto-aerotaxis. It may be possible 
that MTB respond by other routes in order to find optimal condition outside from 
OATZ (Simmons et al., 2006). Moreover, the first study of phototaxis in MTB 
Magnetospirillum magneticum strain AMB-1 was reported by Chen et al. in 2011. 
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They found out that Magnetotactic AMB-1 cells migrated toward light, and migration 
increased with higher light intensity. The study demonstrated that the phototaxis 
response proved to be independent of the geomagnetic field and affected the formation 
of magnetosome (Chen et al., 2011). 
 
1.3.3 Magnetosome formation 
The fundamental organelle of MTB is the magnetosome, which is defined as an 
intracellular, membrane-bounded magnetic iron-bearing inorganic crystal (Bazylinski 
and Frankel, 2004; Lefèvre et al., 2011). Many studies have been done using 
Magnetospirillum magneticum AMB-1 (AMB) and Magnetospirillum 
gryphiswaldense MSR-1 (MSR) as model strains of MTB in the laboratory. These 
Alphaproteobacteria class MTB are known for their magnetosomes containing single 
chains of cuboctahedral magnetite (Fe3O4) crystals. It was observed in this strain that 
magnetosomes biosynthesis comprises of four important steps (Uebe and Schüler, 
2016): 
1) the magnetosome membrane is invaginated from the cytoplasmic membrane, 
which then developing either vesicle-like permanent invaginations or detached 
vesicles.  
2) magnetosome proteins are sorted to the magnetosome membrane, either before, 
simultaneously or following invagination, 
3) iron is transported into the magnetosome membrane invagination before 
initiating biomineralization to form magnetite crystals,  
4) a highly ordered magnetosome chain is then assembled and positioned for 
segregation during cell division  
The formation of bacterial magnetosomes is a tightly-regulated process involving 
genetic control over the biomineralization of perfectly shaped and sized magnetic 
crystals as well as highly ordered crystal chains arrangement to function as magnetic 
field sensor (Schüler, 2008). The molecular mechanism of magnetosome formation 
remained poorly understood for some time, however it was observed that genetic 
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controls of magnetosome biosynthesis are associated with a set of magnetosome 
membrane (mam) and magnetic particle-membrane specific (mms) genes as can be 
seen in Figure 1-5  (Arakaki et al., 2003; Grunberg et al., 2004). These specific genes 
are clustered in a single chromosomal region, named genomic magnetosome island 
(MAI) (Ullrich et al., 2005; Fukuda et al., 2006). 
 
Figure 1-5: Sequential steps of the hypothesized mechanism of magnetosomes 
formation and magnetite biomineralization in magnetotactic bacteria. Image 
taken from (Kerans et al., 2018). 
The MAI extends across about 100 kb and are organized into five polycistronic 
operons: one large (16–17kb) mamAB operon and the small feoAB1, mamGFDC, 
mms6 and mamXY operons as can be seen in Figure 1-6. The mamAB operon contains 
several genes that are involved in important steps in the synthesis of magnetosome. 
The mamAB operon is also fundamental in maintaining some process of 
biomineralization. It was found that without mamAB operon, there is no magnetic 
phenotype. In contrast, the four small operons encode non-essential proteins that have 
accessory roles in, specifically in regulating the biomineralization of crystals as well 
as controlling size and shape of the crystal. This role involves the putative iron 
transporters FeoAB1 and MamZ; the tubulin-like protein FtsZm; and the 
magnetotactic bacteria-specific proteins MamC (also known as Mms13), MamD (also 
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known as Mms7), MamF, MamG, MamX, MamY, Mms6, MmsF, Mms36 and Mms48 
(Scheffel et al., 2008; Lohße et al., 2011; Rong et al., 2012; Raschdorf et al., 2013).  
 
 
Figure 1-6: Schematic representation of the genomic magnetosome island 
(MAI). Schematic picture of MAI genes consists of the five operons regulating genes involved 
in the magnetosome biogenesis. The genes are coloured according to the features of their 
encoded proteins. Image taken from Uebe and Schüler (2016). 
Since the MAI is critical in encoding factor for multi-steps process of magnetosome 
formation, Kolinko and coworkers (2014) attempted to produce sustainable magnetic 
nanostructures in Rhodospirillum rubrum, photosynthetic model organism, by 
introducing expression cassettes comprising of 30 genes of MAI (Kolinko et al., 
2014). The study validated the proof of principle that magnetic crystal nanostructure 
can be produced in non-magnetic bacteria or biotechnologically relevant hosts by 
genetic engineering using genes from MTB. Therefore, this finding is important in 
developing nanomagnetic material biomedical application, such MNHT or for 
endogenous expression of magnetic reporters for bioimaging. 
 
1.3.4 Magnetosome membrane formation. 
The growing of magnetic crystal within magnetosome required a specialized ‘nano-
reactor’ compartmentalization, where factors such pH environments, iron and redox 
are finely controlled. For this reason, magnetosome membrane (MM) plays a major 
role in creating this compartmentalization allowing strictly regulated magnetosome 
biomineralization and cell protection from toxic products. The magnetosome 
membrane was demonstrated to comprise a 5–6 nm proteinaceous phospholipid 
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bilayer which is invaginated from the cytoplasmic membrane (Balkwill et al., 1980; 
Gorby et al., 1988; Komeili et al., 2006; Katzmann et al., 2010).  
Studies conducted on both MSR and AMB have shown that the invagination process 
occur simultaneously from several nonspecific cellular locations, as was confirmed by 
tracking de novo magnetosome biogenesis by time-lapse fluorescence microscopy and 
cryoelectron tomography, using inducible gene expression systems (Raschdorf et al., 
2013; Cornejo et al., 2016). In MSR, it was found that the invagination of 
magnetosome membranes is likely to proceed immediately since the initial stages of 
membrane deformation was not detected (Raschdorf et al., 2016). Interestingly, 
magnetosome vesicles can be empty or filled with iron, which confirms the 
invagination mechanism is independent to biomineralization process (Komeili et al., 
2004; Katzmann et al., 2010; Cornejo et al., 2016). 
The invagination ability of MTB is generally thought to depend on specific proteins 
that provide the energy required to generate the magnetosome membrane. MamB 
seems to have a function in magnetosome membrane invagination and iron 
transportation; whereas MamI and MamL are integral membrane proteins associated 
with the MM. MamB is believed to play a major role in guiding the formation of 
multiprotein complexes to induce invagination in the later steps of magnetosome 
biogenesis (Uebe and Schüler, 2016). Another protein associated with membrane 
invagination is MamY, which has been found to be involved in constriction of the cell 
membrane to create the magnetosome cell membrane (Tanaka et al., 2011). 
 
1.3.5 Biomineralization 
Following the magnetosome compartments are formed and positioned, the final step 
in magnetosome biogenesis is the biomineralization of magnetite. The 
biomineralization process involves iron transport, initiation of crystallization, crystal 
maturation, and control over size and morphology (Komeili, 2012). The first important 
step is the transport of iron from the extracellular environment into the cell. MTB are 
capable of accumulating significant amounts of intracellular iron that are at least 100 
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times higher than non-MTB species such as E. coli. For most MTB, the iron uptake 
process is regulated in response to environmental oxygen levels which mainly occurs 
in anaerobic conditions (Blakemore et al., 1985; Schüler and Baeuerlein, 1996, 1998; 
Heyen and Schüler, 2003). 
A genetic study investigating the ferric uptake regulator (Fur) transcription factor in 
MSR-1 indicate that the overall balance of cellular iron must play an important role in 
the biomineralization process. The study showed that deletion of the fur homolog in 
MSR-1 resulted in the production of fewer magnetite crystals. (Uebe et al., 2010). In 
agreement with this finding, Yijun and coworkers (2017) also found that iron uptake 
and magnetosome formation were dramatically inhibited by disruption of fur-like 
proteins, suggesting some transport of iron from a cytoplasmic pool into 
magnetosomes may be required for magnetite formation (Yijun et al., 2007). 
After the iron uptake process, the next step is the initiation of crystallization which is 
likely a process where the chemical environment of the magnetosome needs to be 
modified to allow for transformation of concentrated iron into nuclei of magnetite 
(Komeili, 2012). In 2007, Faivre and coworkers found iron-containing Ferritin-like 
protein in the cellular membrane fraction. They suggested that the iron within this 
protein is co-precipitated, along with soluble ferrous iron, to form magnetite 
crystallites at the cell membrane, which are then matured into magnetite within the 
magnetosome. In addition, they also believed that the steps involved in magnetite 
formation and biochemical iron uptake are distinct, suggesting magnetite formation 
occurs via membrane-associated crystallites, while the final step of magnetite crystal 
growth possibly is spatially separated from the cytoplasmic membrane (Faivre et al., 
2007). A genetic analysis study has showed that the deletion of mamM, mamN, mamE 
and mamO in AMB-1 results in magnetosome membranes with a full complement of 
magnetosome proteins, yet without mineral formation, suggesting the important role 
of these genes in the biomineralization process (Murat et al., 2010). Moreover, the 
study also tested the hypothesis that the absence of crystal formation could also be a 
consequence of the inability of the mutant to properly localize magnetosome proteins. 
It was found that the absence of MamE protein resulted in mislocalized of MamA and 
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MamJ, which are not essential for biomineralization, suggesting that MamE may act 
as precursor or enzyme to control the localization of other magnetosome proteins. The 
empty magnetosome could be a consequence of the mislocalization of at least a subset 
of magnetosome proteins (Murat et al., 2010). 
Crystal maturation process occurs to form a stable crystal state, enabling the 
magnetosome chain’s ability to reorient cells in magnetic field. In the initial crystal 
form, the magnetites are composed of a single magnetic domain in a 
superparamagnetic state, meaning that the direction of their dipole moment is unstable. 
Once the maturation process started, they reach a size > 35 nm, and become a stable 
single domain magnetic crystal (Komeili, 2012). A genetic study has demonstrated 
that the deletion of mamS, mamT,or mamR results in a reduction in size of the crystal 
and defects in their morphology (Murat et al., 2010). 
FtsZ-like proteins are a copy of FtsZ, defined as bacterial tubulin-like cell division 
proteins found in three Magnetospirillum species (Richter et al., 2007; Ding et al., 
2010). FtsZ-like proteins genes are localised into the MAI region, in MamXY operon, 
a feature that suggests a possible involvement of these proteins in magnetosome chains 
assembly or in Magnetospirillum cells division (Jogler and Schuler, 2009; Müller et 
al., 2014). 
 
1.4 MMS6 PROTEIN 
1.4.1 Mms6 protein and its function 
In 2003, Arakaki and his coworkers found Mms6 protein may be directly involved in 
biological magnetite crystal formation in MTB.  The protein was isolated from 
magnetosomes of M. magneticum AMB-1 together with the other magnetosomes 
associated proteins, after lipid membrane stripping and treatments based on detergent 
and heat (Arakaki et al., 2003). The group found four proteins which showed common 
features in their amino acid sequences which contain hydrophobic N-terminal and 
hydrophilic C-terminal regions: magnetosome membrane specific5 (Mms5), 
magnetosome membrane specific7 (Mms7), magnetosome membrane specific13 
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(Mms13) and Mms6. These proteins were called “Mms”, which stands for their 
magnetosome membrane specific (Mms) localization and were numbered according 
to their molecular mass (Arakaki et al., 2003). 
Mms6 has a negative charge at neutral pH, being different from all the other Mms 
proteins that are positively charged (Arakaki et al., 2003). In 2006, a proteomic study 
identified magnetosome membrane proteins also to be prevalent in the cytoplasmic 
membrane, several of which are related to magnetosome biosynthesis, such as Mms13. 
Mms6, however, was not found in other membrane fractions of the cell, suggesting 
this protein is specifically targeted to the magnetosome membrane (Tanaka et al., 
2011). 
Mms6 gene sequence shows a high consensus among different MTB species, 
especially in the C-terminal region. The sequence codes for a protein of approximately 
12–15 kDa, which is larger than the 6 kDa species identified in magnetosomes by 
SDS/PAGE. This finding suggests Mms6 protein undergoes in vivo protease cleavage 
to form 6 kDa truncated protein (Arakaki et al., 2003; Grunberg et al., 2004). 
In 2014, Nudelman and Zarivach demonstrated structure prediction of magnetosome-
associated proteins which indicates Mms6 has secondary structure. It was predicted 
that this structure is formed by an unstructured N-terminal domain followed by one 
transmembrane helix and a C-terminal, suggesting it may form α-helix structure. It 
was believed that the C-terminal domain (CTD) can act as an iron binding site which 
was predicted by the 3D model protein structure on its (Nudelman and Zarivach, 
2014). 
In 2010, Tanaka and his coworkers discovered that the Mms6 protein is tightly 
associated with magnetite crystals. They performed in vitro mms6 gene deletion 
experiments to understand the role of Mms6 in Magnetospirillum magneticum AMB-
1. The study found smaller magnetite crystals with uncommon crystal faces in Δmms6 
mutant strain, while the wild-type and complementation strains synthesized highly 
ordered cubo-octahedral crystals. In addition, Δmms6 mutant strain also displayed 
drastic changes in the profiles of the proteins tightly bound to magnetite crystals. It 
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was observed that Mms6 plays a role in the regulation of a nano-sized crystallographic 
structure in in vivo biomineralization in MTB. Moreover, by analyzing the protein 
profiles in gel images, Δmms6 mutant strain also showed the drastic decrease of the 
Mms5, Mms7, and Mms13 protein expressions in the protein fraction obtained from 
the magnetite crystal surface, suggesting Mms6 protein may also be involved in other 
Mms protein interactions and as it co-locates on the magnetite crystal surface (Tanaka 
et al., 2010). 
Arakaki et al. (2014) demonstrated that all mms genes were involved in different ways 
in the promotion of crystal growth and defining the surface structure of the magnetic 
nanocrystals in M. magneticum strain AMB-1. In their study, various mms gene 
deletion mutants were designed and the magnetite crystals formed by the mutant 
strains were characterized. Deletion of mms6 or mms7 resulted in decreased of the 
amount of proteins in the outside region of the magnetosome chain. Furthermore, 
based on the phenotypic characterization, formation of elongated nanocrystal was 
shown in Δmms6 and Δmms7 mutant strains (Arakaki et al., 2014). 
Using high-resolution transmission electron micrograph, the functions of Mms 
proteins can be estimated from the magnetosome crystal faces modeled for each Δmms 
strain mutants (Arakaki et al., 2014). Using this predictive model, it was observed 
Mms proteins have different dimensional effects on the crystal growth of magnetite 
due to their preferences of proteins for binding to specific sites during crystal growth, 
which determine their specific surface structures on magnetite crystals (Arakaki et al., 
2014). This was in agreement with previous in vitro study which showed the active 
site for Mms6 is most likely present in its C-terminal region, which contains acidic 
amino acids (Arakaki et al., 2010). 
 
1.4.2 Synthesizing MNP with Mms6 in vitro 
Despite the nature of the magnetite precipitation and biomineralization process within 
the magnetosome not yet being clearly understood, purified Mms6 has been 
investigated in synthetic magnetite formation reactions to look for effects on the MNP 
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products (Arakaki et al., 2003, 2010; Amemiya et al., 2007; Prozorov et al., 2007; 
Galloway et al., 2011, 2012; Bird et al., 2016). Magnetite (Fe3O4), is formed by ferric 
(Fe3+), and ferrous iron (Fe2+), at the 2:1 stoichiometric ratio. Most of methods to 
produce magnetite synthetically involve in vitro precipitation and series of pH titration 
of mixtures of iron. By adding purified Mms6 to these in vitro methods, the size, shape 
and material purity of the resulting nanoparticles can be compared with protein-free 
nanoparticles prepared under identical conditions (Arakaki et al., 2003, 2010; 
Amemiya et al., 2007; Prozorov et al., 2007; Bird et al., 2016).  
In 2003, Arakaki and his coworkers reported that addition of Mms6 at 20 µg/ml to a 
room-temperature co-precipitation reaction resulted in a product which was mainly 
magnetite and few alternative iron oxide precipitates, suggesting the ability of Mms6 
to promote a reaction towards magnetite (Arakaki et al., 2003). Furthermore, the 
magnetite also displayed a cuboidal shape, and a narrow size distribution, similar to 
the ones observed in the magnetosomes. In a good agreement with this, recent findings 
also demonstrated similar result despite using lower concentration of Mms6 protein 
(Amemiya et al., 2007) and different ratios of iron in the mixture (Galloway et al., 
2011), and using a surface system as a mimic of the interior of magnetosome 
membrane (Bird et al., 2016). 
Amemiya et al. (2007) showed Mms6-mediated synthesis of magnetite nanocrystal by 
partial oxidation of ferrous hydroxide generated nanocrystal of a uniform size and 
narrow size distribution with a cubo-octahedral morphology, similar to bacterial 
magnetite observed in M. magneticum AMB-1. In the absence of Mms6, the crystal 
produced were octahedral, larger with an increased size distribution. In the presence 
of Mms6, iron ions bind to the iron binding site of Mms6, concentrating them about 
the protein aggregate. It was suggested that the self-assembled aggregate mediated by 
Mms6 acting as a template and regulating the crystal size to approximately 20 nm. 
Therefore, the study also proposed that Mms6 has important roles in controlling the 




Recently, Shipunova et al. (2019) reported surface modification of nanoparticles 
mediated by Mms6 protein. The study developed a novel method of magnetite 
nanoparticles stabilization using recombinant protein for the targeted delivery to 
HER2/neu oncomarker for cancer diagnostic purposes. The study found that a 
biocompatible Bs-C-Mms6 fusion protein containing the C-terminal part of the Mms6 
(magnetite-binding protein of magnetotactic bacteria) and Barstar (an inhibitor of 
bacterial ribonuclease Barnase) was able stabilize magnetic nanoparticles formed by 
co-precipitation, allowing stable protein-coated of nanoparticle in physiological 
condition (Shipunova et al., 2019) 
 
1.4.3 Mms6 in vitro: self-assembly and iron binding 
Mms6 alone is not responsible for the formation of magnetite nanocrystals in vivo 
(Tanaka et al., 2011), however Mms6 in vitro activity may provide understanding of 
how magnetosome-related proteins are involved in biomineralization. Mms6 protein 
has been shown to have two phases of iron binding: one high affinity and 
stoichiometric and the other low affinity, high capacity, and cooperative with respect 
to iron. Mms6 protein is amphipathic with a hydrophobic N-terminal domain and 
hydrophilic C-terminal (Wang et al., 2012) This structure was first reported by Wang 
and his coworkers (2012) who found that in aqueous solution the amphiphilic nature 
of Mms6 tends to form micelle-like structures with the C-terminal hydrophilic regions 
exposed, protecting the hydrophobic N-terminal regions within the core. Using size-
exclusion chromatography, the study also identified that self-assemblies of Mms6 
protein form the 200-400 kDA, micelles with most particles consisting of 20−40 
monomers (Wang et al., 2012).  
In 2014, the direct evidence of the localization of the bound iron to the C-terminal 
region of the Mms6 micelles was firstly reported by Kashyap and coworkers. Using in 
situ liquid cell scanning transmission electron microscopy they demonstrated a direct 
visualization of biomimetic iron oxide nanoparticle nucleation mediated by an acidic 
bacterial recombinant protein, Mms6, during an in situ reaction induced by the 
controlled addition of sodium hydroxide to solution-phase Mms6 protein micelles 
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incubated with ferric chloride as can be seen in Figure 1-7. The result of the study 
indicated that slow addition of NaOH to the micelles in situ leads to a contrast change 
at the surface of the micelles, suggesting the formation of an amorphous precursor 
phase. Whereas further addition of NaOH led to nucleation of iron oxide on the Mms6 
protein micelles (Kashyap et al., 2014). Moreover, other study also found that the 
addition of ferric and ferrous iron ions to the Mms6 protein solution promotes 
morphological changes in the micellar structure by transforming the micelle structure 
into 3D-mass fractal-like structure or, alternatively, 2D platelet-like structures (Zhang 
et al., 2015). 
 
Figure 1-7: Schematic of Mms6-mediated iron oxide nucleation of micelle-
bound iron species. Image taken from Kashyap et al. (2014). 
Staniland and Rawlings (2016) hypothesized that Mms6 self-assembles to generate 
protein rafts on the interior of magnetosome membrane, showing a C-terminal surface, 
as seen in the surface of in vitro micelles. To test this, they assessed the ability of 
biomimetic Mms6 to self-assemble on a surface to model self-assembly in the 
magnetosome membrane environment. They found that the biomimetic Mms6 surface 
nucleated and controlled magnetite formation. On the other hand, biomimetic Mms6 
without the N-terminal (named C20Mms6) could self-assembly on the surface, but no 
nucleated surface and magnetite formation was observed indicating the importance of 
the N-terminal region of Mms6 in controlling magnetite formation. Furthermore, a 
glycine–leucine repeating sequence is present in the conserved 6 kDa protein but 
absent in the C20Mms6. This sequence is an important feature of self-assembly 
proteins and is suggested to form a regularly packed structure generated 
by arrangement of hydrophobic residues which could interlock with adjacent Mm6 
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molecules. It is believed that without this structure the magnetite nucleation ability is 
lost (Staniland and Rawlings, 2016). 
Rawlings et al. (2016) suggested that Mms6 is acting as a ‘mineral/ferrous ion buffer’ 
being able to direct mineralization towards magnetite synthesis. They have studied 
magnetite formation in vitro with or without Mms6 at different pH titrations. They 
found that the activity of Mms6 below pH4 is negligible for a range of different 
ferric:ferrous ratios, reducing Mms6 iron binding ability. However as pH increases to 
7, deprotonation occurs forming negatively charged micelles that bind iron, suggesting 
Mms6 is active under these conditions (Rawlings et al., 2016). Although pH inside 
magnetosomes has not been determined, it must be high enough to enable magnetite 
to precipitate, enabling Mms6 for nucleating or shape controlling the magnetite 
(Staniland and Rawlings, 2016). NMR spectroscopy analysis on Mms6 protein 
suggested that DEEVE acidic residue cluster within the C-terminal region of Mms6 
acts as ferrous binding site. Mms6 is found to be active in ferrous-rich conditions in 
vitro, thus it is thought that in vivo conditions in the magnetosome are likely to be 
similar with respect to pH, the ability of Mms6 to form a self-assembled charged 
surface and the availability of ferric precursors in a ferrous-ion-rich solution in order 
to promote the crystallization of magnetite, as illustrated in Figure 1-8. Therefore, it 
was suggested that Mms6 plays a key role in binding both ferric and specifically 







Figure 1-8:  Mms6 protein with its sequence in magnetotactic bacterial 
magnetosome. The hydrophilic acid-rich region is shown in blue color, whereas the 
hydrophobic membrane region is shown in pink color. Experimental schematic showing pH 
recording during addition of base to ferric/ferrous solution with or without Mms6 micelles is 
also illustrated. Mms6 is found to be active in ferrous-rich conditions in vitro. Image taken 
from Rawlings et al. (2016). 
 
1.5 MESENCHYMAL STEM CELLS 
1.5.1 Mesenchymal stem cells distinctive characteristic 
In 1974, mesenchymal stem cells (MSC) were identified by Friedenstein as 
proliferating fibroblastic cells from bone marrow capable of differentiating into 
osteoblasts, chondrocytes and adipocytes (Friedenstein et al., 1974). Afterwards, the 
term ‘MSC’ was adopted by the Caplan group to define a population of stem cells with 
capability of self-renewal and differentiation into multiple lineages including cartilage, 
adipose, and bone (Caplan and Dennis, 2006). 
Self-renewal refers to the ability to proliferate whilst maintaining the undifferentiated 
state: the cell divides symmetrically creating two identical copies of itself for long 
periods of time. Depending on the stem cell, self-renewal is a well-modulated process, 
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involving complex signaling networks (He et al., 2009). Multipotency is defined as 
the ability of a progenitor cell to differentiate into a limited number of cell types with 
specific functions. MSC’ plasticity to differentiate in different cell lineages 
(osteogenic, adipogenic, and chondrogenic), together with their immunomodulatory 
and anti-inflammatory properties, and their ability to migrate to sites of tissue 
injury/inflammation make these cells attractive in regenerative medicine and drug 
delivery (Figure 1-9) (Chapel et al., 2003; Mouiseddine et al., 2007; Nixon et al., 2012; 
J. R. Park et al., 2015; J. S. Park et al., 2015). 
In 2006, the International Society for Cell Therapy produced the minimal criteria to 
define human MSC. They must adhere to plastic in culture and differentiate into 
osteocytes, chondrocytes and adipocytes. In addition, they also must express CD105, 
CD90 and CD73 and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha 
or CD19, and HLA-DR surface molecules (Dominici et al., 2006). Moreover, MSC 
should escape immune recognition. Although MSC do not express MHC class II 
antigens, the expression of these molecules can be upregulated following exposure to 
inflammatory cytokines or during MSC differentiation (Le Blanc and Ringdén, 2005). 
Due to these distinctive characteristics the clinical application of these cells has been 
extensively studied, especially in regenerative medicine such as Orthopaedics where 
MSC are used to repair large bone defects (Bashir et al., 2014), in haematology, where 
they have been used to support the engraftment of hematopoietic stem cells  (Fouillard 
et al., 2007; De Becker and Van Riet, 2015), and as a cell based technology for delivery 
of anticancer treatments (Ďuriniková et al., 2014; Hammer et al., 2015; J. S. Park et 
al., 2015; Qiao et al., 2015). 
MSC have been isolated from a wide range of sources including bone marrow (BM) 
(Gnecchi and Melo, 2009), adipose tissue, umbilical cord (UC) (Bieback and Kluter, 
2008; Hermantara et al., 2016; Rizal et al., 2018), liver (Lu et al., 2014), and multiple 
dental tissues (G. T.-J. Huang et al., 2009). Each of these sources has its own 
advantages and disadvantages. BM is the most characterized and documented source 
of MSC. However, the collection of MSC from BM is painful, invasive, and 
characterized by a low yield (Gnecchi and Melo, 2009). Adipose tissue is another 
25 
 
popular source, mainly because a large number of MSC can be obtained through 
minimally invasive methods (Bieback and Kluter, 2008). Although there are many 
sources for MSC, the quality of the MSC is highly variable from donor to donor and 
is significantly affected by age and aging disorders. To overcome this problem, MSC 
can also be derived from induced pluripotent stem cells (iPSC)  (Lian et al., 2010). 
MSC derived from iPSC show similar distinctive characteristics of MSC, such as the 
potential for adipogenesis, osteogenesis, and chondrogenesis, and display higher 
capacity for proliferation and stronger telomerase activity, leading to better 
engraftment and survival after transplantation (Lian et al., 2010). 
 
Figure 1-9:Mesenchymal stem cells distinctive characteristic. Isolation of MSC can 
be from numerous connective tissues but is most common from bone marrow. The MSC 
plasticity to differentiate into osteogenic, adipogenic, and chondrogenic different cell 
lineages, together with their ability to migrate to sites of tissue injury/inflammation; secretion 
major histocompatability complex (MHC) of angiogenic, chemoattractant, and antiapoptotic 
factors; immunomodulatory and anti-inflammatory properties through reduced T-cell activity 
and MHC suppression. NK, Natural killer. Image taken from Nixon et al. ( 2012). 
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1.5.2 Mesenchymal stem cells homing and migration 
The exact mechanisms used by MSC to migrate and home to tissues have are not fully 
understood. However, it is generally suggested that MSC follow a similar process to 
that described for leukocyte homing. Firstly, the cells come into contact with the 
endothelium by tethering and rolling, resulting in a deceleration of the cells in the 
blood flow. In the second step, G-protein-coupled receptors activate the MSC cells, 
followed by integrin-mediated activation-dependent arrest in the third step. Finally, in 
the last step, the cells transmigrate between endothelial cells and through the 
underlying basement membrane (Butcher and Picker, 1996). Different molecules play 
a distinctive role in MSC migration and engraftment to the site of injury. Selectins on 
the endothelium are primarily involved in the first step. For bone marrow homing in 
particular, the expression of haematopoietic cell E-/L-selectin ligand (HCELL), a 
specialized glycoform of CD44 on the migrating cell, is very important (Sackstein, 
2004). Although MSC express CD44, they do not express HCELL (Sackstein et al., 
2008). The G-protein coupled receptors that are involved in the activation step are 
typically chemokine receptors. It has been extensively demonstrated that the CXCR4- 
stromal derived factor-1 (SDF-1) axis is critical for bone marrow homing (Moll et al., 
2012). Both molecules are very physiologically important, as knock-outs are lethal due 
to bone marrow failure and abnormal heart and brain development (Nagasawa et al., 
1996; Zou et al., 1998). CXCR4 expression has been enhanced both directly by 
designed transfection or transduction studies to improve the MSC homing efficiency 
by introducing plasmid into the cells by viral (Bobis-Wozowicz et al., 2011) or non-
viral means (Otani et al., 2009; Wiehe et al., 2013) or indirectly, by using molecules 
or processes that favour CXCR4 expression. To improve  MSC CXCR4 expression a 
number of strategies have been proposed, such as treating the MSC culture before of 
the injection with a cocktails of cytokines (Shi et al., 2007) like flt3 ligand stem cell 
factor (SCF), IL3, IL6 and hepatocyte growing factor (HGF), insulin-like growing 
factor 1 (IGF-1), tumour necrosis factor α (TNF α), IL 1β, interferon γ (IFN γ). 
Integrins are important players in the stable activation-dependent arrest in the third 
step of homing. Inhibition of integrin β1 can block MSC homing (Ip et al., 2007). 
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Integrins form dimers that bind to adhesion molecules on the endothelial cells. Integrin 
α4 and β1 combine to form very late antigen 4 (VLA-4), which interacts with vascular 
cell adhesion molecule 1 (VCAM-1). VCAM-1-VLA4 interaction is functionally 
involved in MSC homing (Rüster et al., 2006; Segers et al., 2006). 
 
1.5.3 Engineering mesenchymal stem cells for therapy 
The clinical application of MSC is often hindered by poor in vivo performance with 
respect to survival, retention, and engraftment. To overcome this problem, genetic 
engineering is one approach to improve the in vivo performance of MSC. In general, 
engineering MSC by genetic modification is achieved via viral vector transduction. 
However, non-viral vectors are becoming attractive as alternative techniques recently  
(J. S. Park et al., 2015). 
Engineering MSC by genetic modification using viral transduction has been 
promising. Standard protocols can lead to 90% transduced cells without detrimental 
effect on cell self-renewal or differentiation (Nolta et al., 1994; Mosca et al., 2000). In 
principle, the use of viral transduction allows transgene integrate into host genome, 
thus it can also offer a long-term and stable expression of the gene of interest. The 
most common vectors include retrovirus, lentivirus, baculovirus, and adeno-associated 
virus (AAV) (Airenne et al., 2013). Retrovirus offers highly stable expression of gene 
of interest in the host genome, allowing long-term protein production which is ideal 
for treatment of genetic diseases. However, it could also lead to insertional 
mutagenesis and activation of oncogenes (Hacein-Bey-Abina et al., 2008; Wu and 
Dunbar, 2011). Lentivirus also enables stable transgene expression through integration 
into the genome. Non-integrating lentiviral vectors have also been designed which can 
be useful to overcome the problems associated with integration (Banasik and McCray, 
2010). Baculovirus, neither replicates nor integrates into the host genome and is 
capable of transducing with high efficiency. Baculovirus can transduce adipose-
derived mesenchymal stem cells (AD-MSC) with 95% efficiency and have shown no 
toxic effect on the cells (Lu et al., 2012). Finally, AAV is one of the most promising 
viral vectors due to its non-pathogenic feature to humans and results in long-term gene 
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expression. However, a large fraction of the human population have neutralizing 
antibodies against AAV, which significantly reduces their potential use in in vivo 
application (Nayak and Herzog, 2010). 
Komarova and coworkers (2010) studied the feasibility of enhancing MSC tumour 
targeting by expressing an artificial tumour-binding receptor on the MSC surface using 
viral transduction approach. To test this, genetically modified adenoviral vectors 
encoding an artificial receptor (MSC-AR) were used to transduce human MSC, 
generating cells expressing an artificial receptor that binds to erbB2, a tumour cell 
marker. MSC-AR properties were tested in vitro in cell binding assays and in vivo 
using two model systems: transient transgenic mice that express human erbB2 in the 
lungs and ovarian xenograft tumour model. The levels of luciferase-labeled MSC in 
erbB2- expressing targeted sites were determined by measuring luciferase activity. The 
result demonstrated the expression of AR enhanced binding of MSC-AR to erbB2-
expressing cells in vitro, and showed an increased retention of MSC-AR in lungs 
expressing erbB2. This result clearly showed targeting abilities of MSC can be 
enhanced by adenoviral-mediated genetic modification to produce artificial receptors, 
thus could increase a number of cell carriers in tumours and enhance efficacy of cell-
based therapy (Komarova et al., 2010). 
The issue related to using viral transduction approaches have been the possibility of 
oncogene activation and the lack of targeted integration.  To overcome this problem, 
Benabdallah and coworkers used zinc finger nuclease (ZFN) to add erythropoietin 
gene (Epo) into the chemokine (C-C motif) receptor-5 gene locus of MSC. Adenovirus 
vectors were utilized to deliver ZFN into MSC, while integrase-defective lentiviral 
vectors were utilized to deliver Epo. The MSC derived from human BM, adipose 
tissue, and umbilical cord blood was transduced with Epo by the ZFN-driven targeted 
gene addition. These cells were injected into the peritoneum of non-obese diabetic 
severe combined immunodeficient interleukin-2Rc null mice, resulting the hematocrit 
levels increased from an average of 49% to more than 60% at day. This study clearly 
demonstrates the potential of site directed insertion compared to the conventional 
random integration using viral vectors (Benabdallah et al., 2010). Moreover, other 
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techniques such as transcription activator-like effector nucleases (TALENS), and 
clustered regularly interspaced short palindromic repeats (CRISPR) can be also used 
for site-directed integration (J. S. Park et al., 2015). 
Despite viral transductions have high efficiency, the major drawback of these vector 
has been the high production cost and adverse immune reactions. Some viral vectors 
have limitations in the packaging capacity of exogenous DNA and the possibility of 
oncogene activation (J. S. Park et al., 2015). Therefore, non-viral vectors have been 
an alternative option which offer versatility in design choices and scale-up 
manufacturing. In addition, they are low in immune stimulation and also favorable for 
short term protein expression in therapy, which requires only a transient expression. 
However, the main issue with these techniques so far is MSC are difficult to transfect 
without affecting their viability, resulting in very low efficiencies (J. S. Park et al., 
2015; Kaestner et al., 2015).  
Current methods used to transfect MSC can be classified into chemical methods and 
physical methods. Lipid agents, polymeric carriers, dendrimers, and inorganic 
nanoparticles are common chemical methods used to transfect variety of cell types. 
However, lipid and polymeric agents typically can transfect 2–35% of MSC (Santos 
et al., 2011). The conventional cationic liposome method was not effective for MSC 
transfection as it resulted in very low transfection efficiency even close to 0 % (Mun 
et al., 2016). In contrast, recent report also indicated 95-100% transfection rate when 
human AD-MSC transfected using Lipofectamine 2000® transfection reagent (Mirzaei 
et al., 2018). 
Dendrimers have demonstrated great success in transfecting a wide variety of cell 
types but not MSC, particularly resulting lower transfection efficiency at 10-17% 
(Gheisari et al., 2008) Inorganic nanoparticles such as gold nanoparticles (AuNPs) 
have emerged as attractive nonviral gene vectors due to their ease of synthesis, tunable 
size and shape, flexible surface modification, and tunable optical and electronic 
properties. Gold nanoparticles designed with Jet-poly(ethylenimine) (PEI) reagent can 
condense DNA on the surface to achieve a 2.5-fold increase in transfection efficiency 
over conventional Jet-PEI polyplexes (Uchimura et al., 2007). 
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Recent report by Peng and coworkers (2016) demonstrated the synthesis of 
antimicrobial peptide conjugated cationic gold nanoparticle as highly efficient carriers 
for gene delivery to MSC with antibacterial ability. The gold-peptide complexes 
combine the advantages of cationic gold and antibacterial peptides: the presence of 
cationic can effectively condense DNA and the antimicrobial peptides are important 
for the cellular & nucleus entry enhancement to achieve high transfection efficiency 
and antibacterial ability. The study showed the gene transfection efficiency in rat MSC 
was strongly improved by using the gold-peptide complexes, showing highest 
transfection ability when the peptide content was about 2.5% of the gold nanoparticles. 
While the gold/pDNA without peptide complexes also showed strong gene 
transfection ability, lead to about 1/3 luciferase expression of that expressed by gold-
peptide/pDNA complexes. This result showed promising nanoparticle-peptide 
conjugation as non-viral gene vectors for MSC-based therapy and antibacterial 
abilities in clinic(Peng et al., 2016). 
Physical transfection approaches include electroporation and nucleofection (J. S. Park 
et al., 2015). Although these methods offer high transfection efficiency, the main 
obstacles have been the significant cell death (~40%) if not handled properly (Aslan 
et al., 2006). Electroporation uses an electrical pulse to transiently open the pores of 
the cells, allowing the nucleic acid to enter the cytoplasm. Nucleofection also uses 
electrical pulse but the nucleic acid is directly introduced into the nucleus of cells. 
Other physical approach such as sonoporation uses mechanical vibration to increase 
the transport of nucleic acid into the cells by enhancing the permeability of the cell 
membrane (J. S. Park et al., 2015).  
 
1.5.4 Mesenchymal stem cells as drug and nanoparticle carrier 
MSC have been regarded as a potential approach for drug and gene delivery. These 
recombinant MSC act as cell vehicles to carry various genes and drugs to divergent 
organs for therapy, owing to the high affinity of the injury or tumour sites and 
migration ability. Bonomi and coworkers (2015) investigated MSC isolated from the 
amniotic membrane of human term placenta (hAMSC) as candidates for drug delivery 
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in vitro. They primed hAMSC with paclitaxel (PTX) and investigated their ability to 
resist the cytotoxic effects of PTX, to upload the drug, and to release it for up to 120 
hours when co-culturing with human ductal pancreatic adenocarcinoma cell lines. The 
result showed hAMSC are highly resistant to the cytotoxicity of PTX loading even at 
highest dosage of 10µg/ml, suggesting potential use of placental MSC as vehicles for 
delivery of cytotoxic agents (Bonomi et al., 2015).  
The idea of using MSC for delivering chemotherapeutics as an alternative option for 
therapy was also reported by Pessina and coworkers (2013), who demonstrated both 
in vitro and in vivo study, where PTX loaded MSC further attract and kill leukemia 
cells, inhibit angiogenesis and tumour growth (Pessina et al., 2013). In recent report, 
Coccè and coworkers (2017) studied MSC isolated and expanded from gingival papilla 
(GinPa-MSC). These cells were studied for their ability to uptake and release three 
antineoplastic drugs: PTX, Doxorubicin (DOX) and Gemcitabine (GCB). The result 
indicated that GinPa-MSC efficiently uptake the drugs and then released them in active 
form and in sufficient amount to promote a dramatic inhibition of squamous cell 
carcinoma growth in vitro (Coccè et al., 2017). 
Beside the promising use as a vehicle for anti-tumour drugs, MSC also can uptake drug 
loaded and diagnostic nanoparticles to specific target sites. Drug-loaded nanoparticles 
can be uptake through endocytosis pathways by cells as intracellular drug stores and 
maintain sustained release, thus decreasing anticancer-drug cytotoxicity and 
chemotherapeutic loss by rapid drug efflux (Wu et al., 2019). Due to the tumour 
tropism of MSC, drug-conjugated nanoparticles loaded MSC were localized in the 
tumour tissues like prostate cancer tissue (Levy et al., 2016), lung (Sadhukha et al., 
2014; Zhao et al., 2017), and glioma tissue (Pacioni et al., 2015; Wang et al., 2018). 
Wang and coworkers (2018) utilized MSC as lung cancer-targeted drug delivery 
vehicles by loading nanoparticles (NP) with anti-cancer drug.  IR-780 dye, a 
fluorescent probe was used to represent docetaxel (DTX) in NP, delivered via MSC 
accumulated in the lung. The study demonstrated both in vitro MSC/A549 cell 
experiments and in vivo MSC/lung cancer experiments showing the intercellular 
transportation of NP between MSC and cancer cells, suggesting exocytosis-
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endocytosis process between both cells. Moreover, in vivo experiments indicated that 
the MSC/NP/DTX drug delivery system resulted in primary tumour inhibition 
efficiency similar to that of a NP/DTX drug system, suggesting a promising lung-
targeted drug delivery for the treatment of lung cancer. 
Duchi and coworkers (2013) investigated the combination of photodynamic therapy, 
nanoparticles and MSC in killing osteosarcoma in vitro. Fluorescent core-shell PMMA 
nanoparticles (FNPs) were post-loaded with a photosensitizer, namely meso-tetrakis 
(4-sulfonatophenyl) porphyrin (TPPS) and loaded into MSC. The result showed the 
incorporation of TPPS@FNPs into MSC is nontoxic until an external photoactivation 
is applied. The result also indicated TPPS@FNPs were internalized through 
endocytosis mechanism with no significant motility alteration. It was observed that 
upon the first light irradiation MSC undergo cell death, while the TPPS@FNPs 
continue to be available at the diseased site for successive irradiations, suggesting a 
very promising use of MSC as nanoparticle carrier and therapeutic agent. (Duchi et 
al., 2013). 
Other nanoparticles that have been extensively studied for photothermal cancer 
therapy is gold nanoparticles (AuNPs) due to their ability to generate heat upon near-
infrared irradiation. Kang and coworkers (2015) demonstrated that MSC can aggregate 
pH-sensitive gold nanoparticles (PSAuNPs) in mildly acidic endosomes of target 
tumours, and be used for photothermal therapy. These aggregated structures had a 
higher cellular retention in comparison to pH-insensitive, control AuNPs (cAuNPs). 
When PSAuNP-laden MSC (MSC-PSAuNPs) injected intravenously to tumour-
bearing mice, the tumour-targeting efficiency was improved, resulting a 37-fold higher 
tumour-targeting efficiency (5.6% of the injected dose). Moreover, when laser 
radiation was applied, elevated temperature at 8.3 °C higher than control was observed, 
suggesting a significantly improved anticancer effect (Kang et al., 2015). 
MSC can also serve as cellular vehicles for delivery of nanoparticles to brain tumours 
due to the difficulty of delivering therapeutic agents to tumour and to the infiltrating 
tumour cells. To test this, Roger and coworkers (2010) investigated two types of NPs 
loaded with coumarin-6: poly-lactic acid NPs (PLA-NPs) and lipid nanocapsules 
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(LNCs). Both PLA-NPs and LNCs provide considerable drug encapsulation capacity 
and also manifest sustained release functions at the site of action. These NPs were 
loaded into a unique subpopulation of human MSC named “marrow-isolated adult 
multilineage inducible” (MIAMI) cells. The results of study indicated that these NPs 
can be efficiently internalized into MSC with no significant effect on cell viability and 
differentiation. Furthermore, these NP-loaded cells were able to migrate toward an 
experimental human glioma model, suggesting a potential approach of MSC-based 
cellular carriers for NPs in brain tumours (Roger et al., 2010). 
Magnetic resonance (MR) contrast agents are valuable tools in the diagnostic 
evaluation and follow-up of managed treatment. Recently, superparamagnetic iron 
oxide nanoparticles (SPION) are being used as contrast agent for intracellular 
magnetic labeling of stem cells and variety of cells types in order to monitor cell 
trafficking by magnetic resonance imaging (MRI) as part of cell-based therapy (Frank 
et al., 2004). Boutry and coworkers (2008) investigated the influence of MNP 
incubation concentration on MSC and fibroblasts cells in culture. Cells were incubated 
for 48h with increasing iron concentrations of SPION (25–1000mg Fe/ml Endorem®). 
The study demonstrated that intracellular iron content increased as a function of the 
iron concentration in the incubation medium, suggesting the cells labeling with SPION 
was found to be dose-dependent uptake. The study also showed higher uptake capacity 
of the MSC as compared with an established fibroblast cell line.  Even more 
interesting, efficient magnetic labeling with commercially available 
superparamagnetic MRI contrast agents was simply done by mixing the magnetic 
nanoparticle to the cell culture medium, resulting no significant effect in cell viability 
(Boutry et al., 2008). 
Other report also investigated the tracking of MSC with SPION-loaded Poly (lactide-
co-glycolide) microparticles for MRI. The study demonstrated internalization of 
SPION (10 nm) loaded biodegradable poly(lactide-co-glycolide) microparticles in 
MSC increases magnetic resonance parameters such as the r2 relaxivity (5-fold), 
residence time inside the cells (3- fold) and R2 signal (2-fold) compared to SPION 
alone. Both in vitro and in vivo experiments also showed no significant effect on cell 
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properties such as viability, proliferation, migration and their ability to home to sites 
of inflammation, suggesting a promising opportunity for longitudinal tracking of MSC 
without compromising cell phenotype including cell migration/homing ability 
(Kultima et al., 2012). 
The SPION-labelled MSC or MNP-labelled MSC can also be used for magnetic 
targeting as reported by Riegler and coworkers (2012) who investigated MSC labelled 
with FluidMAG-D SPION for vascular injury therapy. The study indicated that 
magnetic targeting of MSC gives rise to a 6-fold increase in cell retention following 
balloon angioplasty, which reduced restenosis three weeks after cell delivery in a 
rabbit model using a clinically applicable permanent magnet. No negative effects on 
cell viability, differentiation or secretion patterns was also noticed on FluidMAG-D 
SPION labelled MSC (Riegler et al., 2013).  
More advanced approach was also reported by Yin and coworkers (2016) who 
proposed dual purpose of delivering and activating a heat-inducible gene vector that 
encodes TNF-related apoptosis-inducing ligand (TRAIL) in adipose-derived 
mesenchymal stem cells (AD-MSC), providing an attractive approach to enhance the 
control over the activation of stem cell-based gene therapies. The study indicated a 
decrease in ovarian cell viability due to the mild magnetic hyperthermia-activated 
secretion of TRAIL from the engineered AD-MSC as determined by significant 
activation of caspases in vitro. Whereas, in vivo experiments showed when engineered 
AD-MSC were delivered into a metastatic ovarian cancer mouse model and magnetic 
hyperthermia was applied, AD-MSC were found to secrete TRAIL, which 
significantly decrease tumour volume compared to controls over a two-week period 
(Yin et al., 2016).  
 
1.5.5 MSC as double-edged sword in tumour growth.  
Despite promising use of MSC-based therapy to target tumour, the exact role of MSC 
in tumour progression is still unknown. Studies have shown that MSC are involved in 
tumour growth and metastasis, while others indicate the inhibitory effect of MSC on 
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growth of tumours such as hepatoma and leukemia, suggesting MSC migrate towards 
tumour microenvironment and are involved in both pro-tumourigenic and 
antitumourigenic functions (Ramasamy et al., 2007; Qiao et al., 2008; Norozi et al., 
2016). Norozi and coworkers (2016) explained these dual functions of MSC as double-
edge sword since they can be regarded both as friends or enemies in suppression or 
progression of solid tumour cells.  It is believed MSC behavior at tumour sites is 
dependent upon a variety of factors, including the type and origin of MSC, the cancer 
cell line under study, in vivo or in vitro conditions, the factors secreted by MSC and 
interactions between MSC, host immune cells and cancer cells (Norozi et al., 2016). 
In regard to MSC function in tumour, they seem to be capable of immunosuppressive 
and immunomodulatory (Niess et al., 2016). They are capable of modulating their 
local tissue environment through direct cell-cell contacts or through secretion of 
different immune-related molecules in order to repair or regenerate tissue. While 
suppression of immune response by MSC may facilitate tissue remodeling and repair, 
however this may be risky in progression of cancer (Kuhn and Tuan, 2010). 
Tumour stroma, also known as the tumour microenvironment that surrounds 
expanding cancer cells with immediate contact is believed to mainly function as a pool 
of surrounded and recruited “normal” cells that then become manipulated by cancer 
cells to support the formation of an organ-like macroscopic tumour (Hanahan and 
Coussens, 2012). These cells can be categorized as infiltrating immune cells, cancer-
associated fibroblasts (CAFs), and angiogenic vascular cells (AVCs; endothelial cells 
and pericytes) (Tlsty and Coussens, 2006). Both experimental and clinical studies have 
indicated supporting evidence that MSC contribute to the cancer stroma. Expanding 
tumours persistently alter their surrounding tissue causing an inflammatory response, 
suggesting tumours behave in the body like wounds (Dvorak, 1986). 
Cuiffo and Karnoub classified four categories by which MSC within the tumour stroma 
may influence tumour growth (Cuiffo and Karnoub, 2012) : 1) through direct actions 
on tumour cells: 2) through indirect effects; such as the enhancement of angiogenesis; 
3) through their immunosuppressive properties; and 4) as progenitors for tumour 
stromal cells.  
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In regard to MSC direct action, they seem to be capable of releasing chemokines, 
cytokines, and growth factors on cancer cells, which aid tumour proliferation, 
invasion, and metastasis. Studies have shown MSC-derived CXCL1/2 and 
CXCL12/SDF-1 can enhance cancer cell proliferation through signaling on their 
respective CXCR2 and CXCR4 receptors expressed by cancer cells (Rhodes et al., 
2010; Halpern et al., 2011). Other reports also have shown that IL-6 and IL-8 released 
by MSC enhance malignancy in breast and colorectal cancer models (Liu et al., 2011; 
Tsai et al., 2011), and epidermal growth factor (EGF) secreted by MSC enhances 
tumourigenesis in a breast cancer model (Yan et al., 2012). Whereas, though their 
indirect effect, MSC within the tumour stroma could promote tumour growth by 
promoting process of tumour angiogenesis, in particular, by recruitment of endothelial 
progenitor cells and by enabling the formation and maturation of tumour vasculature 
(Koike et al., 2004; Au et al., 2008). 
MSC could defend tumour cells from both adaptive and innate immune systems, 
suggesting their immunomodulatory function within tumour stroma. Despite not 
necessarily based on cancer models, it has been proven that MSC are capable of 
participating in the major key immune activities involved in the process of tumour 
formation (Cuiffo and Karnoub, 2012). Furthermore, MSC may also involve in the 
tumour microenvironment by providing a cell pool and molecules which may result 
the differentiation of MSC toward a more specialized stromal cells. Studies have 
shown that the transdifferentiation of MSC to CAFs and myofibroblasts, which aid 
tumour growth, was indicated after signaling from tumour-conditioned medium 
(Mishra et al., 2008), tumour-derived exosomes (Cho et al., 2012), and xenografts 
from breast, pancreatic, and ovarian cancers (Spaeth et al., 2009) as well as prostate 
cancer (Jung et al., 2013). 
On the other hand, the inhibitory effect of MSC on tumour may involve decreased 
activity of signaling pathway of AKT, Wnt/β-catenin, Bcl-2, c-Myc, proliferating cell 
nuclear antigen and surviving, which result in decreased proliferation, G1 arrest, 
suppression of oncogenes, and increased apoptosis (Ramasamy et al., 2007; Gao et al., 
2015). Cousin and coworkers (2009) studied the effect of human stromal cells derived 
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from adipose tissue (ADSC) on pancreatic tumour cell (PDAC) proliferation. The 
study demonstrated that co-culture of pancreatic tumour cells with ADSC and ADSC-
conditioned medium sampled from different donors inhibited cancer cell viability and 
proliferation. ADSC-mediated inhibitory effect was further conducted to other 
epithelial cancer-derived cell lines (liver, colon, prostate), resulted in induced cancer 
cell necrosis following G1-phase arrest in vitro. Moreover, a single intra-tumoural 
injection of ADSC in a model of pancreatic adenocarcinoma also resulted in a 
significant inhibition of tumour growth. It was believed that the anti-proliferative 
effect of ADSC on pancreatic cancer cells may be mediated at least in part by a 
secreted molecules which could alter cell cycle progression, and the capability of 
ADSC to modify the microenvironment of the tumour and thus inhibit its proliferation 
(Cousin et al., 2009). 
Despite the main reason behind the duality behavior of MSC function against tumours 
is not well understood, it may be dependent upon several factors, including large 
variety of cytokines, growth factors produced by MSC, type of cancer cell line tested, 
and the type and source of MSC (Norozi et al., 2016). Akimoto and coworkers (2013) 
investigated anticancer therapeutic application of MSC from two different MSC 
sources: umbilical cord blood-derived MSC (UCB-MSC) and adipose-tissue-derived 
MSC (AD-MSC). They found that UCB-MSC inhibited primary brain tumour growth 
and caused apoptosis through secretion of tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL), whereas AD-MSC promoted tumour growth. The opposite 
effects of AD-MSC was believed due to higher CXCL12 expression on AD-MSC 
which might act as antiapoptotic factor inhibiting the TRAIL pathway. The result of 
this study clearly demonstrate that differences of MSC source must be evaluated when 




1.6 MAGNETIC HYPERTHERMIA 
1.6.1 Magnetic nanoparticle-mediated Hyperthermia  
Hyperthermia therapy (HT) is defined as a therapeutic treatment of diseases in which 
tissues are heated above normal physiological ranges. It has been an 
established alternative therapy for cancer treatment, in part due to the likelihood 
that its application could result in fewer side effects than standard chemotherapy or 
radiotherapy. Depending on the degree of cellular damage induced, hyperthermia 
treatment can be classified into two different ranges. In conditions of moderate 
temperature increases (41-46°C), the treatment may alter the functionality of 
intercellular proteins, leading to cellular degradation and apoptosis (Sellins et al., 
1991; Deatsch and Evans, 2014). In thermoablation, hyperthermia treatment at 
temperatures greater than 46°C results in direct cell death, tissue necrosis, coagulation 
or carbonization (Kumar and Mohammad, 2011) 
In clinical application for cancer therapy HT can be classified into three categories: 
local, regional and whole-body hyperthermia (van der Zee, 2002). In general, local 
hyperthermia can be induced with external or internal energy sources which are used 
to increase tumour temperatures as high as possible, as long as the tolerance limits of 
the surrounding normal tissues are not exceeded. For larger areas of treatment or for 
deeper tissues, regional hyperthermia is commonly used by perfusion of organs or 
limbs with heated blood or heater fluids for a defined duration to obtain therapeutic 
effects. Whole body hyperthermia is typically used to treat metastatic disease.  The use 
of a flexible infra-red chamber or simply wrapping the patient in heated blankets are 
the most common examples in whole-body hyperthermia (van der Zee, 2002). 
Despite the promise of HT in the clinical setting, a major drawback with conventional 
HT application is the difficulty of controlling the desired temperature at the local 
tumour region without damaging adjacent normal tissue. Indeed, although raising the 
normal physiological temperature can kill a great number of tumour cells normal 
tissues are also affected under these conventional hyperthermia treatments. To 
overcome this problem, the development of novel hyperthermia systems such as the 
use of Magnetic nanoparticle-mediated hyperthermia (MNHT) has advanced and 
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attracted attention for medical applications (Ito et al., 2005). The concept of MNHT is 
the conversion of dissipated magnetic energy into thermal energy under an oscillating 
magnetic field. This approach was first proposed in 1957 by Gilchrist et al. in a study 
investigating the application of magnetic materials for hyperthermia treatment of 
cancer (Gilchrist et al., 1957). Since then this concept has advanced into a well-
researched field due to the introduction of MNP. Principally, the MNHT approach 
relies on the ability of MNP to transform electromagnetic energy into heat which 
results in an increase of temperature in well-defined regions of the human body where 
tumour cells and exogenous nanoparticles are located. Therefore, MNP can be 
controlled remotely from outside of the body by applying or removing an oscillating 
magnetic field. The electromagnetic radiation used in magnetic hyperthermia is in the 
range of radio-frequency (between several kHz and 1 MHz) which is non-toxic and 
gives sufficient penetration depth to access inner organs in the body (Bañobre-López 
et al., 2013). 
In a review by Kumar and Mohammad (2011), MNHT treatment was stated as having 
a number of advantages compared to the conventional HT. These are: 1) MNP can be 
taken up by tumour cells thus improving the effectiveness of hyperthermia by 
delivering therapeutic heat directly to them, 2) the use of the frequencies of oscillating 
magnetic fields to pass through the body are non-invasive and produce heat selectively 
only in tissues where MNP are located(Rand et al., 1985); MNP can also effectively 
cross blood-brain barrier (BBB), thus can be used for treating brain tumours (Liu et 
al., 2010); 4) MNHT treatment may also induce antitumoural immunity (Kobayashi et 
al., 2014); 5) The heating can be stimulated at cellular levels effectively through 
alternating magnetic field (AMF), 6) MNP could be administered through a number of 
drug delivery routes, and importantly 7) MNHT can also be utilized for controlled 
delivery of drugs which opens up possibilities for the cancer theranostic approaches 




1.6.2 Mechanisms of action of hyperthermia  
Despite the exact mechanism of direct HT-induced cell death being not well 
understood, the thermal energy required for induction of cell death is likely to be close 
to the energy needed for protein denaturation or inactivation, leading to membrane 
alteration and cytoskeletal damage. Protein denaturation can also have an effect in the 
alteration of DNA synthesis and repair (Hervault and Thanh, 2014).  
It is known that cancer cells are more susceptible to increases in temperature than the 
surrounding normal cells, in part explained by the higher sensitivity to heat for cells in 
the mitosis phase of the cell cycle (Hildebrandt et al., 2002; Lepock, 2003). In vivo 
studies have also shown that temperatures in the range of 40–44°C cause more 
selective damage to tumour cells (van der Zee, 2002). This may be related to basic 
physiological differences between cancerous and normal tissue vasculature. Due the 
fast proliferation of tumour cells, the architecture of the vasculature in growing 
tumours is disorganised and abnormal compared to normal tissue vasculature. Owing 
to these structural differences, when hyperthermia is applied at temperatures over 
42°C, tumour blood flow is likely to be decreased while in normal tissue it significantly 
increases. As a consequence, the slower blood flow in tumour leads to a lower heat 
dissipation rate, thereby further increasing the local intratumoural temperature 
whereas in normal tissue increased blood flow would act to maintain a lower 
temperature. Moreover, the abnormal structure of vasculature also results in poor 
tumour perfusion, resulting in oxygen and nutrient deprivation which are even more 
favored with the reduction of the blood flow caused by HT (Hildebrandt et al., 2002; 
Hervault and Thanh, 2014). 
In addition to direct cell killing effects, HT also affects cell shape and induces changes 
in the cellular environment. Cellular membrane becomes more fluidic and less stable, 
preventing the function of transmembrane transport proteins, cell surface receptor and 
cell attachment. Elevated fluidity of cell membranes occurs in thermosensitive, but not 
thermotolerant cells (Calderwood and Hahn, 1983; Konings and Ruifrok, 1985; Majda 
et al., 1994). Cells exposed to HT treatment also show membrane blebbing, a 
distinctive feature of apoptosis-mediated programmed cell death. Moreover, although 
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not directly related to hyperthermia cell death but a reflection of altered cell 
physiology, several reports have shown changes in membrane potential, elevated 
intracellular sodium and calcium content, and increasing potassium-efflux under 
hyperthermia conditions (Hildebrandt et al., 2002).  
Disruption of the cell cytoskeleton is also likely to be important in HT induced cell 
injury (Pawlik et al., 2013). The cytoskeleton orchestrates many cell functions, such 
as cell division, macromolecules transport, protein synthesis regulation and 
intracellular organelles distribution and anchoring. HT exposure reduces the number 
of actin stress fibers, alters microtubule assembly leading to a looser meshwork and 
collapses vimentin filaments into perinuclear complexes. Subsequent mitotic 
catastrophe occurs likely leading to  apoptosis (Pawlik et al., 2013).  
 
1.6.3 Hyperthermia-induced apoptosis 
HT induces cancer cell death through apoptosis, a programmed cellular suicide as a 
homeostatic mechanism to maintain cell populations in tissues (Hildebrandt et al., 
2002). The degree of apoptosis and the apoptotic pathway vary in different cancer cell 
types. Since apoptosis plays a fundamental role in maintaining a proper balance 
between cell survival and cell death, dysregulation of this defense mechanism process 
promotes uncontrolled cellular proliferation and accumulation of genetic defects, 
which ultimately result in tumourigenesis. Chemotherapy- and radiotherapy-induced 
killing of cancer cells is mainly mediated through activation of apoptosis, thus 
impairment of apoptotic pathways can also result in cancer cells developing resistance 
to conventional anti-cancer agents(Plati et al., 2011). 
Apoptosis can be triggered by activation of caspases in two different pathways: the 
intrinsic or mitochondrial pathway and the extrinsic or death receptor pathway, as can 
be seen in Figure 1-10 (Ahmed et al., 2015). Most studies report that HT kills cells 
through activation of the intrinsic apoptotic pathway. Caspase-2 plays an important 
role in cell death by acting on microtubules organisation in this pathway (Ahmed et 
al., 2015). Several reports indicate that caspase-2 forms a complex with its adaptor 
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protein named RAIDD (RIP-associated Ich-1/Ced-3-homologue protein with a death 
domain) immediately after HT treatment. This complex then activates caspase-2 and 
cleaves Bid (BH3 interacting-domain death agonist) which then stimulates 
mitochondrial outer membrane potential (MOMP), cytochrome c release, and 
formation of an Apaf-1-caspase-9 apoptosome (Bonzon et al., 2006; Tu et al., 2006; 
Ho et al., 2008; Bouchier-Hayes et al., 2009). 
With regards to the extrinsic apoptotic pathway, hyperthermia activates an apoptotic 
pathway initiated by specific ligands such as antigen 1 or Fas ligand (Reap et al., 
1997), the cytokine tumour necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL) (Yoo and Lee, 2007), and the TNF-α ligand that plays a major role in binding 
TNFR1 and TNFR2 receptors in the extrinsic apoptotic pathway (Ahmed et al., 2015). 
In the pathway initiated by Fas ligand, Fas can either directly activate downstream 
effector caspases or trigger the mitochondrial apoptosis amplification loop. This 
pathway involves series of activation mechanism orchestrated by caspase-8 result in 
the release of cytochrome c, which binds to Apaf-1 and caspase-9 apoptosome 
complex (Tran et al., 2003). Mild hyperthermia has been shown to enhance TRAIL-
induced cytotoxicity of CX-1 human colorectal cancer cells through the activation of 
caspases-8, -9 and -3 and cytochrome c release from mitochondria (Yoo and Lee, 
2007). The apoptotic signal of TRAIL is transduced by binding to the death receptors 
TRAILR1 (DR4) and TRAILR2 (DR5), which are expressed prevalently on the 
surface of tumour cells more than on the surface of normal cells and thus triggers the 
extrinsic apoptotic signal. This pathway involves caspases-8 and -10 in forming a 
death-inducing signaling complex. Caspase-8 can either activate caspase-3 in 
cooperation with Caspase-10 or participate in the mitochondrial apoptosis pathway 





Figure 1-10: Extrinsic and intrinsic apoptotic pathways triggered by HT. Extrinsic 
apoptotic pathway: HT activates the ligand TRAIL, Fas ligands, and the TNF-α ligand. TRAIL 
binds to death receptor DR4 and DR5, starting the apoptosis signal; as a consequence, the 
surface of FADD is exposed, and forms the death signalling complex with the help of caspase-
8 and caspase-10. Caspase-8 can either activate caspase-3 in cooperation with Caspase-10 
or participate in the mitochondrial apoptosis pathway. Fas could either activate the 
mitochondrial amplification loop (involving caspase-8, Bid and cytochrome c) or the 
downstream caspases. TNF-α binds THFR1 and TNFR2 receptors, inducing apoptosis 
through extrinsic pathway. The repetition of HT favours the down-regulation of the FLIP 
protein, which inhibits caspase-8 and favours the TNFR-mediated apoptosis signalling. 
Intrinsic apoptosis pathway: Caspase-2 acts on microtubules and forms a complex with 
RAIDD. The complex Caspase-2/RAIDD cleaves Bid, creating tBid, which stimulates the 
mitochondrial outer membrane potential (MOMP), cytochrome c release, and the formation 
of Apaf-1-caspase-9 apoptosome. The intrinsic apoptosis signalling could be triggered also 
by the independent pathway which involves Bim. Bim favours the Bax/Bak-independent 
activation of caspase-3 in the absence of MOMP, and it is also destroyed by heat stress, 
together with actin and tubulin. 
Image taken from Ahmed et al. (2015). 
44 
 
1.6.4 Hyperthermia activates heat shock proteins (HSPs) 
Molecular chaperones are needed for a range of major cellular functions including 
recovery from cellular stress. Heat shock proteins (HSPs) are molecular chaperones 
that act as  “stress protein” due the wide range of stimuli able to cause stress induction 
such as heat, oxidative injury, sodium arsenite, heavy metals, amino acid analogues 
and serum deprivation (Fuller et al., 1994). Based on their molecular weight, HSPs 
can be divided into six subfamilies: the large HSPs of 100- 110 kDa, the HSP90 family, 
the HSP70 family, the HSP60 family, the HSP40 family, and small HSPs of 18-30 kDa 
(Jäättelä, 1999). The HSP70 family is the most conserved and widely studied class of 
HSPs. Human cells contain several HSP70 family members including highly stress-
inducible HSP70. The synthesis of stress-inducible HSP70 enhances the ability of 
stressed cells to deal with increased concentrations of unfolded and/or denatured 
proteins under various stress stimuli. Several studies either enhanced or reduced 
expression of HSP70 in a wide range of cell lines have suggested that HSP70 is a 
general survival protein capable to cover a prominent role in cell protection from heat 
as well as maintaining the resistance of most cells to apoptosis and/or necrosis (Fuller 
et al., 1994; Jäättelä, 1999; Kaur et al., 2000).  
HT is known to induce HSPs. Since the expression of HSPs protects cells from heat-
induced apoptosis, HSP expression is considered to be a critical factor in HT treatment. 
A connection between HSP-expression and hyperthermia came from a study 
investigating a stress-inducible form of HSP-70/72 that is expressed on the surface of 
cultured cells. The study suggested that HSP 70/72 was expressed either constitutively 
or heat-induced, and, is likely capable to stimulate an MHC-independent tumour cell-
lysis, probably acting as foreign antigens by themselves and activating the immune 
response against tumour cells (Multhoff et al., 1997, 1999; Botzler et al., 1998). 
Impaired tumour immune responses could be due to poorly immunogenic tumour cells 
with insufficient concentrations of intracellular HSP–peptide complexes. Previous 
reports have demonstrated the importance of HSPs in immune reactions, including 
HSP70, HSP90 and gp96, and suggested that HSPs chaperon tumour antigens (Udono 
and Srivastava, 1993; Srivastava et al., 1994; Vanaja et al., 2000; Castelli et al., 2001). 
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It was suggested that the antitumour activity of MNHT may consist of two possible 
mechanism: a direct killing effect by hyperthermia and an indirect, immune-mediated 
antitumour effect. In the latter case, MNHT increases immunogenicity during 
hyperthermia treatment which also improve the therapeutic outcome when combined 
with immunotherapy or chemotherapy. MNHT stimulates antigen presentation via the 
expression of intracellular HSP70-–peptide complexes as well as enhance function of 
the endogenous antigen-processing machinery and increases density of MHC class I–
peptide complexes at cell surfaces (Ito et al., 2001; Ito, Shinkai, et al., 2003; Kobayashi 
et al., 2014). 
 
1.6.5 Hyperthermia stimulates production of reactive oxygen species 
Reactive oxygen species (ROS) are a by-product of oxygen metabolism in the cell 
respiration system. In conditions of oxidative stress ROS levels are elevated as a 
consequence of an imbalance between the production of ROS and the available 
neutralizing antioxidants. ROS such as superoxide and hydrogen peroxide (H202) are 
produced at low levels during normal cellular metabolism and play important roles in 
both physiological and pathological processes (Boveris and Chance, 1973). ROS are 
involved in regulation of cell death through various stimuli. It has been known that 
high levels of oxidative stress can kill tumour cells or at least prevent tumour growth. 
Therefore several studies have focused on increasing the formation of ROS under HT 
treatment and enhance tumour cell death (El-Orabi et al., 2011; Franke et al., 2013; 
Hou et al., 2014; Fu et al., 2017; Yang et al., 2018). Recent reports investigating the 
HT application in human osteosarcoma (U-2 OS) cells showed that HT exposure at 43 
°C for 60 min was able to induce apoptosis by triggering mitochondrial dysfunction, 
ROS accumulation, and caspase activation (Hou et al., 2014). In vivo and in vitro HT 
induced radiosensitization in breast cancer stem-like cells (CSCs) and pancreatic CSCs 
was associated with increased intracellular ROS level in CSCs, which suggests a new 
approach for improving CSCs radiosensitivity (Fu et al., 2017). 
Recently MNHT was shown to efficiently induce higher ROS production when 
compared to conventional HT (extrinsic HT), leading to enhanced pancreatic cancer 
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cell death (Ludwig et al., 2017). This study also demonstrated that increasing levels of 
ROS with increasing temperatures correlated well with the induction of apoptosis. 
Interestingly, the exposure of cells to bare MNP also increased formation of ROS 
which potentially could be a consequence of partial degradation of internalized MNP 
in endolysosomes. Besides being more efficient in increasing ROS production, MNHT 
exposure may also significantly reduce the expression of the proliferation markers Ki-
67, TOP2A, and TPX2 compared to extrinsic HT (Ludwig et al., 2017). 
 
1.6.6 Basic physic of magnetic hyperthermia 
Brownian-Néel relaxation and hysteresis losses are two main mechanism responsible 
for heat dissipation from magnetic nanoparticles in MNHT (Rosensweig, 2002; Suto 
et al., 2009; Carrey et al., 2011). Hysteresis losses are observed in multidomain MNP, 
whereas Brownian-Néel relaxation mainly occurs in single domain nanoparticles such 
as superparamagnetic nanoparticles. The Brownian-Néel relaxation mechanism is 
accomplished by rotating the magnetic moment of each particle against an energy 
barrier. In case the rotation results in the wholesale rotation of the particle itself, then 
the particle has gone through Brownian relaxation and thermal energy is promoted 
through shear stress in the surrounding fluid. On the other hand, if the moment rotates 
while the particle itself remains fixed, then the particle has undergone Néel relaxation 
and thermal energy is dissipated by the rearrangement of atomic dipole moments inside 
the crystal as can be seen in Figure 1-11 (Deatsch and Evans, 2014; Das et al., 2019). 
The Néel (τN) and Brownian (τB) relaxation times are given by the following 















where τ, τ0, K, VM,k,T, ɳ, and VH are the effective relaxation time, the characteristic 
flipping frequency, the magnetic anisotropy constant, the volume of the nanoparticle, 
the Boltzmann constant, the temperature, the viscosity of the fluid, and the 
hydrodynamic volume of nanoparticles, respectively.  
 
Figure 1-11: Schematic illustration of heat dissipation models in a magnetic 
nanoparticle in response to the alternating magnetic field.  The short straight 
arrows represent the magnetic moment direction, the curved arrows represent the movement 
or change in direction, and the dash lines represent the domain boundaries in multi-domain 
particles. In Néel rotation model, the magnetic moment rotates while the particle remains 
fixed, whereas in Brownian rotation, the magnetic moment remains fixed with respect to the 
crystalline axes while the particle rotates. Image taken from Suriyanto et al. (2017). 
 
The equations above demonstrate that the Néel relaxation time highly depends on the 
MNP size, whereas the Brownian relaxation time also depends on the hydrodynamic 
size of nanoparticle as well as strongly depends on the viscosity of the fluid. For this 
reason, smaller MNP will provide more effective intracellular hyperthermia due to less 
energy required for rotation of magnetic moments and low restriction of nanoparticles 
rotation in cellular environments of high viscosity (Das et al., 2019). It was proposed 
that the ideal nanoparticle size to optimize the balance between Néel and Brownian 
contribution to thermal losses for maghemite nanoparticles should be around 15 nm 




When MNP exposed to external AMF, the heat dissipation occurs and is given by the 
following equation (Rosensweig, 2002; Suto et al., 2009): 
4)		P = 	µ0χ״fH
2 
where P, µ0, χ״, f, and H are the values of heat dissipation, the permeability of free 
space or the magnetic field constant, the magnetic susceptibility, the frequency of the 
applied magnetic field, and the strength of the applied magnetic field, respectively. 
This equation explains that the MNP under AMF produce heat because of delay in the 
relaxation of the magnetic moment under an external AMF with a time lapse required 
for magnetic reversal lower than relaxation times of nanoparticles. The equation also 
indicates that heat dissipation value depends on the frequency and amplitude of the 
applied magnetic field as well as the magnetic properties of nanoparticles.  
The generated heat by AMF and its quantity from AMF are measured using SAR, also 
referred to as specific loss power (SLP), which is the amount of electromagnetic 
energy power absorbed per unit and mass (Suto et al., 2009). SAR is described as the 
ability to produce heat through magnetic connection between the magnetic field and 
moments of MNP. Different types of MNP demonstrate varied heating mechanisms. 
The generated heat by such mechanisms are dependent on the intrinsic and extrinsic 
characteristics of MNP such as particle shape, particle size, types of coating material 
and surface functionalization, as well as AMF parameters, such as frequency and 
amplitude (Hedayatnasab et al., 2017; Das et al., 2019). The SAR value of 
nanoparticles in solution is calculated by using the following equation (Mornet et al., 
2004): 






where C is the specific heat capacity of the solvent, dT/dt is the initial slope of the 
time-dependent heating curve, ms is the mass of the solvent, and mm is the mass of 
magnetic nanoparticles. Ideally, MNP capable of generating high SAR values are 
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desired for effective clinical application of MNHT as they allow using a lower dosage 
of nanoparticle solutions (Das et al., 2019). 
 
1.6.7 Types of magnetism 
Understanding the behavior of magnetic nanomaterial is important to design optimal 
MNP for MNHT. Magnetism originates from the orbital and spin motions of electrons. 
The intensity of the interaction among them generated different magnetism strength, 
thus based on the arrangement of magnetic dipoles in absence or presence of an 
external magnetic field, nanomaterials are classified into five categories, such as 
diamagnetic, paramagnetic, ferromagnetic, ferrimagnetic and anti-ferromagnetic as 
can be seen in Figure 1-12 (Spaldin, 2003; Jeong et al., 2007). If a material does not 
have magnetic dipoles in the absence of an external field, but generate magnetic dipole 
in opposite direction to the applied field the material is referred to as diamagnetic. 
Diamagnetic materials also exhibit little magnetization. In paramagnetic 
nanomaterials, the materials have randomly oriented dipoles in absence of magnetic 
field, but they can be aligned in the same direction upon interaction with an external 
magnetic field. For a ferromagnetic material, or material with a permanent magnetic 
moment, the magnetic dipoles always exist in the absence and presence of an external 
field. For ferrimagnetic material, some weak magnetic dipoles also exist in antiparallel 
to the neighboring stronger dipoles in absence of magnetic field. In contrast, 
antiferromagnetic material has zero net magnetization and the neighboring dipoles are 
antiparallel and neutralize each other in absence of magnetic field (Jeong et al., 2007; 
Hedayatnasab et al., 2017).The ferromagnetic and ferrimagnetic materials also display 
superparamagnetic behavior above the blocking temperature (TB). The value of TB is 
experimentally determined using SQUID (superconducting quantum interference 
device) measurement by the merging point of the zero-field-cooled (ZFC) and field-
cooled (FC) magnetization curves (Jeong et al., 2007).  
Superparagnetism is a form of magnetism which appears in small ferromagnetic or 
ferrimagnetic nanoparticles. Nanomaterials with superparamagnetic behavior displays 
the magnetization drops to zero when the applied magnetic field is removed, 
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suggesting an external magnetic field is able to magnetize the nanoparticles, similarly 
to a paramagnet. However, their magnetic susceptibility is much larger than that of 
paramagnets. Due to this unique feature, nanomaterials which show 
superparamagnetic behavior are preferred in biomedical application as they can only 
be activated to generate heat by the applying external magnetic field. Due to this 
feature recent work on MNHT has focused more on superparamagnetic nanoparticles. 
These are nanosized particles with single-domain configuration due to the 
energetically instability of domain wall. The use of these particles for hyperthermia 
offers benefits of allowing better dispersion of particles and avoiding the formation of 
particle aggregations, which could lead to serious adverse problems derived from the 
formation of clots in the blood circulation system.  (Lévy et al., 2008; Villanueva et 
al., 2010; Silva et al., 2011; Bañobre-López et al., 2013; Goya et al., 2013; Sato et al., 
2014; Shevtsov et al., 2014; Suriyanto et al., 2017).  
 
 
Figure 1-12: Alignment of the magnetic moment of individual atoms of iron. 
Schematic representation of magnetic dipoles arrangements of different materials such as 
diamagnetic, paramagnetic, ferromagnetic, ferrimagnetic, and antiferromagnetic materials in 




1.6.8 Magnetic hyperthermia for tumour therapy 
The applicability of MNP with adequate heating properties for clinical application or 
in vivo trial is dependent on the evaluation of them in in vitro studies. In this regard, if 
the in vitro results were remarkable, giving sufficient heating capabilities in 
physiological tolerable range, then they would be applied for in vivo trials 
(Hedayatnasab et al., 2017). As can be clearly seen in Figure 1-13, in most in vitro 
studies, MNP in fluid are placed in a micro-centrifuge tube or Petri dish in the center 
of a circular coil (with certain diameter). The sample is then exposed to AMF, and the 
temperature changes over time (dT/dt) throughout the process are measured by a 
thermocouple connected to a data processing system to record the temperature (TH) 
(Khandhar et al., 2012; Chiriac et al., 2015; Liu et al., 2015; Soetaert et al., 2017; 
Zuvin et al., 2019). In general, the MNP and experimental setup are designed to 
achieve desirable TH at between 42 °C and 47 °C, because MNP within this range are 
prone to burn cancerous cells. Overheating may occur and thus causing some 
unwanted effect in healthy cells at over this secure temperature range (Hedayatnasab 
et al., 2017).  
Although it may be preferable to use a high magnetic field strength and frequency in 
order to produce a large amount of heat, however, it may cause side effects on the 
human body. Therefore, the magnetic frequency is generally set between 0.05 and 1.2 
MHz (Rast and Harrison, no date; Suriyanto et al., 2017). Based on an experimental 
study, it was suggested that the usable limit of applying the magnetic field on the 
human body was up to the magnetic field intensity of 35.8 Amp-turns/meter at a 
frequency of 13.56 MHz (Atkinson et al., 1984). However, other experimental result 
also suggests that the acceptable values for the product between the magnetic field 
amplitude and frequency may be two to four times larger than the safety clinical setting 
of of 4.85 x 108A/m/s. This was suggested to enable lower dosage of nanoparticles 




Figure 1-13: Schematic of experimental setup for in vitro magnetic 
hyperthermia application. MNP in fluid are placed in a micro-centrifuge tube or Petri 
dish in the center of a circular coil (with certain diameter). The sample is then exposed to 
AMF, and the temperature changes over time (dT/dt) throughout the process are measured by 
a thermocouple connected to a data processing system to record the temperature (TH). Image 
taken from Hedayatnasab et al. (2017). 
 
Several pre-clinical or in vitro magnetic hyperthermia studies have been performed in 
an attempt to improve the cancer treatment aiming at minimizing the side effects on 
healthy cells. Majeed et al. synthesized silica-coated iron oxide (Fe3O4-SiO2) 
nanoparticles with tunable shell thickness and investigated the effect of surface coating 
on specific absorption rate (SAR) under AMF. They found that the coated Fe3O4 
generate higher temperature than that by uncoated group, suggesting that the silica 
coated MNP can be attributed to extent of increase in Brownian motion. The 
synthesized MNP were also evaluated in vitro by assessing their MNHT effect on L929 
and human cervical cancer cells (HeLa cells) using sulforhodamine-B assay, resulted 
in ∼55% cell death more in cells treated with silica coated MNP under AMF as 
compared to untreated control (Majeed et al., 2014). Similar approach was also tested 
by Rana and coworkers using other type of MNP coating such as cross-linked 
polyaniline to coat superparamagnetic Fe3O4 nanoparticles for MNHT application 
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(Rana et al., 2014). The magnetic material was synthesized by cross-linking of 
polyaniline shell on the surface of carboxyl PEGy- lated Fe3O4 nanoparticles resulting 
in a high SAR of 120 W/g at low concentration due to the high magnetic sensibility 
and colloidal stability, suggesting the polyaniline shell of magnetic nanoparticles 
increased the heat activated toxicity toward fibrosarcoma cancer cell lines after AMF 
application.  
Mondal et al. synthesized MNP coated with biocompatible hydroxyapatite and used 
them as a heat mediator for MNHT for cancer treatment. This MNP effectively killed 
the MG-63 cancer cells at a temperature between 42°C and 47°C after 30 min exposure 
to AMF. Moreover, the synthesized nanoparticles show minimal or no cytotoxic effect 
on cell lines when AMF was not applied. They also investigated the mechanism of cell 
death by transmission electron microscopy (TEM) analysis, which indicated that cell 
degradation and formation of blebs due to the generation of reactive oxygen species 
(ROS) by heat stress (Mondal et al., 2017).  
In order to study the thermal heating effects resulting from Brownian motion and 
hysteresis losses in cellular environment, Makridis et al. (2014) investigated MnFe2O4 
nanoparticles at various concentrations and embedded the MNP in aqueous media of 
varying agar concentration that resemble the cellular environments. The study 
indicated that the heating profile of nanoparticles demonstrated by SLP values was 
significantly decreased compared to water due to the restriction of Brownian relaxation 
in high viscous media. Moreover, application of two subsequent MNHT cycles on 
human osteosarcoma Saos-2 cells incubated with manganese ferrite MNP resulted in 
cytotoxicity effect on Saos-2 osteoblasts cancer cell line (Makridis et al., 2014). 
Recent report in 2018 by Jang et al (2018) showed magnesium doped γ- Fe2O3 as a 
new strong hyperthermia agent which exhibited 100 times higher value of intrinsic loss 
power (ILP) compared to commercial Fe3O4 (Feridex) via controlled distribution and 
concentration of dopant ions in octahedral iron vacancy sites of γ- Fe2O3. Due to this 
high value, they then performed in vitro and in vivo magnetic hyperthermia studies 
using U87 glioblastoma cancer cell lines and Hep3B xenografted animal models, 
which revealed the complete destruction of the tumour via its exceptionally high 
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heating power under a biological safe range of applied magnetic field (Jang et al., 
2018).   
Biomolecule functionalized MNP is advantageous in therapy due to higher selectivity 
and lower cytotoxicity compared to unconjugated nanoparticles. To increase the 
effectiveness of tumour-targeted therapy, Sadhukha and coworkers designed a peptide 
functionalized nanoparticle, which aimed to EFGR-tumour-targeted for magnetic 
hyperthermia of lung cancer. Inhalation delivery of EGFR-targeted MNP were 
performed and it was found that EGFR targeting enhances tumour retention of MNP. 
Moreover, the magnetic hyperthermia experiment resulted in significant inhibition of 
in vivo lung tumour growth in an orthotopic mouse lung tumour model (Sadhukha, 
Wiedmann, et al., 2013). Other biomolecule such as galactose functionalized alginate-
coated iron oxide nanoparticles (Fe3O4@Alg-GA) was also tested for targeted 
hyperthermia therapy by Liao et al. (2015), which showed that approximately 95% 
HepG2 cancer cells were killed by Fe3O4@Alg-GA MNP under AMF due to their 
enhanced cellular uptake via receptor-mediated endocytosis (Liao et al., 2015). Other 
specific MNP uptake mechanism via lysosomes was also observed when synthesized 
glucose functionalized citric acid-coated iron oxide nanoparticles were internalized 
into CT26 colorectal cancer cells, as reported by Wydra and coworkers (2015). These 
cells were then exposed to an AMF to determine the potential to deliver therapy. 
Cellular ROS generation and apoptotic cell death was enhanced with field exposure. 
The nanoparticle coatings inhibit the Fenton-like surface generation of ROS 
suggesting that the cellular ROS measured is attributed to a thermal or mechanical 
effect of the internalized nanoparticles (Wydra et al., 2015).  
In recent times, studies have been focused on the development of innovative 
multimodal therapies to improve the efficiency of cancer treatments, such as 
combining anticancer action of MNHT and drug released under AMF to cancer cells. 
In attempt to design controllable drug released mediated by hyperthermia for cancer 
treatment, Aoyagi research group developed a smart nanofiber composed of a 
temperature-responsive polymer with both cytotoxic drug doxorubicin and MNP for 
enhanced hyperthermic chemotherapy. When the smart nanofiber exposed under 
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AMF, the MNP generate heat to collapse the polymer networks in the nanofiber, 
allowing the release of doxorubicin from the nanofiber into human melanoma cells. 
The result showed cell viability was decreased to 70% following 5 min exposure of 
AMF (Kim et al., 2013). Other similar study investigating double effect of 
hyperthermia and chemotherapy also reported by Kim and coworkers (2015), who 
constructed magnetic micelles consisting of poly(ethylene glycol)-poly(lactide) (PEG-
PLA), iron oxide nanoparticles, and encapsulated anticancer drug doxorubicin into 
hydrophobic PLA of PEG-PLA. At least 78% adenocarcinoma A549 cells cells were 
killed through the double effects of magnetic hyperthermia and rapidly released 
doxorubicin under AMF application (Kim et al., 2015). Therefore, these works have 
shown the potential for combined synergistic effects of chemotherapy and 
hyperthermia. 
 
1.6.9 Clinical trials of magnetic hyperthermia 
The toxicity of MNP is one of important aspect to consider in the clinical trials of 
MNHT. Other aspects such as the safety of any technical equipment must also be 
considered because the AMF generators are electrical appliances that use high voltages 
and currents. Moreover, the safety of insulators which need to be carefully placed with 
a patient’s body, as well as temperature-monitoring systems are also important for the 
safe use of MNHT (Kobayashi, 2011). Studies on mice has shown that the systemic 
administration of magnetite cationic liposomes (90 mg, i.p.) in mice resulted in over 
50% of the magnetite had accumulated in the liver and 3% had accumulated in the 
spleen. However, there was no significant accumulation of magnetite in the liver or 
spleen at 14 days after injection, suggesting that the magnetite had been biodegraded 
by the reticuloendothelial system (Ito et al., 2003). 
In 2005, Johannsen et al. firstly reported clinical application of magnetite-
nanoparticle-mediated hyperthermia in locally recurrent prostate cancer, using the 
sophisticated MFH 300F-type magnetic induction hyperthermia instrument. The core 
diameter of magnetic fluid is 15 nm, with aminosilicane coating. The concentration of 
iron particles is 112 mg/mL.  The nanoparticles were injected transperineally into the 
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prostate of a 67-year-old patient under transrectal ultrasound and fluoroscopy 
guidance. Treatments were performed by using an alternating magnetic field of 100 
kHz, 4.0–5.0 kA/m magnetic field strength, with once a week treatment, 60 min per 
treatment session, continuing 6 times. During the first treatment, the maximum and 
minimum intraprostatic temperatures were 48.5 and 40.0°C. While during the sixth 
treatment, the maximum and minimum intraprostatic temperatures were 42.5 and 
39.4°C during the sixth treatment (Johannsen et al., 2005). 
In 2007, Johannsen and coworkers reported the phase I clinical study of magnetic 
hyperthermia treatment of 10 patients with local recurrence of prostate cancer who had 
received magnetic induction hyperthermia. The result indicated that hyperthermia 
nanoparticles can still be observed in the prostate within 1 year. No systemic toxicity 
was observed for 17.5 months (3–24 months) of the median follow-up. The acute 
urinary retention was found in four patients with a history of urethral stricture. No 
significant treatment-related discomfort was found, the effect on quality of life was 
only temporary. The study concluded that the MNHT treatment of local recurrence of 
prostate cancer is feasible, well tolerated without significant side effects (Johannsen et 
al., 2007). 
In 2007, Maier-Hauff et al. reported a clinical study of intracranial thermotherapy 
using MNP combined with external beam radiotherapy for treatment of 14 patients 
with recurrent glioblastoma multiforme. A 3-dimensional image guided intratumoural 
injection of MNP coated with aminosilane (15 nm; 112 mg/mL) was performed on 
patients. To design the specific treatment program and treatment dose based on the 
MNP distribution and expected heat distribution, data analysis using magnetic 
resonance imaging (MRI) and computed tomography (CT) were performed, then 
instillation of 0.1–0.7 mL (median 0.2 mL) of magnetic fluid per milliliter was injected 
into the tumour tissues. Patients then received 4-10 (median: 6) thermotherapy using 
100 kHz magnetic frequency and 2.5-18 kA/m magnetic field strength of AMF. For 
the external beam radiation, patients without undergoing radiotherapy received 60 Gy 
irradiation and 10 Gy added boost, whereas patients with recurrent tumours received 
20–30 Gy of irradiation. The result of the study indicated that thermotherapy using 
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magnetic nanoparticles was tolerated well by all patients without significant side 
effects. Intratumoural median maximum temperature reached median 44.6°C (42.4°C–
49.5°C), suggesting that deep cranial thermotherapy using magnetic nanoparticles are 
feasible and can be safely applied on glioblastoma multiforme patients to increase the 
therapeutic effect (Maier-Hauff et al., 2007).  
The first study on the autopsy findings of two glioblastoma patients treated with 
MNHT following instillation of MNP was reported in 2009 by Van Landeghem and 
coworkers. Three patients with malignant glioma received local tumour magnetic fluid 
injection. MNHT treatment was applied to two patients, while the other one did not 
undergo the treatment. The autopsy conducted on the patient who died just before 
application of MNHT, which they found a significant decrease in phagocytic activity 
of the infiltrating macrophages compared to the patients receiving complete MNHT. 
The study concluded that the MNHT temperatures between 49.5 °C and 65.6 °C as 
obtained in both patients, result in extended tumour necrosis followed by enhanced 
infiltration of macrophages and subsequent phagocytosis of necrotic debris and 
nanoparticles (van Landeghem et al., 2009). 
One key challenge in MNHT application is how to obtain a homogenous distribution 
of MNP in tumour. To overcome this problem, Wust et al. (2006) conducted magnetic 
fluid magnetic induction hyperthermia treatment for 22 patients with relapsed tumour 
entities in different parts to determine and evaluate the temperature distributions using 
three different implantation methods: infiltration under CT fluoroscopy (group A), 
TRUS (transrectal ultrasound) – guided implantation with X-fluoroscopy (group B) 
and intra-operative infiltration under visual control (group C). 14 patients were in 
group A or B, while 8 patients were treated in group C. The MNP used is aminosilane 
coated superparamagnetic nanoparticle with 15 nm core diameter with 112 mg/mL 
iron particles concentration. The result indicated no discomfort or mild discomfort was 
observed in patients following the instillation of MNP. For the AMF application, the 
magnetic field strength selected was 3.0–6.0 kA/m for the pelvis tumours, 7.5 kA/m 
for neck and chest tumours and >10.0 kA/m for the head. Post-implantation analysis 
after nanofluid infiltration indicated that specific absorption rate (SAR) value was 60–
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380 W/ kg with the tumour coverage of ³ 40 °C distributed in 90 % tumour area in 
Group A) and in 85 % tumour area in Group B. However, the targeted tumour coverage 
of ³ 42 °C unfortunately only distributed in 30% tumour area in Group A and 
significantly less with only 0.2 % tumour area in Group B. Although the targeted 
thermoablation temperature of ³ 46 °C in in the whole target area was not obtained, 
the study indicated the decrease of nanoparticle mass of approximately 10% was 
observed in 100 days, or only 3% heating loss in one month if all other parameters 
remain constant, suggesting MNHT treatment could be potentially used for 
multimodal treatment concepts (Wust et al., 2006).  
In 2007, Matsumine and coworkers reported a clinical study aimed to develop novel 
hyperthermic treatment modality using magnetic materials for metastatic bone 
tumours. The study involved treatment of 16 bone lesions in 15 patients (HT group) 
with metastatic bone tumours. Seven lesions were fixed with intramedullary nailing 
after scraping out, one lesion was conducted with the prosthesis implantation after an 
excision and the remaining eight lesions were fixed by intramedullary nailing for the 
involved bones, and these lesions were filled with calcium phosphate bone cement 
containing Fe3O4 magnetic nanoparticles. The MNHT treatment was conducted at 1 
week after the surgery. Moreover, for comparison purposes with MNHT patients, the 
study also assessed 8 patients (Op group) who did not undergo radiotherapy and 
hyperthermia treatment after surgery and 22 patients (Op + RT group) underwent 
postoperative radiotherapy. The result indicated that there were no significant 
complications in the MNHT group. On radiographs, 87 %, 38 %, and 91% were, 
considered to demonstrate an effective treatment outcome in HT group, Op group, and 
Op + RT group, respectively. The patients in HT group showed a statistically 
significant radiographic outcome than the surgery alone (Op) alone (P = 0.0042), 
whereas no significant differences were found in the postoperative magnetic induction 
hyperthermia group (HT) compared with the postoperative radiotherapy group (Op + 
RT), suggesting the MNHT treatment had a satisfactory local control rate for 
metastatic bone tumour (Matsumine et al., 2007). 
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1.6.10 Magnotosomes for tumour therapy 
Magnetosomes have potential use in MNHT because they provide the most powerful 
source of heat under AMF application due to their ferrimagnetic behavior, cubic shape, 
large structure and thermally stable magnetic moment (Alphandéry et al., 2013). 
Alphandéry and coworkers found that magnotosomes are nontoxic, with rats surviving 
up to a quantity of magnetosomes administered of 480mg per kg of animal. When 
AMF applied to suspensions of magnetosomes, high loss power per cycle of 5–11 
J/kgFe was observed suggesting that the magnetosomes are good candidates for MNHT 
treatments of tumours (Alphandéry et al., 2013). 
In 2011, Alphandéry et al. reported that the chains of magnetosomes extracted from 
AMB-1 magnetotactic bacteria have antitumoural activity. The study investigated the 
cell viability of MDA-MB-231 breast cancer cells in the presence of magnetosomes 
suspension under AMF application of 183 kHz and field strengths of 20, 40, or 60 mT. 
Results revealed that only chains of magnetosomes and not individual separated 
magnetosomes made the tumour fully disappeared after 30 days from treatment. The 
temperature reached during the treatment with chains of magnetosomes was 45 °C - 
46 °C, suggesting that the specific arrangement of chains of magnetosomes likely 
crucial to induce the hyperthermia effect. In addition, the chains also prevent 
agglomerations, and the resulting toxic effect, while the heating is distributed more 
uniformly inside the cell. The author also concluded that higher efficiency of the 
extracted chains of magnetosomes compared with that of the other nanoparticles is 
attributed to three factors: 1) a specific absorption rate (SAR) higher for the 
magnetosomes than for the chemically synthesized superparamagnetic iron oxide 
nanoparticles, 2) a more uniform heating for the chains of magnetosomes than for the 
individual magnetosomes and 3) the ability of the chains of magnetosomes to penetrate 
within the cancer cells or bind at the cell membrane following the AMF application 
which enables efficient cell destruction. Moreover, in vivo experiment using mouse 
showed that following the injection of ∼1 mg of chains of magnetosomes directly 
within the xenografted breast tumours under the skin of mouse and by applying an 
AMF of frequency 183 kHz and magnetic strength 40 mT, three times during 20 min, 
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total disappearance of tumour was observed, suggesting potential of chains of 
magnetosomes extracted from whole magnetotactic bacteria for application in MNHT 
for cancer therapy. Furthermore, biodistribution analysis result also indicated that 
extracted chains of magnetosomes administered directly within xenografted breast 
tumours progressively left the tumours during the 14 days following their 
administration and were then eliminated in large proportion in the feces (Alphandéry 
et al., 2011). 
Later in 2012, the same research group, Alphandéry et al. also reported the use of 
chains of magnetosomes isolated from Magnetospirillum magneticum strain AMB-1 
for MNHT treatment of tumours. The application of 198 kHz frequency and average 
magnetic field strength of 20 or 30 mT AMF resulted in efficient inhibition of cell 
proliferation on HeLa and MDA-MB-231 cancer cells loaded with chain of 
magnetosomes. However, when the chains are heated during 5 hours at 90 °C in the 
presence of 1% SDS, to denature the filament binding of magnetosomes and to obtain 
individual magnetosome, and used them in MNHT treatment, no significant cell 
proliferation inhibition was observed. The result revealed that individual 
magnetosomes are prone to aggregation, are not stable in solution and do not generate 
efficient inhibition of cancer cell proliferation under application of AMF, suggesting 
the increased efficiency was related to much less particle aggregation for the 
magnetosome chains than for the individual magnetosomes, thus enabling efficient 
magnetosome internalization by cancer cells (Alphandéry et al., 2012). 
In agreement with the finding above, Liu and coworkers (2012) reported that 
magnetosomes could be new natural biologic magnetic nanoparticles to be used in 
MNHT. They investigated the properties of magnetosomes such as morphology, 
magnetic properties and their heating effects under magnetic field and compared them 
to the chemically synthesized magnetic nanoparticles (MNP). Cytotoxicity studies 
using human breast cancer cells MCF-7 loaded with magnetosomes indicated that 80% 
of cell population died following AMF application (300 kHz magnetic frequency and 
110 Gs field amplitude) reaching a temperature of 47 °C. In addition, the acute toxicity 
evaluation in mice shows that the lethal dose magnetosomes is much higher than MNP, 
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suggesting the relatively high biocompatibility of magnetosomes (R. T. Liu et al., 
2012). 
In contrast with the finding above, Manucci et al. (2014) found that the magnetosomes 
enter the cells not as chains but as single nanoparticles or short chains. They extracted 
magnetosomes from Magnetospirillum gryphiswaldense strain MSR-1 and 
investigated the interaction with cellular elements and anti-neoplastic activity both in 
vitro and in vivo, with the aim of developing a new theranostic approach for neoplastic 
diseases. In vitro result indicated a strong uptake of magnetosomes with no evident 
signs of cytotoxicity on human colon carcinoma HT-29 cell cultures and also showed 
three phases in the interaction: adherence, transport and accumulation in Golgi 
vesicles. Histological analysis showed fibrous and necrotic areas close to 
magnetosomes injection sites in mice subjected to a complete thermotherapy protocol 
using three AMF application (187 kHz and 23kA//m on alternate days, over a week), 
suggesting magnetosomes as promising candidates for theranostic applications in 
cancer therapy (Mannucci et al., 2014). 
In 2017, Alphandéry et al research group investigated the potential use of 
magnetosomes for MNHT treatment of tumour and found that 40% of mice bearing 
intracranial U87-Luc tumours display full tumour disappearance following only 10 % 
magnetosome distribution coverage of the whole tumour volume after intratumour 
administration of 40 µg of chains of magnetosomes and 12 to 15 magnetic sessions 
(30 mT; 198 kHz; 30 min). Even more interesting, the study measured the percentage 
of endotoxin release, which was at 1 to 3% during the first 2 magnetic sessions, then 
strongly increases to 11% and 32% following the third and fourth magnetic session 
respectively, suggesting that endotoxins, which are initially at magnetosome surface, 
are progressively released from magnetosomes under AMF application. Therefore, it 
seems possible to simultaneously produce heat and release an immune-stimulating 
substance such as endotoxins or anticancer drugs-conjugated to magnetosomes, which 
could improve the therapeutic effect (Alphandéry et al., 2017a).  
Other report by the same research group above also demonstrated  an approach to 
design magnetosomes coated with poly-L-lysine (M-PLL) in order to stabilize the 
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magnetosomes in suspension (Alphandéry et al., 2017b). M-PLL-enhanced antitumour 
efficacy was demonstrated by administering 500-700 mg in iron of M-PLL to 
intracranial U87-Luc tumours of 1.5 mm3 and by exposing mice to 27 magnetic 
sessions each lasting 30 min, during which an AMF of 202 kHz and 27 mT was 
applied. Treatment conditions were adjusted to reach a typical hyperthermia 
temperature of 42 °C during the first magnetic session. The in vitro result revealed 
that the percentage of cell death of M-PLL increased from 60 % before AMF 
application to 90% after AMF application. For in vivo experiment, only 20 % of the 
treated mice showed antitumour efficacy following the administration of chemically 
synthesized MNP and 23 magnetic sessions. In contrast, living glioblastoma cells 
loaded with M-PLL were 100 % fully disappeared at 68 days following tumour cell 
implantation (D68) and AMF treatment. Even more interesting, histological analysis 
of their brain tissues revealed an absence of tumour cells, suggesting that they were 
fully healed (Alphandéry et al., 2017b).  
Recently, Mannucci et al. (2018) investigated the theranostic potential of chains of 
magnetosomes for AMF application on xenograft model of glioblastoma. They 
injected a single intratumoural magnetosomes into the mice, then conducted AMF 
application three times a week. The MRI analysis showed significant inhibition of the 
tumour growth in subjects exposed to the AMF, showing visible necrotic tissue at the 
tumour site. In contrast, tumour volume that was initially free from magnetosomes 
keeps growing. The MRI analyses also revealed inhomogeneous distribution of 
magnetosomes inside the tumour tissue which may strongly limit their therapeutic 








1.7 HYPOTHESIS AND AIMS 
The roles of Mms6 that have been described provide an insight into how Mms6 could 
function in magnetic nanoparticle synthesis. Moreover, the distinctive characteristic of 
MSC and the ability to perform genetic modification on these cells that have been 
described provide an insight into how MSC could be engineered to express certain 
protein and to target tumour site. Therefore, it was hypothesized that MSC could be 
engineered to express Mms6, thus enabling MSC able to self-express MNP which can 
be utilized for tumour targeting and MNHT.  
The main aims of the study were: 
1. To transfect AD-MSC with the MTB genes, mms6, using transient and stable 
transfection technique 
2. To demonstrate Mms6 mRNA and protein expression in AD-MSC following 
the transfection 
3. To investigate the effect of mms6 gene expression on MSC functionality 
4. To confirm whether the expression of mms6 by MSC leads to the production of 
MNP, as seen for the MTB 

















































 MATERIALS AND METHODS 
2.1 MAGISTER GENE DESIGN AND CLONING 
2.1.1 MAGISTER gene design 
A specific DNA sequence containing M. magneticum strain AMB-1 mms6 DNA 
bacterial synthetic gene was used in this study. The mms6 DNA fragment was 
optimised for mammalian cell expression by using mms6 gene codon optimization and 
by adding a Kozak sequence at the N terminus of the mms6 gene. This particular gene 
sequence was named MAGISTER (MAG) gene. In order to detect mms6 protein 
expression, protein tag markers were used. Two types of constructs were used:  
1) mms6 + single tag marker 
This construct has polyhistidine-tag at the N terminus of the mms6 DNA 
fragment, as illustrated in Figure 2-1. 
 
 
Figure 2-1: MAGISTER gene construct with a single tag marker. The 
construct has polyhistidine-tag at the N terminus of the mms6 DNA fragment. 
 
2) mms6 + double tag marker 
This construct has polyhistidine-tag at the N terminus and GFP-tag at the C 




Figure 2-2: MAGISTER gene construct with double tag markers. The construct has 
polyhistidine-tag at the N terminus and GFP-tag at the C terminus of the mms6 DNA fragment 
 
There were 4 different MAGISTER gene constructs with double tag markers, 
depending on different codon optimization of the mms6 gene, used in this study (Table 
2-1): 
1) MagWT contains the original sequence of M. magneticum strain AMB-1 mms6 
gene 
2) Mag01 was kindly designed by Dr. Greg Kudla (Group leader of RNA 
synthetic biology group, MRC Institute of Genetics & Molecular Medicine, 
University of Edinburgh) 
3) Mag02 was designed by Dr. Chris Boyd (Group leader of gene therapy for 
cystic fibrosis research group, MRC Institute of Genetics & Molecular 
Medicine, University of Edinburgh) 
4) Mag03 was designed by GeneArt® Gene Synthesis service (Thermo Fisher 
Scientific) 
All of these MAG fragments were synthesized and cloned into pcDNA3.1 plasmid at 
NheI/HindIII restriction site by GeneArt® Gene Synthesis service. All these constructs 
were specifically used in the experimental works in Chapter 4. 
For the MAGISTER gene construct with single tag marker, only Mag02 sequence was 
used. The sequence was synthesized and cloned into pcDNA3.1 plasmid at 
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KpnI/EcoRI restriction site by GeneArt® Gene Synthesis service. This construct was 
specifically used in the experimental works in Chapter 3. 
 
Table 2-1 MAGISTER gene design with double tag markers 
Gene/Plasmid Code DNA Fragment 
MAGISTER-WT (MagWT) His - mms6 Wild Type - GFP 
MAGISTER-01 (Mag01) His - mms6 codon optimised 1 - GFP 
MAGISTER-02 (Mag02) His - mms6 codon optimised 2 - GFP 
MAGISTER-03 (Mag03) His - mms6 codon optimised 3 - GFP 
 
2.1.2 Bacterial heat shock transformation  
To clone the MAGISTER sequence, bacterial transformation was performed. In Brief, 
2 µl of plasmid was added to 50 µl of DH5α competent cells (Thermo Fisher Scientific) 
in a microcentrifuge tube and incubated for 30 minutes on ice. The tube was then 
placed into the waterbath at 42°C for 70 seconds. Thereafter the tube was immediately 
transferred back on to ice and incubated for 3 minutes, then 900 µl of SOC (Super 
Optimal Broth with Catabolite repression) medium was added into the tube. Cells were 
incubated at 37°C with shaking for 1 hour to allow bacterial growth before being plated 
to Luria Broth (LB) agar medium. The bacteria were then centrifuged at 6000 rpm and 
500 µl of supernatant was discarded. The remaining pellet and supernatant were then 
resuspended. 100 µl of the bacteria were then plated to Luria Broth (LB) agar medium. 
The bacteria were then centrifuged at 6000 rpm and 500 µl of supernatant was 
discarded. The remaining pellet and supernatant were then resuspended. 100 µl of the 
bacteria were then plated on to premade Luria Broth/ampicillin plate. The plate was 




2.1.3 Gene cloning and mini scale plasmid purification 
Following overnight incubation, a single colony of DH5α cells were picked and put 
into 5 ml LB media supplemented with 5 µl (1000x concentration) ampicillin. Cells 
were incubated at 37°C with 225 rpm shaking for 16 hours to allow bacterial growth. 
Following 16 hours incubation, one colony from the plate was transferred into 5 ml of 
LB medium supplemented with 5 µl (1000x concentration) ampicillin. The bacterial 
culture was allowed to grow with shaking (225 rpm) at 37°C for overnight. Thereafter, 
500 µl of culture was stored at -80ºC in 50% glycerol. The remaining cells were then 
collected via centrifugation at 4°C for 5 min at 13000 rpm, then the plasmid was 
purified from the DH5α cells using the standard protocol of QIAprep spin MiniPrep 
Kit (Qiagen) to obtain a high purity of plasmid. 
In order to evaluate whether the MAG gene had been successfully amplified, 
restriction enzyme digestion by KpnI/EcoRI (for Mag gene with single tag marker) or 
HindIII/NheI (for Mag gene with double tag marker) restriction enzymes was 
performed. Briefly, 1 µg plasmid DNA, five units of restriction enzyme and 5 µl of 
10x CutSmart buffers were used in each reaction. The reactions were made up to a 
volume of 50 µl in distilled water and incubated at 37 °C for 2 hours. Enzymes were 
heated for 20 min at 85°C after digestion. The digestion products were then visualized 
by conducting electrophoresis on 2% (w/v) agarose gels with SYBRTM Safe DNA gel 
stain.  
 
2.1.4 Gene cloning and large-scale plasmid purification  
In order to obtain an adequate amount of MAGISTER gene plasmid to be used in this 
study, a large scale of MAGISTER gene cloning and plasmid purification was 
performed. Briefly, the DH5α cells containing MAGISTER plasmid from glycerol 
stock were plated using streak method on to pre-made LB/Amp agar. The plates were 
then incubated at 37°C overnight.  
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Following incubation, a colony of DH5α cells was picked and put into 5 ml LB media 
supplemented with 5 µl (1000x concentration) ampicillin. Cells were incubated at 37 
°C with 225 rpm shaking for 7 hours to allow bacterial growth. The bacteria culture 
was then added to 200 ml LB media supplemented with 200 µl Ampicillin (1000x) 
and left to grow overnight at 37°C on a 225 rpm shaker. 
Following overnight incubation, plasmid purification was performed. Plasmid 
EndoFreeMaxi kit (Qiagen) was used to purify plasmids according to the 
manufacturer’s instructions. Briefly, bacteria culture was centrifuged at 6000 rpm for 
10 minutes and the supernatant was removed. Bacteria pellets were resuspended in 10 
ml of Buffer P1, supplemented with RNase A and LyseBlue at 1:1000. 10 ml of Buffer 
P2 was added and was inverted 6 times and left to incubate at room temperature for 5 
minutes, at which point the solution turns blue. 10 ml of Buffer P3 was added, inverted 
six times and incubated on ice for 20 minutes. The solution was centrifuged at 13000 
rpm for 10 minutes at 4°C. At the same time, a Qiagen tip was equilibrated with 10 ml 
Buffer QBT and allowed to empty by gravity flow. The supernatant was removed from 
the sample into a Qiagen syringe, which was used to dispense the sample into the 
Qiagen tip and remove any suspended pellet that remained. The sample was allowed 
to flow through the tip and was washed twice with 30 ml of Buffer QC. The Qiagen 
tip was moved to a new 50 ml falcon tube and the DNA was eluted with 10 ml of 
Buffer QF. The tip was then discarded, and the eluted DNA was precipitated with 10.5 
ml isopropanol and mixed. The sample was centrifuged at 16000 rpm for 30 minutes 
at 4°C. The supernatant was removed and 5 ml of 70% ethanol was added to the tube 
to wash the pellet. The sample was then centrifuged at 16000 rpm for 5 minutes. The 
pellet was dissolved in 500 µl of ddH2O. DNA concentration was measured using the 
NanoDrop1000 spectrophotometer (Labtech). 
In order to evaluate whether the MAGISTER gene has been successfully amplified 
without mutation, the gene was sequenced. DNA sequencing was carried by the 
Institute of Genetic and Molecular Medicine sequencing service, University of 




Primer Forward (5'-3'): CGCAAATGGGCGGTAGGCGTG  
Primer Reverse (5'-3'): TCAGATCCGGTCGGCCACCCA 
The sequencing information received was visualized and processed using DNA Baser 
Sequence Assembler. The sequencing results were then aligned to match the original 
sequence using the Basic Local Alignment Search Tool (BLAST) software. 
 
2.2 LENTI-mms6 GENE CONSTRUCTION 
2.2.1 Lenti-mms6 plasmid construct 
To reprogram the AD-MSC stably expressing mms6 gene, a lentiviral construct of 
MAGISTER gene was generated. The pSicoR-Ef1α-mCh-Puro lentiviral plasmid and 
the pcDNA 3.1 – mms6 were used in the lenti-mms6 plasmid construction. The 
pSicoR-Ef1α-mCh-Puro lentiviral plasmid was a gift from Dr. Chris Boyd, while the 
pcDNA 3.1 – mms6 (Mag01 gene construct without his-tag and GFP-tag) was a gift 
from Dr. Lisa Lungaro (former member of Donald Salter research group, IGMM). The 
mms6 gene insert was extracted with restriction enzymes XbaI/NotI (New England 
Biolabs) from the pcDNA 3.1 plasmid and the resulting product was ligated into the 
SpeI/NotI sites of pSicoR-Ef1α-mCh-Puro plasmid to create the Lenti-mms6 construct. 
The protocol used as described in the following section. 
 
2.2.2 mms6 gene fragment extraction 
For extraction of the DNA fragment containing mms6 gene from pcDNA 3.1 plasmid, 
the plasmid was extracted with restriction enzymes XbaI/NotI (New England Biolabs) 
following the manufacturers protocol. The digestion product was then analysed by 
electrophoresis, then extracted from the gel using QIAquick gel extraction kit 
(Qiagen). To extract the DNA, the digestion DNA product from the agarose gel was 
excised with a clean, sharp scalpel. The weight of the gel slice was then measured in a 
colorless tube, then the gel slice was dissolved in 3 volumes Buffer QG to 1 volume 
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gel. After the gel slice has dissolved completely, 1 gel volume isopropanol was added 
to the sample and mixed. To bind the DNA, the sample was then applied to the 
QIAquick column and centrifuged for 1 min at 13000 rpm. The flow-through was 
discarded and 500 µl Buffer QG was added to the QIAquick column and centrifuged 
for 1 min at 13000 rpm. The flow-through was again discarded, then the QIAquick 
column was placed back into the same tube. To wash, 750 µl Buffer PE was added to 
QIAquick column and centrifuged for 1 min at 13000 rpm. After discarding the flow-
through, the QIAquick column was then centrifuged again for 1 min at 13000 rpm to 
remove residual wash buffer. Afterwards, to elute DNA, 50 µl Buffer EB (10 mM 
Tris·Cl, pH 8.5) was added into the QIAquick membrane and centrifuged for 1 min.  
The DNA concentration was then measured using the NanoDrop1000 
spectrophotometer. 
 
2.2.3 Plasmid dephosphorylation and ligation. 
The ligation of the mms6 gene insert into the pSicoR-Ef1α-mCh-Puro plasmid was 
performed using Rapid DNA Dephos and Ligation Kit (Roche). The plasmid vector 
(1µg) was digested with restriction enzymes SpeI/NotI (New England Biolabs) 
following the manufacturer’s protocol. Once digested with the enzymes, the vector 
sample was then dephosphorylated using a reaction as shown in Table 2-2. The mixture 
was left for 15 minutes at 37°C. For the ligation reaction, a 1:3 ratio of vector to insert 
was used. The ligation reaction was set up as shown in Table 2-3. The ligation mixture 
was left for 5 minutes at room temperature before used for the transformation process 
into DH5α cells to amplify the plasmid. Once the plasmid yield was purified, the 
samples were then sent to the IGMM sequencing department who sequenced vectors 
in both directions, using the following primers:  
Primer Forward (5'-3'): CGCAAATGGGCGGTAGGCGTG  
Primer Reverse (5'-3'): TCAGATCCGGTCGGCCACCCA 
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The sequences were checked against mms6 DNA sequence (Mag01) using online 
BLAST software. Afterwards, the plasmid was then sent to Biomolecular Core 
Department – SURF, the University of Edinburgh who performed the lentivirus titer 
production.  
Table 2-2: Dephosphorylation reagent concentration 
Reagent Final Concentration Volume (µl) 
Vector DNA 200 ng 10 µl 
rAPID Alkaline Phosphatase 
Buffer, 10 x conc. 
1 x 2 µl 
rAPID Alkaline Phosphatase 1 U 1 µl 
Water  7  µl 
 Total 20 µl 
 
Table 2-3: Ligation reagent concentration 
Reagent Final Concentration Volume (µl) 
Vector DNA 50 ng 5 
Insert DNA 150 ng 3 
DNA Dilution Buffer (5 x)  1 x 2 µl 
T4 DNA Ligation Buffer (2x) 1 x 10 µl 
T4 DNA Ligase 5 U 1 µl 





2.3 CELL CULTURE 
All cell culture procedures were performed in laminar air flow hoods. Cells were 
cultured in their specific medium and incubated in the incubator at 37°C with 5 % CO2. 
Adipose-derived human mesenchymal stem cells (AD-MSC) were purchased from 
American Type Culture Collection (ATCC). The Human Embryonic Kidney 293T 
(HEK293T) cell line was kindly provided by Micaela Rios Visconti, PhD (MRC 
Institute of Genetics & Molecular Medicine, University of Edinburgh). The cell culture 
media and the cell culture maintenance procedure can be found at the following 
sections. 
 
2.3.1 Cell culture medium 
Adipose-derived human mesenchymal stem cells (AD-MSC) standard culture 
medium: Mesenchymal Stem Cell Basal Medium for Adipose, Umbilical and Bone 
Marrow-derived MSC, supplemented with Mesenchymal Stem Cell Growth Kit for 
Adipose and Umbilical-derived MSC – Low Serum, 100U/ml penicillin and 100µg/ml 
streptomycin (P/S). The complete medium was prepared by adding 10 ml of Growth 
Kit and 5 ml of P/S into 485 ml of MSC basal medium.  
HEK293T cell line culture medium: DMEM medium, high glucose, supplemented 
with 10% FBS and 1% of 100U/ml/100µg/ml P/S. The complete medium was prepared 
by adding 50 ml of FBS and 5 ml of P/S into 450 ml of DMEM medium. 
Adipose-derived human mesenchymal stem cells (AD-MSC) FeQ doped medium: 
AD-MSC culture standard medium with the addition of 3.4 µl/ml of FeQ solution, to 




2.3.2 Passaging of cells 
Cells were passaged when they reached the 80% of confluence. Cells were washed 
with 10 ml of 1x PBS and then incubated with 1 ml of Trypsin-EDTA 0.25% for 2 
minutes in the incubator at 37°C with 5% CO2. Cells were then resuspended and 
collected in 10 ml of complete medium. The cell suspension was then centrifuged at 
1000 rpm for 5 minutes. The supernatant was discarded, and the cell pellet was 
resuspended in 1 ml of complete medium. Then 200 µl of cell suspension was put into 
T75 flask containing 10 ml of complete medium (1:5 ratio). 
 
2.3.3 Storage of cells 
The freezing medium was made by adding 1 part of DMSO to nine parts of FBS. 5 x 
106 cells were added to each vial. Cells were stored to -80°C for one day and then 
transferred to liquid nitrogen for longer storage. 
 
2.4 TRANSIENT GENE TRANSFECTION 
In order to investigate the efficient way to transfect AD-MSC with MAGISTER genes, 
several approaches of transient transfection technique were used in this study. 
HEK293T cells, as a relatively easy cell line to transfect, were also used in this study 
as a positive control. A lipid-based transfection, a multi-component non-lipid 
transfection and an electroporation transfection technique were used as described in 
the following sections. The transfection efficiency was measured by flow cytometry 
to determine the most efficient technique to transfect AD-MSC with the MAGISTER 
gene construct. 
 
2.4.1 Non-Lipid transfection 
X-tremeGENE™ HP DNA (Roche), a multi-component non-lipid transfection 
reagent, was used to transfect cells. Briefly, cells were seeded at 1 x 105 cells per well 
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in 24-well plates one day prior to transfection. On the day of transfection, OptiMEM 
media (Gibco) was prepared in tubes at 100 µl per tube. DNA plasmid (3 µg) was put 
into the OptiMEM media, then 9 µl (1:3 ratio to the DNA concentration) of 
transfection reagent was added to the mixture. The complexes were then mixed and 
incubated for 20 minutes. Then, the complex solution was gently added into the cells. 
Each sample transfection was performed in triplicate. Cells mixed with transfection 
reagent without plasmid were used as negative control. The cells were then incubated 
at 37°C with 5% CO2 for 48 hours before the transfection efficiency was quantified by 
flow cytometry. 
 
2.4.2 Lipid-based transfection  
Lipofectamine 3000® transfection 
Lipofectamine 3000® (Life Technologies) transfection reagent is a lipid-based 
transfection reagent that has been commonly used to transfect eukaryotic cells. To 
perform the transfection, cells were seeded at 1 x 105 cells per well in 24-well plates 
one day prior to transfection. On the following day, 3 µg of MAGISTER plasmid was 
diluted in 50 µl of OptiMEM media. Separately, Lipofectamine 3000® (9 µl) solution 
was diluted in 50 µl of OptiMEM media. The individual solutions were then mixed 
gently and allowed to incubate for 5 minutes at room temperature, after which they 
were combined and allowed to incubate at room temperature for another 20 minutes. 
The cell medium was then replaced with prewarmed 500 µl media. Then, the complex 
solution was gently added into the cells. Each sample transfection was performed in 
triplicate. Cells mixed with transfection reagent without plasmid were used as negative 
control. The cells were then incubated at 37°C with 5% CO2 for 4 hours, after which 
the cell media was replaced with standard growth media. After incubation for a total 





Fugene® HD transfection 
Fugene® HD (Promega) transfection reagent is a novel, non-liposomal complex 
designed to transfect DNA into a wide variety of cell lines with high efficiency and 
low toxicity. To perform the transfection, cells were seeded at 1 x 105 cells per well in 
24-well plates one day prior to transfection. On the day of transfection, OptiMEM 
media was prepared in tube at 100 µl per tube. DNA plasmid from each construct (3 
µg) was put into the OptiMEM media, then 9 µl of transfection reagent/plasmid was 
added to the mixture. The complexes were then mixed and incubated for 20 minutes. 
Then, the complex solution was gently added into the cells. Then, the complex solution 
was gently added into the cells. Each sample transfection was performed in triplicate. 
Cells mixed with transfection reagent without plasmid were used as negative control. 
The cells were then incubated at 37°C with 5% CO2 for 48 hours before the 
transfection efficiency was quantified by flow cytometry. 
 
2.4.3 Nucleofection 
Electroporation, or electropermeabilization, is a physical transfection technique in 
which a specific electric field is applied to cells. Nucleofection, an electroporation-
based technique, also uses electrical pulse but the nucleic acid is directly introduced 
into the nucleus of cells. When the cell is exposed to the electric shock, the 
permeability of the cell membrane is increased allowing the DNA entering the cells. 
The Human MSC Nucleofector™ Kit (Lonza) was used to transfect AD-MSC using 
this approach. Briefly, 24-well plates were prepared by filling the appropriate number 
of wells with 500 µl of culture medium then pre-incubated the plates in a humidified 
37°C 5% CO2 incubator. A pellet of cells was prepared at a density 1 x 105 cells in a 
tube, then mixed with 100 µl of Human MSC Nucleofector™ solution. The cell 
suspension was then mixed with 3 µg DNA plasmid. Afterwards, the nucleofection 
samples were transferred into an Amaxa™ certified cuvette. The cuvette then inserted 
into Nucleofector™ Device (Amaxa). The electroporation process was performed on 
the device by using the U-23 program. Thereafter, the cell suspension was taken out 
from the cuvette and seeded into prewarmed 24-well plates. Each sample transfection 
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was performed in triplicate. Cells transfected without plasmid were used as negative 
control. The cells were then incubated at 37°C with 5% CO2 for 48 hours before the 
transfection efficiency was quantified by flow cytometry. 
 
2.5 STABLE GENE TRANSFECTION 
To assess whether AD-MSC can be reprogrammed to stably expressing mms6 gene, a 
stable mms6 gene transfection was performed. A lentiviral vector carrying mms6 gene 
that was designed as described in section 2.2 was used to transduce AD-MSC. The 
preparation and the process of this technique is described in the following section. 
 
2.5.1 Puromycin kill-curve 
A standard protocol of puromycin kill-curve was performed as a first critical step to 
determine the minimum antibiotic concentration needed to kill all the cells over the 
course of two weeks. Briefly, Puromycin (Sigma) was dissolved in 10 ml of ddH2O 
giving a stock concentration of 1 mg/ml. In order to set up a kill-curve assay, 5 x 104 
cells were seeded in triplicate for 8 different puromycin concentrations in a 24-well 
plate and left overnight. The concentrations tested were 0, 0.5, 1, 2, 4, 6, 8, 10 µg/ml. 
The selection media containing Puromycin was added to cells providing selection 
pressure. The medium was changed every three days until 100% of cells had 
undergone cell death in the lowest concentration condition. 
 
2.5.2 Virus transduction 
For virus transduction, 1 x 104 AD-MSC and HEK293T cells as control were seeded 
in into one well of a 24-well plate and grown overnight. The virus-containing 
supernatant was diluted in growth medium supplemented with polybrene (final 
concentration: 8 mg/ml) and added to the cell culture. The MOI (Multiplicity of 
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Infection) number of 10, 15 and 30 were used for the transduction of AD-MSC, 
whereas MOI ratio of 5 and 10 were used for transduction of HEK293T cells. 
The MOI was determined as virus volume (ml) x virus titer (TU/ml)/plated cell 
number. Two days later, the medium was refreshed with selection medium (growth 
medium supplemented with 2 µg/ml Puromycin) to generate stable cells expressing 
the mms6 gene. The selection medium was changed every 3 days and cells were 
passaged each time they reached confluence. The mCherry red fluorescence produced 
by cells was then observed every 5-7 days during the selection process for three weeks. 
The successful cells stably expressing mCherry red fluorescence were then expanded 
for the later experiments. 
 
2.6 RNA RELATED INVESTIGATION 
2.6.1 RNA Extraction  
RNA extraction was performed using RNAeasy Mini Kit (Qiagen). Briefly, cells were 
trypsinized and resuspended in PBS. Once the supernatant was removed, 350 µl of 
lysis buffer was used to resuspend the cells. The resuspend was then transferred to a 
1.5 ml reaction tube. Then 350 µl of 70% ethanol was added to the lysate. The lysate 
was transferred into Mini spin column placed in the 2 ml collection tube, then was 
centrifuged at 13,000 rpm on a table top micro centrifuge for 15 seconds. After 
centrifugation, 700 µl of wash buffer (RW1) added into the spin column and 
centrifuged at 13,000 rpm for 15 seconds. Once the flow-through discarded, 500 µl of 
wash buffer (RPE) added into the spin column and centrifuged at 13,000 rpm for 15 
seconds. The flow-through was discarded. Afterwards, 700 µl of wash buffer (RPE) 
added into the spin column and centrifuged at 13000 rpm for 2 minutes. After that, the 
spin column was then placed into 1.5 ml collection tube, then 50 µl of RNAase-free 
water was added to elute the RNA from the membrane into the collection tube and 




2.6.2 RNA Concentration Measurement 
Yield and purity of RNA samples were determined using a Nanodrop1000 
spectrophotometer. The absorbance was measured at wavelength 260 nm, 280 nm, and 
230 nm. The absorbance ratio of RNA samples at 260/280nm of 0.8 - 1 and absorbance 
ratio at 260/230 nm in a range 2.0 – 2.2 were considered as highly pure. 
 
2.6.3 Primer design 
To determine the MAGISTER gene expression, a set of DNA primers were designed 
using Primer3 Software. The human Glyceroaldehude-3-Phosphate Dehydrogenase 
(GADPH) was chosen as housekeeping gene. The primers were then purchased from 
Integrated DNA Technologies (USA).  
Primers to be used with cDNA synthesized from RNA of cells transfected with 
MAG02 gene of mms6 with single tag marker (His6x) was designed to generate 
amplicons of 142 bp:  
Forward : 5’ GGA CCA AAG TGG CAC TGG 3’  
Reverse : 5’ CCC ACT ACG CCC AAG ATG AT 3’ 
 
While Primers to be used with cDNA synthesized from RNA of cells transfected 
with MAGISTER gene of mms6 with double tag marker (His-GFP) was designed to 
generate amplicons of ~150 - 230 base pairs. The DNA sequence of the primers can 












Table 2-4: Primers for PCR of MAGISTER Gene with His-GFP tag marker 
Gene Forward Primer (5’ 
– 3’) 
Reverse Primer (5’ – 3’) Product 
Size  





















2.6.4 cDNA synthesis and DNAse I treatment 
cDNA was synthesized by reverse-transcribing 1 µg of RNA. cDNA was synthesized 
following qScriptTMcDNA Synthesis kit (Quanta Biosciences) protocol as listed in 
Table 2-5. RNA samples (1ug/ µl) were added to 4 µl of x qScript cDNA superMix 
(which contained random oligo-dT), and then water was added up to 20 µL of final 
total volume. The reaction was then mixed using vortex and briefly centrifuged before 
running on the Thermocycler (Tetrad2 DNA Engine, Bio-Rad). Thermocycling 
conditions used are listed in  
Table 2-6. Then 1/10 of the reaction (2 µl) were used for RT-PCR amplification. 




2.6.5 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Amplification of MAGISTER DNA fragment was performed was using the Taq 
MasterMix kit (Qiagen) in a Thermocycler (Tetrad2 DNA Engine, Bio-Rad). Two 
reactions were run in parallel for MAGISTER internal gene amplification and for 
GAPDH amplification. Reactions were prepared on ice to a total volume of 25 µl 
according to the protocol provided by Qiagen as listed in Table 2-7. Reactions were 
run alongside a negative control where RNA was substituted for dH2O. The PCR 
reaction was performed in the Thermocycler using condition as listed in Table 2-8. 
 
2.6.6 DNA agarose gel electrophoresis 
In order to investigate the MAGISTER amplified fragment, the PCR products were 
resolved in a 2% agarose gel. Briefly, 2 g of agarose were mixed with 150 ml of 0.5 x 
TBE and dissolved using microwave. Then, 0.01% diluted SYBR™ Safe stain 
(Invitrogen) was added to the gel to visualize the DNA under UV image analyzer. The 
gel then cooled at room temperature, and then 20 µl of the sample were loaded into the 
gel and run in running buffer made of 0.5 x TBE in horizontal gel electrophoresis 
system (Bio-Rad) at a constant voltage of 110V for 100 minutes. Samples were run 
alongside a 100bp DNA ladder (New England BioLabs) in order to determine the 
molecular weight (MW) of the PCR product. Then, the gel was then visualized under 
UV light to image the DNA bands.  
 
Table 2-5: Reagent concentrations for cDNA production 
Reagent Volume (µl) 
RNA (1 µg/µl)  Variable  
qScript supermix  4 
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H2O  Variable 
Total 20  
 
 
Table 2-6: Thermocycler condition for qScript cDNA production 







Table 2-7: Reagent concentrations for End-Point PCR 
Reagent Volume (µl) 
Taq MasterMix (2x)  12.5  
Forward primer  1  
Reverse primer  1  









Table 2-8: Thermocycler condition for End-Point PCR 
Step Temperature (°C) Time (mm:ss) 
Initial Denaturation 95 00:30 
35 Cycles 95 00:45 
55 00:45 
70 01:00 
Final Extension 72 05:00 




2.7 PROTEIN RELATED INVESTIGATION 
2.7.1 Protein extraction  
Western blot technique was used in this study to investigate protein expression. For 
this, the protein extraction was performed on cell lysates from samples. In brief, cells 
were washed in cold PBS and scraped in cold RIPA buffer (Santa Cruz). The RIPA 
84 
 
reaction buffer was supplemented with protease and phosphatase inhibitors as listed in 
Table 2-9. The cell lysates were left on ice for 10 minutes before being centrifuged for 




Table 2-9: Reagent concentration for complete RIPA buffer 
Reagent Volume per 1 ml of RIPA buffer  
(µl) 
Sodium orthovanadate (Na3VO4) 10 
Phenylmethylsulfonyl fluoride (PMSF) 10 
Proteinase Inhibitor 20 
 
2.7.2 Protein Quantification 
The protein concentration was then quantified from the cell lysates against a bovine 
serum albumin standard pre-diluted set (Thermo Fisher Scientific), based on the 
method of Bradford using Bio-Rad protein assay. Briefly, 10 µl of each standard and 
sample solution were loaded into 200 µl of diluted dye reagent in microtiter plates 
well. Once incubated at room temperature for 5 minutes, the plate was then read at 595 




2.7.3 Gel Electrophoresis 
Western blots were performed in 4-15% Mini-Protean TGX gel (Bio-Rad), held in a 
vertical tank filled with 10% TGS (Bio-Rad) electrophoresis running buffer. The 
protocol was set-up according to the manufacturer’s instructions. In brief, 20 µg of 
protein lysates was solubilized in 4x Laemmli (Bio-Rad) loading buffer (62.5 mM 
Tris-HCl, pH 6.8 sample buffer, 10% glycerol, 1% LDS, 0.005% Bromophenol Blue, 
10% 2-mercaptoethanol). The protein samples were then denatured for 5 minutes at 95 
°C. The samples then loaded along with a protein ladder (Licor) at 180V for 35 
minutes.  
 
2.7.4 Electrophoretic Transfers 
Protein were then transferred on a nitrocellulose membrane (Sigma), using a wet 
transfer technique. Initially, a transfer buffer (Bio-Rad) was prepared and cooled to 
4°C. A blotting sandwich of pre-soaked sponges, pre-soaked filter paper, 
polyacrylamide gel and pre-soaked nitrocellulose membrane were carefully prepared 
on the transfer tank to allow the negatively charges protein to transfer from the gel to 
the membrane. The transfer sandwich was set up with the following configuration: 
sponge, filter paper, nitrocellulose membrane, gel, filter paper and sponge. The 
sandwich was topped with a 1x transfer buffer, and the tank was programmed at 100 
V for 60 minutes on an ice bucket.  
 
2.7.5 Immunostaining and Antibody Detection  
Once the transfer finished, the membrane was saturated in 5% non-fat dry milk 
(Marvel) diluted in 0.1% TBST buffer (0.05 M Tris-HCl, 0.15 M NaCl, 0.1% Tween-
20, pH 7.6) for an hour at room temperature. The membrane was then incubated 
overnight at 4°C under slow agitation in the primary antibody (anti-His and anti-B-
actin from Abcam) diluted at 1:1000 in 5% non-fat milk, in 0.1% TBST. 
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After being washed with 0.1% TBST every 10 minutes for half an hour, the membrane 
was then incubated with second antibody (HRP-linked anti-mouse IgG, Abcam) at a 
dilution of 1:1000 in 5% non-fat milk made in 0.1% TBST under slow agitation at 
room temperature for 1 hour. 
The nitrocellulose membrane was then washed again with 0.1% TBST every 10 
minutes for one hour before being visualized using Clarity Western ECL substrate 
(Bio-Rad) in Odyssey® Fc Imaging System (Li-Cor). The intensities of the bands 
were quantified ImageStudioLite software from Li-Cor. 
 
2.8 FLUORESCENCE IMAGING OF GFP 
The MAGISTER protein expression of transfected cells was investigated by observing 
GFP fluorescence under fluorescence microscope. 18mm glass coverslips were 
sterilized in 70% ethanol, air dried for 10 minutes, exposed to UV for 20 minutes, then 
added to 6-well plates. 4 x 104 transfected cells were used per well and once seeded 
grown for 48 hours. Cells were then washed with ice-cold PBS three times for five 
minutes. Cells were then fixed with formaldehyde 3.7% at 10 minutes at room 
temperature. Cells were washed three times for five minutes with PBS. Coverslips 
were then removed, washed in distilled H2O and mounted on to microscope slides 
using VECTASHIELD® Antifade Mounting Medium with DAPI (Vector 
Laboratories) and dried overnight. Images were obtained using the Nikon E800 
fluorescence microscope. 
 
2.9 FLOW CYTOMETRY ANALYSIS OF GFP EXPRESSING CELLS 
To measure the percentage of GFP-Positive cells following the transfection, flow 
cytometry was performed. Briefly, cells were washed with PBS two times, then 
trypsinized. Cells were collected and centrifuged at 1000 rpm for 5 minutes, then 
diluted in 200 µL of PBS supplemented with 5% FBS. The percentage of GFP positive 




2.10 INDIRECT IMMUNOFLORESCENCE 
Immunofluorescence was performed to characterise population of human MSCs using 
positive and negative selection markers provided by human MSC characterization kit 
(Merck). Briefly, 5 x 104 cells were seeded in 24 well-plate and grown overnight.  Cells 
were then fixed with ice-cold methanol for 15 minutes at -20 °C. In order to reduce 
non-specific background staining, cells were incubated with PBS 3% BSA solution for 
20 minutes. Cells were incubated with anti-CD44, anti-CD90, anti-CD14 and anti-
CD19 1:500 diluted in PBS 1% BSA for one hour. Cells were washed three times for 
five minutes with PBS. 
AlexaFluor 488 (Abcam) antibodies were diluted in PBS 1% BSA solution and added 
to cells for one hour in darkness. Cells were washed three times for five minutes with 
PBS. Cell were washed in distilled H2O and counterstained with VECTASHIELD® 
Antifade Mounting Medium with DAPI (Vector Laboratories) and dried overnight. 
Images were obtained using the Nikon E800 fluorescence microscope. 
 
2.11 TURBIDITY MEASUREMENT OF COMMERCIAL IRON-BASED 
MAGNETIC NANOPARTICLE IN CULTURE MEDIUM. 
Following iron oxide-based MNPs were tested for their colloidal stability in PBS and 
in culture medium: NanoMAG®-D-Spio (Micromod, Germany), BNF-Dextran 
(Micromod, Germany), FluigMAG-CT (Chemicell, Germany) and Ferucarbotran 
(Meito Sangyo, Japan) as can be seen in Table 2-14. 
NanoMAG®-D-Spio are ferrofluids, cluster-typed shape MNP, which have diameter 
size of 50 nm. They are prepared by precipitation of iron oxide in the presence of 
dextran. FluidMAG-CT are ferrofluids consisting of an aqueous dispersion of 
magnetic iron oxides with diameters of 50 nm. The particles are covered with 
hydrophilic polymers which protect them against aggregation by foreign ions. BNF-
Dextran are 80 nm cluster-typed shape Bionized NanoFerrite particles which are 
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prepared via the core-shell method with a core of 75-80% (w/w) magnetite and a shell 
of dextran. Ferucarbotran is an aqueous suspension of multi-core carboxydextran-
coated magnetite nanoparticles (54 nm), originally designed as a liver-targeting MRI 
contrast agent. 
Colloidal stability of these MNP in PBS and culture medium was assessed by 
measuring turbidity of the MNP in medium over time. For this analysis, MNP samples 
were prepared in either 500 µl of culture medium or PBS (500 µg/ml) in 24-well plate. 
Turbidity measurement was performed over a period up to 24 h, namely 0, 2 h, 16 h 
and 24 h. The suspension was measured at 450 nm using a microplate reader.  
 
2.12 PRUSSIAN BLUE STAINING 
For Prussian blue staining, cells were seeded in 12-well plates (5 x 104 cells/well) in 1 
ml medium and grown overnight. A day after, cells were loaded with 200 µg/ml 
Ferucarbotran nanoparticle in 500 µl medium and incubated overnight. Cells without 
MNP served as control. Following overnight incubation, cells were fixed with 
formaldehyde 4% and stained with HT20 Prussian blue iron stain kit (Sigma Aldrich).  
Briefly, equal volumes of Potassium Ferrocyanide Solution (15 ml) and Hydrochloric 
Acid Solution (15 ml) were mix to make 30 ml working Iron Stain Solution. Cells were 
then incubated in the working Iron Stain Solution (1 ml/ well) for 3 minutes. 
Thereafter, cells were washed with distilled water three times. Cells were then 
incubated with Pararosaniline solution (1ml/well) for 5 minutes. Thereafter, cells were 
washed with distilled water for three times and observed at light microscope. Cells 
were pictured using a coloured camera (Micropublisher camera, QIMAGING). 
 
2.13 TRANSMISSION ELECTRON MICROSCOPY (TEM) SAMPLES 
PREPARATION 
1 x 106 cells were collected and centrifuged at 1000 rpm for 5 minutes. The cell pellet 
was then resuspended in 50 µl of cell culture medium and transferred to a 1.5 ml 
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microcentrifuge tube. A sample blocking made of 1% agarose was prepared by 
dissolving 0.5 g agarose powder in 50 ml of 1x PBS in a glass beaker. The solution 
was put in microwave at 800 W for 3 minutes. In the meantime, the bottom of a 0.5 ml 
tube was cut with scissors and it was put upside down with the lid closed in an ice 
bucket. The 1% agarose solution was cooled down for 30 seconds at room temperature, 
then the cell pellet was slowly resuspended in 100 µl of agarose solution avoiding air 
bubbles. After the agarose was solidified, the sample was then immediately transferred 
in a 5 ml bijoux tube filled with 3% glutaraldehyde solution, under chemical hood.  
For Transmission Electron Microscopy, sample preparation was done by Stephen 
Mitchell at Biology Scanning Electron Microscope facility, The University of 
Edinburgh. For this, cells were fixed in 3% glutaraldehyde in 0.1M Sodium Cacodylate 
buffer, pH 7.3, for 2 hours then washed in 3 x 10-minutes changes of 0.1M Sodium 
Cacodylate. Specimens were then post-fixed in 1% Osmium Tetroxide in 0.1M 
Sodium Cacodylate for 45 minutes, then washed in 3 x 10-minutes changes of 0.1M 
Sodium Cacodylate buffer. These samples were then dehydrated in 50%, 70%, 90% 
and 100% ethanol (X3) for 15 minutes each, then in 2 x 10-minute changes in 
Propylene Oxide. Samples were then embedded in TAAB 812 resin. Sections, 1µm 
thick were cut on a Leica Ultracut ultramicrotome, stained with Toluidine Blue, and 
viewed in a light microscope to select suitable areas for investigation. Ultrathin 
sections, 60nm thick were cut from selected areas, stained in Uranyl Acetate and Lead 
Citrate then viewed in a JEOL JEM-1400 Plus TEM. Representative images were 
collected on a GATAN OneView camera. 
 
2.14 AD-MSC DIFFERENTIATION EXPERIMENT 
2.14.1 Osteogenesis 
AD-MSC expressing mms6 (mms6-lenti-transduced AD-MSC) and untransfected AD-
MSC were differentiated in osteogenic culture medium for 10 or 21 days, using 
StemPro Osteogenesis Differentiation Kit (Gibco). Cells cultured in standard growth 
medium were considered as a negative control. The differentiation experiments were 
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performed in the absence of FeQ doping. Briefly, cells were seeded in 24 wells plates 
in triplicate for each cell group. Cells were seeded at a density of 2x104 cells/well 
cultured in standard culture medium. After 48 hours of incubation, the medium was 
replaced with osteogenic medium for the treated group. The medium was continuously 
replaced with fresh medium every 3 days. 
At 10 Days and 21 Days of incubation time point, cells were fixed for the osteogenic 
staining. For this, cells were washed twice with 1 ml of 1xPBS and fixed in 4% PFA 
for 30 minutes at room temperature in fume hood. After fixation, cells were washed 
twice with 1 ml of ddH2O /well and stained with 2% Alizarin Red S solution (pH4.2) 
for 30 minutes. The cells were then washed three times with 1ml of ddH2O/well and 
observed under light microscope and scanned for the analysis. 
 
2.14.2 Adipogenesis 
AD-MSC expressing mms6 (mms6-lenti-transduced AD-MSC) and untransfected AD-
MSC were differentiated in adipogenic culture medium for 10 days, using StemPro 
Adipogenesis Differentiation Kit (Gibco). Cells cultured in standard growth medium 
were considered as a negative control. The differentiation experiments were performed 
in the absence of FeQ doping. Briefly, cells were seeded in 24 wells plates in triplicate 
for each cell group. Cells were seeded at a density of 2x104 cells/well cultured in 
standard culture medium. After 48 hours of incubation, the medium was replaced with 
adipogenic medium for the treated group. The medium was continuously replaced with 
fresh medium every 3 days. 
After 10 Days of incubation, cells were fixed for the adipogenic staining. For this, the 
medium was removed and plates were carefully washed twice with 1 ml of 1x PBS, to 
not disrupt the cells monolayer. The cells were fixated in 4% PFA under the chemical 
hood, then they were incubated for 1 hour at 37°C. After fixation, cells were washed 
twice with 1 ml of 1x PBS, then incubated with 1 ml of 60% isopropanol for 1 minute. 
Then, the isopropanol was disposed and the cells were let dry under the chemical hood. 
At this point, it was added the Oil Red O solution diluted 3:2 in distilled water for 20 
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minutes. Thereafter cells were washed with 1x PBS for three times and imaged 
immediately at light microscope. Cells were pictured using a coloured camera 
(Micropublisher camera, QIMAGING).  
 
2.15 MAGNETIC RESONANCE IMAGING (MRI) 
To perform MRI experiment, mms6 transfected AD-MSC: Mag01-transfected and 
Mag-03 transfected; and lentiviral mms6 transduced cells were prepared for the assay. 
Cells were incubated in FeQ medium for 10 days. Thereafter, 1 x 106 of cells were 
collected and centrifuged at 1000 rpm for 5 minutes. The cell pellet was then 
resuspended in 50 µl of PBS in microcentrifuge tube. A sample blocking made of 1% 
agarose was prepared by dissolving 2 g agarose powder in 200 ml of 1x PBS in a glass 
beaker. The solution was put in microwave at 800 W for 3 minutes. After that, the 
solution was loaded into 50 ml falcon tubes, 40 ml each tube, and cooled down for 5 
minutes at room temperature. Once the solution almost solidified, a microcentrifuge 
tube was used to make a V shape hole on the surface of the gel. The cells were then 
loaded into the hole carefully, before adding 2 ml of agar solution to cover the cells. 
Cells after 24 hours loaded with Ferucarbotran MNP were used as positive control. 
Magnetic resonance imaging was performed using the head matrix coil of a 3T MRI 
system (MAGNETOM Verio, Siemens AG, Healthcare Sector, Erlangen, Germany) 
by Dr. Scott Semple at Clinical Research Imaging Centre, Queen’s Medical Research 
Institute, University of Edinburgh. Phantoms were suspended in a water bath to reduce 
artefact. Multi-gradient-echo T2* acquisitions were acquired from 2.7–21.3ms and 





2.16 SQUID (SUPERCONDUCTING QUANTUM INTERFERENCE 
DEVICE) MAGNETOMETRY ASSAY 
SQUID magnetometer is a very high precision instrument which measures the total 
magnetic moment of a sample. A device called a MPMS is used to measure the 
magnetic moment of a sample by reading the output of the SQUID detector. To 
perform SQUID measurements, 3 x 106 cells were collected and centrifuged at 1000 
rpm for 5 minutes. The supernatant was removed, and the pellet was washed with 1 ml 
of 1x PBS, then centrifuged again at 1000 rpm for 5 minutes. The supernatant was 
discarded, and the pellet was transferred in a 1.5 ml microcentrifuge tube sealed with 
parafilm. The pellet was desiccated at 60°C for 30 minutes in a vacuum-pump 
centrifuge (TVC 2-18, CHRIST). The parafilm that sealed each Eppendorf was 
punctured to avoid sample damage by vacuum. Then, a capsule method of SQUID 
preparation was used to prepare the samples by transferring the dry pellet into a non-
magnetic gelatin capsule. The capsule was then inserted into a plastic straw. Then, the 
straw was mounted into the SQUID sample rod and inserted into MPMS device. 
Magnetization data were taken at temperatures 5K < T < 350 K, using a liquid-He-
cooled variable-temperature installed in the commercial SQUID-magnetometer 
apparatus (MPMS, Quantum Design Inc., San Diego, USA). The temperature-
dependent magnetization was determined in a small, (u0H = 0.01T) between body 
temperature, T = 310 K, and T = 5K. The measurement was performed at varying 
temperatures moving the samples through a pick-up coil system connected to the 
SQUID via a flux transformer in a constant magnetic field, generate by a 
superconducting coil.   
 
2.17 MAGNETHERM SYSTEM DEVICE DESCRIPTION 
To perform in vitro MNHT experimentation, an alternating magnetic field generated 
by a commercial system (MagnethermTM V1.5, nanoTherics Ltd) was used in this 
study. The experimental setup consisted of the following components: a 
radiofrequency induction heater (magneThermTM version 1.5 nanoTherics Ltd), an 
oscilloscope (ISO-TECH ISR622 20 MHz), a laboratory power supply (EA-PS 3032-
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20B, EA Elektro Automatic), a function generator (SFG-2004, GW Instek), and a 
circulating water-cooling system.  
The radiofrequency induction heater was used to generate AMF to expose the MSC by 
high-frequency induction through 9-turn water-cooled, copper coil inside the device.  
Three different capacitors used in the magneThermTM: a 200 nF capacitance; a 22 nF 
capitance; and a 6.2 nF capitance to achieve the desired frequency range for the 9-turn 
coil. The function generator was used to generate a square waveform at three different 
frequencies:  178.3 kHz (23.89 mT), 540 kHz (24.87 mT), and 1030 kHz (13.37 mT). 
The DC power supply was supplied by a Digimess Concept series DC power supply 
SM5020 device. An oscilloscope was used to monitor the signal voltage passing 
through the coil. A continuous circulating water from sink drain system was used as 
water-cooling system to prevent the sample being exposed to the non-specific heating 
caused by the heat induction by the high-frequency magnetic fields in the coils.  
 
2.18 IN VITRO ALTERNATING MAGNETIC FIELD (AMF) 
EXPERIMENTATION 
2.18.1 Media used in the experiments 
Standard Medium: Mesenchymal Stem Cell Basal medium supplemented with 
Mesenchymal Stem Cell Growth Kit + Penicillin/streptomycin (100 U/ml/100µg/ml), 
and without FeQ. 
Iron Source Medium: Mesenchymal Stem Cell Basal medium supplemented with 
Mesenchymal Stem Cell Growth Kit + Penicillin/streptomycin (100 U/ml/100ug/ml), 
and FeQ. 
Ferucarbotran nanoparticles medium: Mesenchymal Stem Cell Basal medium 
supplemented with Mesenchymal Stem Cell Growth Kit + Penicillin/streptomycin 




2.18.2 AD-MSC Monolayer Culture and AMF Exposure Experimentation. 
AD-MSC expressing mms6 monolayer culture and AMF exposure 
procedure 
AD-MSC expressing mms6 (lenti-transduced AD-MSC) were cultivated with the iron 
source medium in T75 flask for 10 days. After 10 days incubation, the cells were then 
collected and seeded in sterile 35 mm Petri dishes at the density of 5 x 105 cells each 
Petri dish in 2 ml of standard medium. The cells were incubated at 37°C, 5 % CO2 
overnight before the AMF exposure at the following day. 
For the AMF exposure, six sterile 35mm Petri dishes, each containing a single 
monolayer of mms6-expressing MSC, were prepared as explained above. Then, three 
Petri dishes were exposed one by one to an AMF for 1 hour, in the magneTherm 
device, while the other three Petri dishes were placed in the magneTherm system under 
the similar conditions, but with the AMF switched off, as a control. After the AMF 
exposure, Petri dishes were incubated overnight in the incubator at 37°C and 5% CO2. 
The next day, the cell viability was assessed by AlamarBlue cell viability assay. 
Experiments were set in three different frequencies of AMF: 178.3 kHz (23.89 mT), 
540 kHz (24.87 mT), and 1030 kHz (13.37 mT). 
 
 
Ferucarbotran nanoparticle-loaded MSC monolayer culture and AMF 
exposure procedure. 
AD-MSC were seeded in sterile 35mm Petri dishes at the density of 5 x 105 cells each 
Petri dish in 2 ml of Ferucarbotran nanoparticles medium. The cells were incubated at 
37°C, 5 % CO2 overnight. The following day, the cells were washed with 1x PBS three 
times before replaced the medium with the standard medium and exposed the cells 
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with AMF exposure. After the AMF exposure, Petri dishes were incubated overnight 
in the incubator at 37°C and 5% CO2.  
For the AMF exposure, six sterile 35mm Petri dishes, each containing a single 
monolayer of Ferucarbotran nanoparticle-loaded MSC, were prepared as explained 
above. Then, three Petri dishes were exposed one by one to an AMF frequency for 1 
hour, in the magneTherm device, while the other three Petri dishes were placed in the 
magneTherm system under the similar conditions, but with the AMF switched off, as 
a control. After the AMF exposure, Petri dishes were incubated overnight in the 
incubator at 37°C and 5% CO2. The next day, the cell viability was assessed by 
AlamarBlue cell viability assay. Experiments were set in three different frequencies of 
AMF: 178.3 kHz (23.89 mT), 540 kHz (24.87 mT), and 1030 kHz (13.37 mT). 
 
2.18.3 MSC in 3D Culture and AMF Exposure Experimentation 
AD-MSC expressing mms6 in 3D culture and AMF exposure procedure 
AD-MSC expressing mms6 (lenti-transduced AD-MSC) were cultivated with the iron 
source medium in T75 flask for 10 days. After 10 days incubation, the cells were then 
washed with 1x PBS twice before trypsinized and centrifuged at 1000 rpm for 5 
minutes. Cells were then prepared in a 1.5 ml microcentrifuge tube at the concentration 
of 1 x 106 cells for each tube. The cells were then centrifuged again at 1000 rpm for 5 
minutes, to create a cell pellet. The supernatant was discarded and replaced with 50 µl 
standard medium.  
For the AMF exposure, six tubes of samples, each containing a single 3D cells of 
mms6-expressing MSC, were prepared as explained above. Then, three tubes were 
exposed one by one to an AMF of 540 kHZ frequency for 1 hour, in the magneTherm 
device, while the other three tubes were placed in the magneTherm system under the 
similar conditions, but with the AMF switched off, as a control. After the AMF 
exposure, cells were resuspended in 1 ml standard medium, then the 200 µl of 
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suspension cells were seeded into 6-well plate. The cells then incubated overnight in 
the incubator at 37°C and 5% CO2.  
After the AMF exposure, cells were resuspended in 1 ml standard medium, then the 
200 µl of cell suspension were seeded into 6-well plate in triplicate and incubated 
overnight in the incubator at 37°C and 5% CO2. The next day, the cell viability was 
assessed by AlamarBlue cell viability assay. 
 
Ferucarbotran nanoparticle-loaded MSC in 3D culture and AMF exposure 
procedure 
AD-MSC were cultivated in sterile T75 flask with the standard medium at the density 
of 5 x 105 cells each flask, until confluent. The medium was then replaced with the 
ferucarbotran nanoparticles medium. The cells were incubated at 37°C, 5 % CO2 
overnight. The following day, the cells were washed with 1x PBS three times before 
collected and centrifuged at 1000 rpm for 5 minutes. The cells were then prepared in 
a 1.5 ml microcentrifuge tube at the concentration of 1 x 106 cells for each tube. The 
cells were then centrifuged again at 1000 rpm for 5 minutes, to create a cell pellet. The 
supernatant was discarded and replaced with 50 µl standard medium. 
For the AMF exposure, six tubes of samples, each containing a single 3D cells of 
ferucarbotran nanoparticle-loaded MSC, were prepared as explained above. Then, 
three tubes were exposed one by one to an AMF of 540 kHZ frequency for 1 hour, in 
the magneTherm device, while the other three tubes were placed in the magneTherm 
system under the similar conditions, but with the AMF switched off, as a control.  
After the AMF exposure, cells were resuspended in 1 ml standard medium, then the 
200 µl of cell suspension were seeded into 6-well plate in triplicate and incubated 
overnight in the incubator at 37°C and 5% CO2. The next day, the cell viability was 




2.18.4 Cell Viability determination by AlamarBlue assay 
AlamarBlue Cell Viability Assay Description 
AlamarBlueTm is a reagent used to quantify cellular metabolic activity. The kit 
employed for these experiments relies on the indicator dye which incorporates an 
oxidation-reduction (REDOX) indicator that both fluorescence and changes colour in 
response to the chemical reduction of growth medium, resulting from living cells. The 
reagent solution contains blue-coloured molecule resazurin, which is non-toxic and 
non-fluorescent. The solution also cell permeable, which, when the molecule enters 
inside the cells, and chemically reduced by a metabolic activity of cells, turns into the 
highly fluorescent red-coloured resorufin. Both the fluorescence and the colour change 
resulted from this reaction can be monitored on a plate reader of a fluorescence 
spectrophotometer. By comparing this change of two or more cell populations, it is 
possible to do direct measurement of cell metabolic activity as well as viable cell 
concentration.  
 
AlamarBlue Cell Viability Assay experimental procedure 
Following the AMF exposure and overnight incubation in the incubator at 37°C and 
5% CO2, AlamarBlue reagent was added to the cell medium at 1/10th ratio of cell 
medium volume. Then, the cells were incubated in the incubator at 37°C and 5% CO2. 
After 4 hours incubation, the fluorescence change of the sample was then measured at 
the plate reader (FLUOstar Omega, BMG LABTECH) by excitation at 544 nm and 
emission at 590 nm.  
Results are presented both as relative fluorescence units (RFU) than as the percentage 
of cell viability, against controls considered as 100% viable. This percentage was 
calculated according to (Zachari et al., 2014): 






Blanks are represented by the medium without cells and with the addition of 10% 
AlamarBlue reagent. 
 
2.18.5 Cell apoptosis by TUNEL assay 
Cell apoptosis detection using TUNEL assay description 
Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) 
assay has been designed to detect apoptotic cells that undergo extensive DNA 
degradation during the late stages of apoptosis. The method is based on the ability of 
the enzyme terminal deoxynucleotidyl transferase to incorporate labeled dUTP into 
free 3'-hydroxyl termini generated by the fragmentation of genomic DNA into low 
molecular weight double-stranded DNA and high molecular weight single stranded 
DNA. TUNEL staining generally considered as a method for the detection of DNA 
damage (DNA fragmentation), and under the appropriate circumstances, more 
specifically as a method for identifying apoptotic cells.  
 
 
Cell apoptosis detection using Click-iT® Plus TUNEL assay experimental 
procedure 
AD-MSC expressing mms6 (lenti-transduced AD-MSC) were cultivated with the iron 
source medium in T75 flask for 10 days. After 10 days incubation, the cells were then 
collected and seeded in sterile 35 mm Petri dishes at the density of 5 x 105 cells each 
Petri dish in 2 ml of standard medium. The cells were incubated at 37°C, 5 % CO2 
overnight before the AMF exposure at the following day. 
For the AMF exposure, six sterile 35mm Petri dishes, each containing a single 
monolayer of mms6-expressing MSC, were prepared as explained above. Three Petri 
dishes were exposed one by one to an AMF of 540 kHZ frequency for 1 hour, in the 
magneTherm device. The other Petri dishes were placed in the magneTherm system 
without AMF exposure for an hour, as a control. After the AMF exposure, Petri dishes 
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were incubated overnight in the incubator at 37°C and 5% CO2. The next day, the cell 
apoptosis was assessed by The Click-iT® Plus TUNEL Assay, 
The assay was done based on the manufacturer’s specifications. A day after AMF 
exposure, the cells were fixed for 10 minutes in 4% paraformaldehyde in PBS, at room 
temperature. The cells were carefully washed in PBS three times, to remove all traces 
of formaldehyde. Then, they were permeabilized using 0.5 % Triton X-100. After an 
incubation for 20 minutes, the cells were washed (×2) with DNase free ultrapure water. 
After which, TdT reaction buffer was added to each cover slips prior to 60 minutes 
incubation with tetrathionate reaction cocktail (TdT reaction buffer, EdUTP, TdT 
enzyme). Then, the Petri dishes were washed with 3% bovine serum albumin (BSA) 
in PBS and were added with click-iT reaction cocktail (click-iT reaction buffer with 
Alexa FluorTM 488 dye–labeled and reaction buffer additive). After incubating for 30 
minutes, the samples were washed with 3% BSA in PBS for 5 minutes. The cells were 
washed 3 times in PBS and stained with Hoechst staining (DAPI). Images were 
obtained using the Nikon E800 fluorescence microscope. 
 
2.18.6 HSP70 gene expression analysis by western blot assay 
HSP70 gene expression analysis by western blot assay description  
The HSP70 family is a set of highly conserved proteins that are induced by a variety 
of biological stresses, including heat stress in all organism. These proteins are essential 
constituents of the cellular network of molecular chaperones and folding catalysts. 
HSP70 plays a vital role in several folding processes, such as the folding and assembly 
of newly synthesized proteins, refolding of misfolded and aggregated proteins. A 
protein analysis, western blot, was performed in this study to investigate the effect of 
the AMF exposure on HSP70 protein expression. 
 
HSP70 gene expression analysis by western blot assay description  
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AD-MSC expressing mms6 (lenti-transduced AD-MSC) were cultivated with the iron 
source medium in T75 flask for 10 days. After 10 days incubation, the cells were then 
washed with 1x PBS twice before trypsinized and centrifuged at 1000 rpm for 5 
minutes. Cells were then prepared in a 1.5 ml microcentrifuge tube at the concentration 
of 1 x 106 cells for each tube. The cells were then centrifuged again at 1000 rpm for 5 
minutes, to create a cell pellet in 1.5 ml centrifuge tube. The supernatant was discarded 
and replaced with 50 µl standard medium.  
For the AMF exposure, cells in the microcentrifuge tube were then exposed to 540 
kHZ frequency of AMF for 1 hour. After the AMF exposure, cells were resuspended 
in 1 ml standard medium, then reseeded into T75 flask. The cells then incubated 
overnight in the incubator at 37°C and 5% CO2. AD-MSC expressing mms6 not 
exposed to AMF were used as a control. 
After one day incubation, cells were washed with cold PBS and collected, then western 
blot assay was performed. For this assay, Anti-Hsp70 antibody, rat mAb (Cell 
Signaling) diluted at 1:1000 in 5% non-fat milk, in 0.1% TBST, was used as primary 
antibody. HRP-linked Anti-rat IgG (Cell Signaling) at a dilution of 1:1000 in 5% non-
fat milk made in 0.1% TBST was used as secondary antibody. The nitrocellulose 
membrane was then visualized using Clarity Western ECL substrate (Bio-Rad) in 
Odyssey® Fc Imaging System (Li-Cor). The intensities of the bands were quantified 
ImageStudioLite software from Li-Cor. 
 
2.19 STATISTICAL ANALYSIS 
Each experiment was conducted three times except where stated. The average, 
standard deviation (SD) were calculated from triplicate experiments. GraphPad prism 





2.20.1 List of reagents 
 
Table 2-10: Cell culture reagents 
Reagents Supplier 
Mesenchymal Stem Cell Growth Kit for Adipose and 
Umbilical-derived MSC – Low Serum 
ATCC, USA 
DMEM (Dulbecco’s Modified Eagle Medium) Life Technologies, UK 
FBS (Fetal Bovine Serum) Life Technologies, UK 
Trypsin with 0.25 % EDTA  Life Technologies, UK 
100 x PenStrep (Penicillin/Streptomycin) Life Technologies, UK 
PBS (Phosphate Buffered Saline) Life Technologies, UK 











Table 2-11: RNA Isolation/DNA synthesis/agarose gel electrophoresis/PCR 
reactions/Western blot reagents 
Reagents Company 
Ethanol Sigma Aldrich, UK 
DNA/RNAse free water Life Technologies, UK 
RNA Denaturating Loading Buffer New England Biolabs, UK 
Agarose Sigma Aldrich, UK 
Tris-Borate-EDTA buffer Thermo Fisher Scientific, UK 
RNAeasy Mini Kit Qiagen, UK 
DNAase I Kit Qiagen, UK 
Taq PCR Master Mix Kit (250 U) Qiagen, UK 
qScript cDNA Synthesis Kit Quanta Biosciences/VWR, UK 
SYBR Stain Life Technologies, UK 
DNA ladder/PCR Marker N3234S New England Biolabs, UK 
dNTPs Thermo Fisher Scientific, UK 
Anti-6X His tag® antibody [HIS.H8]  Abcam, UK 
4–20% Mini-PROTEAN®TGX™ Precast 
Protein Gels, 10-well (30 µl/well) 
Bio-Rad, UK 
RIPA Lysis buffer system Santa Cruz Biotechnology, UK 





Anti-beta Actin antibody [mAbcam 8226] Abcam, UK 
m-IgGκ BP-HRP secondary antibody Santa Cruz Biotechnology, UK 
2x Laemmli Sample Buffer Bio-Rad, UK 
Clarity™ and Clarity Max™ Western ECL 
Blotting Substrates 
Bio-Rad, UK 
Pierce™ Bovine Serum Albumin Standard 
Pre-Diluted Set 
Thermo Fisher Scientific, UK 
Tris Buffered Saline (TBS) Tablets Clontech Takara, USA 














Table 2-12: Gene purification from agarose gel/restriction enzymes 
digestion/vector dephosphorylation and ligation 
Reagents Company 
QIAquick Gel Extraction Kit Sigma Aldrich, UK 
EcoRI enzyme New England Biolabs, UK 
NotI enzyme New England Biolabs, UK 
KpnI enzyme New England Biolabs, UK 
XbaI enzyme New England Biolabs, UK 
HindIII enzyme New England Biolabs, UK 
NheI enzyme New England Biolabs, UK 
NEBuffer 3.1 (10x concentrated) New England Biolabs, UK 
Rapid DNA ligation kit New England Biolabs, UK 











Table 2-13: MSC osteogenic/adipogenic differentiation 
Reagents Company 
StemPro Osteogenesis Differentiation Kit Gibco, UK 
StemPro Adipogenesis Differentiation Kit Gibco, UK 
4% Paraformaldehyde Sigma Aldrich, UK 
Alizarin Red Alcian Sigma Aldrich, UK 
Oil Red O Solution Sigma Aldrich, UK 















Table 2-14: Transfection/MNP/TEM reagents 
Reagents Company 
X-tremeGENE™ HP DNA  Invitrogen, UK 
Lipofectamine 3000® Invitrogen, UK 
FugeneâHD Promega, UK 
MSC Nucleofection Kit Lonza, UK 
Polybrene Santa Cruz Biotechnology, 
UK 
3% Glutaraldehyde Sigma Aldrich, UK 
Formaldehyde Sigma Aldrich, UK 
Ferucarbotran Magnetic Nanoparticle, 54 nm Meito Sangyo, Japan 
FluidMAG-CT Magnetic Nanoparticle, 50 nm Chemicell, Germany 
BNF-Dextran Magnetic Nanoparticle, 80 nm Micromod, Germany 
NanoMAG D-Spio Magnetic Nanoparticle 50 nm Micromod, Germany 







Table 2-15:  In vitro AMF experimentation 
Reagents Company 
Alamar Blue Cell Viability Assay Thermo Fisher Scientific, UK 
Click-iT® Plus TUNEL Assay Life Technologies, UK 
HSP70 (6B3) Rat mAb  Cell Signaling Technology, UK 
Anti-rat IgG, HRP-linked Antibody  Cell Signaling Technology, UK 
 
Table 2-16: Bacteria transformation/plasmid amplification/plasmid purification 
Reagents Company 
Subcloning Efficiency DH5αTM Competent Cells Invitrogen, UK 
SOC medium Invitrogen, UK 
Agar Sigma Aldrich, UK 
Ampicilin 1000x Sigma Aldrich, UK 
LB Broth (Luria-Bertani medium) Sigma Aldrich, UK 
Plasmid MiniPrep Kit Qiagen, UK 
Endotoxin-Free Plasmid Maxi Kit Qiagen, UK 
Isopropanol Sigma Aldrich, UK 



























 EXPRESSION OF mms6 IN HUMAN ADIPOSE DERIVED-
MESENCHYMAL STEM CELLS 
3.1 SUMMARY 
A magnetosome gene, mms6,  has been known for its important roles in controlling 
the size and the shape of the nanosized crystal to be specifically cubo-octahedral in 
magnetotactic bacteria (MTB) (Amemiya et al., 2007). Previous study has shown that 
mms6 gene can be expressed in mammalian cells, 9L glioblastoma tumour cells, using 
lipid-based transfection (Zhang et al., 2014). Other MTB gene, magA, which is known 
to be involved in iron transport process in MTB, also can be expressed in human cell 
line, 293FT (Zurkiya et al., 2008). Therefore, the main goal of this chapter was to 
demonstrate the mms6 gene expression in human adipose derived-mesenchymal stem 
cells (AD-MSC). To reach this goal, I performed synthetic mms6 gene molecular 
cloning and examined whether this gene can be introduced and expressed in AD-MSC 
using a non-viral transient transfection technique. The mms6 gene expression in AD-
MSC was determined at mRNA and protein level. Moreover, cell morphology and cell 
viability, essential parameters in transfection techniques, were also investigated in this 
study.  
In order to introduce an MTB gene, mms6, a foreign gene into AD-MSC, a suitable 
gene construct and vector are fundamental. Even more important, the protein must be 
functional since the Mms6 protein has a major role in binding iron to form magnetic 
nanoparticles. For these reasons, a codon optimised mms6 gene was used in the 
synthetic mms6 gene construct. Codon optimisation is the term given to the synthetic 
creation of a gene sequence primarily aim to obtain the optimal codon usage patterns 
for a specific host organism to enhance expression (Patterson et al., 2005). This was 
essential as mammalian expression of foreign genes such bacterial genes is often low 
(Narum et al., 2001). 
A Kozak sequence, which plays a major role in the initiation of translation process in 
mammalian expression, was also added to the mms6 gene construct positioned 
upstream of the start codon of the mms6 gene. In addition, a polyhistidine-tag (6x) 
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sequence was also added into the synthetic mms6 gene construct as a protein 
expression marker. This optimised gene construct was named MAGISTER-02 
(Mag02) and the sequence map can be seen in Figure 3-1. The gene was synthesized 
by GeneArt® Gene Synthesis service and cloned into a mammalian vector plasmid 
pcDNA3.1(+). The name Mag02 was used as a previous codon-optimised mms6 
(Mag01) was designed and already investigated in a previous study by Lisa Lungaro, 
former PhD student in the group. 
As other primary cells, MSC are difficult to transfect (de Carvalho et al., 2018). Hence, 
a suitable transfection technique is required for efficient mammalian expression. This 
study involves transient and stable transfection. Transiently transfected genetic 
materials can be lost by environmental factors and cell division. However, it is 
important to start with transient transfection and evaluate the gene expression before 
moving into stable transfection. Therefore, in this Chapter, a transient transfection 
technique using X-tremeGENE™ HP DNA (Roche), a non-lipid complex polymer, 
was chosen to introduce the synthetic mms6 gene, Mag02, into AD-MSC. Following 
the transfection, the Mag02 expression in AD-MSC was determined using end-point 
PCR and western blotting.  
 
Figure 3-1: Gene construction map of Mag02 gene fragment. The construct contains 
a synthetic codon optimized mms6 gene. It has polyhistidine-tag and Kozak sequence at the N 
terminus. The gene was cloned into a mammalian vector plasmid pcDNA3.1(+) at KpnI and 





The aims of the experiments detailed in this chapter were: 
1. To amplify the plasmid DNA containing Mag02 using molecular cloning 
techniques 
2. To demonstrate expression of Mag02 mRNA in AD-MSC through end-point 
PCR experiments 
3. To demonstrate mms6 protein expression through western blot analysis 
















3.3 AMPLIFICATION OF PLASMID DNA CONTAINING MAG02 
The use of high-quality plasmid DNA as DNA delivery vector that is free of proteins, 
RNA, and chemicals is crucial before starting the transfection procedure. In this study, 
the Mag02 DNA sequence was synthesized by GeneArt® Gene Synthesis service and 
had been cloned to pcDNA3.1 plasmid at KpnI and EcoRI restriction site. This 
particular plasmid was chosen as common mammalian vector. Once the plasmid had 
been amplified by bacterial transformation using DH5α competent E. coli cells, it was 
necessary to purify and analyse the plasmid yield and its DNA quality. Miniprep 
protocol and Maxiprep protocol, a standard commercial plasmid DNA Extraction kit 
via silica spin columns, were employed to purify the DNA plasmid containing Mag02 
fragment.  
Firstly, Miniprep was performed for rapid DNA plasmid isolation and to analyse the 
bacterial clones. This was an important step to determine whether or not the Mag02 
plasmid can be amplified without mutation before conducting Maxiprep in order to 
obtain high quantity of plasmid DNA for the later transfection study. The DNA 
plasmid purified from Miniprep were digested using the restriction enzyme KpnI and 
EcoRI. The digestion products were then visualized via electrophoresis on 1.2% 
agarose gel. These steps were necessary so that I could quickly confirm that the Mag02 
has been successfully amplified with a correct base pair length of 466 bp. Following 
the enzyme digestion, DNA sequencing analysis of the Mag02 gene sequence was also 
carried out to validate the successful of Mag02 DNA amplification. 
Five samples of Miniprep purified plasmid from five different clones were analysed 
using KpnI and EcoRI restriction enzymes. As shown in Figure 3-2, all digested 
samples as indicated in lane 1, 3, 5, 7, 9 showed bands at around 500 bp, suggesting 
the presence of DNA fragment resulted from KpnI and EcoRI enzyme digestion. In 
contrast, the undigested control samples as indicated in lane 2, 4, 6, 8, and 10 did not 
show band. Therefore, this result confirmed that the digestion worked well and I was 
able to identify that all five clones of DH5α were carrying the Mag02 gene fragment. 
Moreover, all five samples showed DNA fragment with size around 500 bp of base 
pair length instead of 466 bp in correspondence to the original sequence. However, it 
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was possible that all of the sizes are correct but the DNA ladder and the DNA 
fragments may be running differently. This is thought to be due to the assumption that 
the amount of salts in the buffer of the DNA ladder and that of the samples loaded 
differ. Too much salt makes the sample run slower so fragments may look larger.  
 
Figure 3-2: Restriction enzyme digestion analysis of plasmid DNA containing 
Mag02 obtained from Miniprep plasmid DNA extraction. Agarose gel 
electrophoretograms demonstrating plasmid DNA containing Mag02 gene fragment 
successfully cut by KpnI and EcoRI restriction enzymes. Lane 2, 4, 6, 8, 10 = plasmid 
containing Mag02 gene fragment cut by KpnI and EcoRI) whereas Lane 1, 3, 5, 7, 9 = 
undigested plasmid as control.  
For closer inspection of the Mag02 fragment of the plasmid from the Miniprep, DNA 
sequencing of Mag02 was carried out. The sequencing results were then aligned to 
match the original sequence using the Basic Local Alignment Search Tool (BLAST).  
The DNA sequencing analysis of the plasmid, as shown in Figure 3-3 indicated that 
the sample sequence result (466 bases) was 100% identity (466/466) to the original 
sequences of Mag02 gene fragment. Therefore, these restriction enzyme digestion and 




Figure 3-3: DNA sequencing analysis of plasmid DNA containing Mag02 
obtained from Miniprep. Detailed side by side alignment information for the DNA 
sequence result for sample (query) and known Mag02 gene sequence (subject). The sample 
sequence result (466 bases) was 100% identity (466/466) to the sequences of Mag02 gene 
fragment. 
After confirming the success of the Mag02 amplification using Miniprep, it was 
necessary to produce high-quantity of Mag02 DNA plasmid by performing Maxiprep. 
This was aimed to obtain a large stock of Mag02 DNA plasmid for later transfection 
experiments. Therefore, similar restriction enzyme digestion assay and DNA 
sequencing analysis were also carried out to analyse the purified plasmid DNA product 
from Maxiprep.  
Two samples of Maxiprep purified plasmid from two different clones were analysed 
using KpnI and EcoRI restriction enzymes. As shown in Figure 3-2, the two digested 
samples as indicated in lane 1 and 3 showed DNA band at around 500 bp, suggesting 
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the presence of DNA fragment resulted from KpnI and EcoRI enzyme digestion. 
Whereas the undigested control samples as indicated in lane 1 and 4 did not show DNA 
band or digested DNA fragment. Therefore, this result confirmed that the Maxiprep 
purified plasmid contains Mag02 gene fragment. 
 
Figure 3-4: Restriction enzyme digestion analysis of plasmid DNA containing 
Mag02 obtained from Maxiprep. Agarose gel electrophoretograms demonstrating 
plasmid DNA containing Mag02 gene fragment successfully cut by KpnI and EcoRI restriction 
enzymes. Lane 1 and 3 = plasmid containing Mag02 gene fragment cut by KpnI and EcoRI) 
whereas Lane 3 and 4 = undigested plasmid as control.  
The expected size of the DNA fragment from restriction enzyme digestion was 466 bp 
instead of ~500 bp as indicated in agarose gel electrophoretograms analysis. Therefore, 
DNA sequencing was conducted.  BLAST analysis of DNA sequencing result, as 
presented in Figure 3-4, indicated that the sample sequence result (466 bases) was 
100% identity (466/466) to the original sequences of Mag02 gene fragment. Overall, 
these results confirmed that the plasmid containing Mag02 gene fragment was 




Figure 3-5: DNA sequencing analysis of plasmid DNA containing Mag02 
obtained from Maxiprep. Detailed side by side alignment information for the DNA 
sequence result for sample (query) and known Mag02 gene sequence (subject). The sample 
sequence result (466 bases) was 100% identity (466/466) to the sequences of Mag02 gene 
fragment. 
 
3.4 EXPRESSION OF MAG02 mRNA IN AD-MSC 
In order to evaluate the mms6 gene expression on AD-MSC, cells were transfected 
with Mag02 plasmid. For this, cells were seeded at 1 x 105 cells per well in 24-well 
plates one day prior to transfection. On the day of transfection, OptiMEM media was 
prepared in tubes at 100 µl per tube. DNA plasmid (3 µg) was put into the OptiMEM 
media, then 9 µl (1:3 ratio to the DNA concentration) of transfection reagent was added 
to the mixture. The complexes were incubated for 20 minutes, then gently added into 
the cells. Each sample transfection was performed in triplicate. Cells transfected with 
transfection reagent without plasmid were used as negative control. The cells were 
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then incubated at 37°C with 5% CO2. Cells were cultured in a FeQ doped medium (34 
µM) for 10 days. Non-transfected AD-MSC cultured for 10 days in similar FeQ doped 
medium (34 µM) were considered as a negative control. Ten days after the 
transfection, RNA was extracted from transfected AD-MSC, and cDNA was 
synthesized. Thereafter, the Mag02 mRNA expression in AD-MSC was determined 
by end-point PCR. To test this, a set of internal primers to obtain an amplicons length 
of 142 bp were designed using PRIMER3 software: 
 
Forward : 5’ GGA CCA AAG TGG CAC TGG 3’  
Reverse : 5’ CCC ACT ACG CCC AAG ATG AT 3’ 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene, a popular housekeeping 
standard gene in expression studies, was used as an internal control. 
 
 
Figure 3-6: Mag02 mRNA expression in AD-MSC determined by end-point PCR. 
A set of internal primers to obtain an amplicons length of 142 was used to determine Mag02 
mRNA expression in AD-MSC. GAPDH was used as internal control. Mag02 mRNA 
expression was detected in AD-MSC at 10 days after transfection, as indicated in lane 8, 10, 
and 12 (tripilicate). Lane 1-6 = Untransfected cells as control; Lane 7-12 = AD-MSC 
transfected with Mag02 plasmid. N = 3. 
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As shown in Figure 3-6, the end point-PCR result showed bands in all three samples 
of AD-MSC transfected with Mag02 plasmid, as indicated in lane 8, 10 and 12. All 
the three bands sat around a little less than 150 bp marker on the ladder, suggesting the 
correct expected size of 142 bp DNA.  As for negative control, band was absence in 
untransfected cells, as shown in lane 2, 4, and 6. Whereas bands of GAPDH internal 
control was shown consistently in all samples both transfected and untransfected cells, 
confirming the validity of the end-point PCR experiment. Therefore, these results 
confirmed Mag02 mRNA expression in AD-MSC at 10 days after transfection.  
 
3.5 EXPRESSION OF MAG02 PROTEIN IN AD-MSC 
After confirming the mms6 expression at transcriptional level as indicated by Mag02 
mRNA in AD-MSC following the transfection, it was necessary to determine whether 
translation was occurring leading to production of Mms6 protein by the transfected 
cells. For this, AD-MSC were transfected with Mag02 plasmid using X-
tremeGENE™ HP DNA transfection reagent. Briefly, cells were seeded at 1 x 105 
cells per well in 24-well plates one day prior to transfection. On the day of transfection, 
OptiMEM media was prepared in tubes at 100 µl per tube. DNA plasmid (3 µg) was 
put into the OptiMEM media, then 9 µl (1:3 ratio to the DNA concentration) of 
transfection reagent was added to the mixture. The complexes were incubated for 20 
minutes, then gently added into the cells. The cells were then incubated at 37°C with 
5% CO2. Two days after the transfection, total protein was extracted from the cells, 
then the Mag02 protein expression was evaluated using Western blot assay. Since the 
Mms6 antibody is not available commercially for the western blot assay, polyhistidine 
tag antibody was used to detect his-tag Mms6 protein expression in AD-MSC. Non-
transfected AD-MSC were considered as negative control, while ß-actin was used as 
internal control in this experiment.  
As shown in Figure 3-7, no his-tag protein was observed on both Mag-02 transfected 
AD-MSC and control cells at 2 days after transfection. The expected size of his-tag 
protein was 35.71 kDA protein. The internal control, ß-actin, was shown in both 
transfected and control cells, showing the expected size of 42 kDA protein. This result 
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suggested that Mag02, or his-tag Mms6 protein expression in particular, was absence 
after the transfection, suggesting AD-MSC were not able to express Mms6 protein. 
Another possibility could be a low transfection efficiency at the level where the Mms6 
protein amount was too low to be detected by Western blot technique.  
 
Figure 3-7: Mag02 protein expression in AD-MSC. Image of western bloting assay 
indicating no his-tag protein with the expected size of 35.71 kDA was detected in Mag02-
transfected AD-MSC at 2 days after initial transfection. β-actin serves as internal control. N 
= 3. 
 
3.6 EFFECT OF MAG02 GENE TRANSFECTION ON CELL VIABILITY AND 
MORPHOLOGY OF AD-MSC 
The ideal method for an optimal transfection technique should have high transfection 
efficiency, low cell toxicity, minimal effects on normal physiology, and be easy to use 
and reproducible. In this section, cell toxicity and morphology of the AD-MSC were 
evaluated following the transfection with Mag02 plasmid using using X-
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tremeGENE™ HP DNA Transfection reagent. Cell viability assay was determined at 
1, 3 and 5 days after transfection using AlamarBlue assay.  
As shown in Figure 3-8, AlamarBlue fluorescence intensity average values were 
7863±97.07 for transfected cells, and 8578±25.48 for control at day 1 after 
transfection, showing 8.33% decreased of cell viability on the transfected cells. At day 
3, AlamarBlue fluorescence intensity average values were 7820±94.16 for transfected 
cells, and 11128±67.42 for control. Whereas at day 5, AlamarBlue fluorescence 
intensity average values were 8550±98.33 for transfected cells, and 11762±56 for 
control. This result demonstrated that the cell viability difference between transfected 
and control group become greater over time after transfection as the fluorescence 
intensity average value of transfected cells were 29.72% and 27.31% significantly less 
compared to control group at 3 days and 5 days after transfection, respectively .  
 
Figure 3-8: Cell viability analysis of AD-MSC transfected with Mag02 plasmid. 
AlamarBlue data showing average of fluorescence intensity of Mag-02 transfected AD-MSC 
compared to untransfected cells. Significant decreased of cell viability was observed at 1, 3, 
and 5 days after transfection using X-tremeGENE™ HP DNA transfection reagent. 
*P<0.0001. Values are presented as mean ± SD. N=3 
 
The cell morphology was also observed up to 10 days after transfection and imaged 
by light microscopy. As shown in Figure 3-9, cells with either a triangular shape, star-
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like cell shape or spindle-shaped morphology were observed in both transfected and 
control cells. No observable morphological differences between two groups, indicating 
the transfection of AD-MSC using X-tremeGENE™ HP DNA transfection reagent 
and the expression of Mag02 mRNA have no effect on AD-MSC morphology at 10 
days after transfection. 
 
 
Figure 3-9: Representative image of AD-MSC cell mophology at 10 days after 
transfection with Mag02. Light microscopy image showing either triangular or spindle-
shaped morphology of cells on both transfected and control cells. No observable 
morphological differences between two groups, indicating the transfection of AD-MSC using 
X-tremeGENE™ HP DNA transfection reagent does not have effect on AD-MSC cell 
morphology. A) Untransfected AD-MSC (5x magnification); B) Untransfected AD-MSC (10X 
magnification); C) Mag02-transfected AD-MSC (5x magnification); D) Mag02-transfected 






The aims of this chapter were as follows: 
1. To amplify the plasmid DNA containing Mag02 gene fragment using 
molecular cloning technique 
2. To demonstrate expression of Mag02 mRNA in AD-MSC through end-point 
PCR experiments. 
3. To demonstrate mms6 protein expression through western blotting analysis 
4. To investigate cell viability and morphology of AD-MSC following the mms6 
gene transient transfection 
My first aim was successful in that I was able to amplify the Mag02 plasmid using 
standard molecular techniques. It was important to amplify and obtain high-quality 
plasmid DNA without any mutation or gene changes on the mms6 gene sequence 
before starting the transfection procedure. The  enzyme restriction digestion and DNA 
sequencing result confirmed that the Mag02 plasmid was succesfully amplified. The 
DNA band indicated that Mag02 fragment from all samples have around 500 bp of 
base pair length instead of 466 bp in correspondence to the original sequence, the DNA 
sequencing result demonstrated that the sample have 100% identity to the original 
sequence, which confirms the successful of Mag02 DNA amplification. 
The end-point PCR result answers the second aim of this chapter as it demonstrates 
that MTB genes, mms6, can be expressed in AD-MSC. This result was in aggrement 
with the result from previous work by Elfick et al. (2017) using another MTB gene, 
mmsF and a different codon optimised mms6 gene (Mag01) (Elfick et al., 2017). The 
study demonstrated mms6 mRNA expression in Mag01-transfected human bone 
marrow-derived MSC cells at 10, 15 and 21 days post-transfection using similar 
transfection reagent as in my study. Sanger DNA sequencing of the PCR transcripts of 
the mms6 gene at 10, 15 and 21 days post-transfection also showed 100% identity with 
the inserted gene (Elfick et al., 2017). However, despite validating mms6 gene 
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expression at the RNA level, that study did not provide evidence of Mms6 protein 
expression although intracellular nanoparticles were identified by TEM.  
Considering the importance of Mms6 protein in binding the iron to form magnetic 
nanoparticles (Wang et al., 2012; Rawlings et al., 2016), it was necessarry to confirm 
Mms6 protein expression through Western blotting assay. Unfortunately, despite the 
successful mms6 mRNA expression up to 10 days after transfection, the Western blot 
assay failed to identify expression of a His-tag Mms6 protein at 2 days after 
transfection. There are a few possible explanations for this: it could be due to low 
transfection efficiency, or it could be the Mms6 protein expression being at low level 
which can not detected by Western blotting. It may also be possible that mms6 mRNA, 
for unknown reason, is not translated into functional Mms6 protein by AD-MSC or 
that the Mms6 protein might be directly degraded by AD-MSC cell system.  
Furthermore, there was also a high likelihood that the bands in end-point PCR result 
reflect the plasmid DNA as contaminant, which potentially resulting in a false positive 
result. The plasmid concentration used in the transfection was 3 µg, which is a lot and 
could contaminate the RNA isolation and end-point PCR assays. To negate this issue, 
DNAse should be used during RNA isolation process to degrade plasmid DNA 
contaminant (Añez-Lingerfelt et al., 2009). Negative control should be also performed 
in the end-point PCR experiments, such as: 1) A no template control omits any DNA 
or RNA template from a reaction, and serves as a general control for extraneous nucleic 
acid contamination, and 2) A no reverse transcriptase control or minus reverse 
transcriptase control involves carrying out the reverse transcription step of a PCR 
experiment in the absence of reverse transcriptase. This control assesses the amount of 
DNA contamination present in an RNA preparation. 
Zhang et al (2014) investigated the possibility of using mms6 as an MR reporter gene. 
They designed a transgenic mammalian cell line, gliosarcoma cell line, that stably 
expresses mms6 by using Lipofectamine 2000® transfection reagent followed by 
Zeocin antibiotic selection (Zhang et al., 2014). In similar way to my study, their mms6 
gene construct also has polyhistidine epitope tag to be used for verifying the expression 
of Mms6 protein. The study was able to demonstrate His-tag Mms6 protein being 
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expressed as well as the ability of the transfected cells to produce intrinsic magnetic 
nanoparticle. However, in my study, unlike cancer cell line or other primary cell types, 
MSC are known difficult cells to transfect (Baek et al., 2016). Common non-viral 
transfection methods used for mammalian cells, such as a cationic lipid-based reagent 
transfection system, still generally show low-to-moderate (less than 15%) gene 
transfer efficiency in transfecting MSC (Wang et al., 2015). The absence of Mms6 
protein expression in this chapter is likely to be related to this. 
Zaragosi and coworkers (2007) reported that only fewer than 5% of AD-MSC were 
successfully transfected using calcium phosphate precipitation and lipofectants 
transfection reagent (i.e., Lipofectamine 2000® and FuGENE transfection reagents) 
(Zaragosi et al., 2006). Similarly, previous study using human bone marrow-derived 
MSC (BM-MSC) also demonstrate poor transfection efficiency of 4.4% with 
FuGENE6 and 6.8% for DOTAP, two commonly used lipid-based non-viral 
transfection reagents (Aluigi et al., 2006). Unsuccessful attempt to generate AD-MSC 
expressing Mms6 protein in this chapter was thought to be related to the low 
transfection efficiency using the X-tremeGENE™ DNA Transfection Reagent, thus it 
was necessary to investigate a more effective transfection approach that suits AD-MSC 
which will be discussed in the next chapter.  
Since the mms6 gene was clearly expressed at transcriptional level and not proven to 
be expressed at the translational level, it was speculated that the codon optimised mms6 
of Mag02 gene construct may be not be optimal for mammalian cell expression. To 
further investigate these possibilities, different codon optimised of mms6 needs to be 
considered. Therefore, further attempts of using different technique of transfection, 
different codon optimised, and different synthetic mmm6 gene construct using double 






 EXPRESSION OF MMS6 PROTEIN IN AD-MSC AND IMPROVING 
AD-MSC TRANSFECTION STRATEGIES. 
 
4.1 SUMMARY 
In this chapter, the focus of the study was to investigate the expression of different 
codon optimised mms6 in AD-MSC. It was hypothesized that certain codon 
optimisation or transfection approaches might be more suitable and efficient for 
expressing mms6 in AD-MSC.   
In Chapter 3, transfected AD-MSC appeared to show no Mms6 protein expression, 
despite mms6 mRNA being detected up to 10 days after transfection using X-
tremeGENE™ Transfection Reagent. Since AD-MSC are recognised as a difficult to 
transfect cell type, a likely reason is low transfection efficiency from using a chemical-
based transfection reagent. Therefore, several non-viral based transfection approaches 
both chemical-based and physical-based, were further investigated in an attempt to 
express Mms6 protein in AD-MSC.  
As discussed in Chapter 3, the absence of Mms6 protein expression could also be due 
to the codon optimisation of mms6 gene (Mag02) which may not allow translation in 
the mammalian cells. Hence, different codon-optimised mms6 were designed and 
investigated: MagWT, Mag01, Mag02 and Mag03.  
MagWT contains the original sequence mms6 gene of M. magneticum strain AMB-1 
mms6 gene without codon optimisation. Mag01 was kindly designed by Dr. Greg 
Kudla (Group leader of RNA synthetic biology group, MRC Institute of Genetics & 
Molecular Medicine, University of Edinburgh). Mag02 was designed by Dr. Chris 
Boyd (Group leader of gene therapy for cystic fibrosis research group, MRC Institute 
of Genetics & Molecular Medicine, University of Edinburgh). Mag03 was designed 
by GeneArt® Gene Synthesis service (Thermo Fisher Scientific).  
Each of these constructs also have a polyhistidine-tag at the N terminus and a GFP-tag 
at the C terminus of the mms6 DNA fragment. The use of these double marker tags 
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was important for investigating Mms6 protein expression due to the non-availability 
of a Mms6 antibody. Each of this construct was cloned into pcDNA 3.1 plasmid at at 
NheI/HindIII restriction site. The details of these codon optimised mms6 gene 
constructs can be seen in Chapter 2. 
End-point PCR, flow cytometry, western blot and GFP imaging analysis were carried 
out to determine the expression of both mms6 mRNA and Mms6 protein. Alamar Blue 
cell viability assays were used to determine the effect of the transfection on AD-MSC 
cell viability. In addition, a lentiviral vector carrying the mms6 gene was also designed 
in order to perform AD-MSC viral transduction. This technique was used to achieve 
stable expression of mms6 in AD-MSC owing to the integration of the virus DNA into 
the host genome. This may be important for increasing Mms6 protein production 
which should improve the internal synthesis of magnetic nanoparticles in AD-MSC. 
 
4.2 AIMS 
The aims of the experiments detailed in this chapter were: 
1. To demonstrate the mRNA expression of different codon optimised mms6 in 
AD-MSC 
2. To demonstrate the protein expression of different codon optimised mms6 in 
AD-MSC 
3. To improve the transfection approach of AD-MSC for transient Mms6 protein 
expression using nonviral-based transfection. 




4.3 EXPRESSION OF DIFFERENT CODON OPTIMISED mms6 IN AD-MSC 
End-point PCR method was used to investigate the mms6 gene expression in AD-
MSC. For this, cells were transfected with each of MAGISTER plasmids using X-
tremeGENE™ Transfection Reagent. Both transfected cells and non-transfected cells 
as a control were cultured in a FeQ doped medium (34 µM) for 10, 15, and 21 days. 
Following the incubation, RNA of the cells from each time point was extracted. 
Thereafter, cDNA was obtained by reverse transcription, and was used for end-point 
PCR.  
A set of internal primer pairs for each of the MAGISTER genes were designed using 
Primer3 software. The amplicon lengths of each primer were the following: 210 bp, 
229 bp, 185 bp and 155 bp for MagWT, Mag01, Mag02, and Mag03, respectively, as 
described in Error! Reference source not found. in Chapter 2. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) primer was used as an internal control. The 
experiment was performed for three times.  
As shown in the Figure 4-1, the bands of mms6 under (+) marks were present in all 
MAGISTER-transfected AD-MSC at 10, 15 and 21 days after transfection. These 
bands were found to be consistent for each sample with the expected size which were 
210 bp for MagWT, 167 bp for Mag01, 185 bp for Mag02 and 155 bp for Mag03, 
respectively.  
As an internal control, the GAPDH bands under (-) marks were also present in all 
MAGISTER-transfected AD-MSC at 10, 15 and 21 days after transfection. These 
bands were found to be consistent for all samples with the expected size of 210 bp. 
Moreover, all negative controls under (#) marks show no bands, confirming the 
validation of the experiment. As an overall result, the end-point PCR demonstrates the 
expression of mms6 mRNA in AD-MSC up to 21 days following transfection with 




Figure 4-1: Image for end point-PCR reaction for different codon optimised 
mms6 gene expression in AD-MSC at 10 days (A), 15 days (B) and 21 days (C) 
after transfection with X-tremeGENE™ Transfection Reagent. The end-point PCR 
demonstrates the expression of mms6 mRNA in AD-MSC up to 21 days after transfection using 
X-tremeGENE™ DNA Transfection Reagent. Panel A = 10 days after transfection; Panel B 
= 15 days after transfection; Panel C = 21 days after transfection. (+) = MAGISTER-
transfected cells; (-) = GAPDH internal control for MAGISTER-transfected cells; (#) = 
negative control/untransfected cells. 766 bp NEB marker used in the gel electrophoresis. N=3. 
 
4.4 MMS6 PROTEIN IS NOT EXPRESSED IN AD-MSC, BUT EXPRESSED 
IN HEK293T CELLS. 
The expression of Mms6 protein in AD-MSC was assessed using Western blot and 
GFP imaging. For this, AD-MSC were transfected with each of MAGISTER plasmids 
using X-tremeGENE™ Transfection Reagent. A common easy to transfect cell line, 
HEK293T cells, were also used and transfected with MAGISTER plasmids using the 
same method. The cells were then incubated in a growth medium for 2 days.  
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For the Western blot assay, 20 µg of protein lysates of cells extracted at 2 days after 
transfection were used. The non-transfected cells of both AD-MSC and HEK293T 
cells were considered as a negative control. Protein lysates were run on a Western blot 
with antibodies specific to His(6x)-tag protein and  ß-actin as loading control. For the 
GFP imaging, the cells were fixed at 2 days after transfection, then observed under 
fluorescence microscope. Cells transfected with pmaxGFP plasmid were used as a 
positive control. Nuclei were counterstained using DAPI. The experiment was 
performed at least three times. 
As shown in the Figure 4-2, no protein bands were detected in AD-MSC transfected 
cells after the transfection with all the four MAGISTER plasmids. However, four 
bands of His-tag protein were found around the expected size of interest (44 KDa) in 
HEK293T transfected cells. The His-tag protein was also absent in the negative 
controls of both AD-MSC and HEK293T cells, while ß-actin proteins with the 
expected size (42 KDa) were consistently expressed in all samples, confirming the 
validation of the experiment. Overall, this result demonstrates Hig-tag Mms6 protein 
expression in each of MAG-transfected HEK293T cells, but absence in MAG-
transfected AD-MSC. 
 
Figure 4-2: Western blot showing His-tag Mms6 protein expression in HEK293T 
cells at 2 days after transfection with X-tremeGENE™ Transfection Reagent. 
Hig-tag Mms6 protein expression was absence in all four MAG-transfected AD-MSC. Blots 
probed for His-tag protein and β-actin as a loading control. N = 3. 
In agreement with the Western blot result, Figure 4-3 shows that HEK293T cells 
transfected with each of MAGISTER plasmids were expressing green fluorescence 
signal which confirmed the expression of GFP-tag Mms6 protein. The GFP expression 
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was also found in the positive control, but absence in the negative control, confirming 
the validation of the experiment. 
 
Figure 4-3: Image for GFP imaging analysis for GFP-tag Mms6 protein 
expression in HEK293T cells at 2 days after transfection with X-tremeGENE™ 
Transfection Reagent. A = MagWT-transfected HEK293T cells; B = Mag01-transfected 
HEK293T cells; C = Mag02-transfected HEK293T cells; D = Mag03-transfected HEK293T 
cells; E = pmaxGFP-transfected HEK293T cells /positive control; F = control/untransfected 
cells. Scale bar = 100 µm. N = 3. 
These results confirm that both non-codon optimised mms6 gene (MagWT) and codon 
optimised mms6 gene (Mag01, Mag02 and Mag03) can be expressed in mammalian 
cells such as HEK293T cells. Unfortunately, this result also confirmed the absence of 
both His-GFP tag Mms6 protein, either non-codon optimised mms6 or codon 
optimised mms6, in transfected AD-MSC. Therefore, this may suggest that the use of 
X-tremeGENE™ Transfection Reagent might not be sufficient to transfect AD-MSC 




4.5 NUCLEOFECTION IMPROVES THE EFFICIENCY OF AD-MSC 
TRANSFECTION. 
After having had difficulties in expressing the Mms6 protein in AD-MSC, it was 
necessary to test other nonviral-based transfection approaches in order to ascertain 
whether this approach could allow a higher transfection efficiency. In general, the 
nonviral-based transfection approach can be classified into chemical and physical 
transfection methods. For this, common chemical-based transfection reagent such as 
FugeneHD®, Lipofectamine 3000® and X-tremeGENE™ HP DNA Transfection 
Reagent were used. In additio, nucleofection, a physical-based transfection method 
using Human Mesenchymal Stem Cell Amaxa™ Nucleofection kit was also 
performed. The transfection efficiency was measured using Flow cytometry to analyse 
the percentage of cells positively expressing GFP from each of transfection 
approaches.   
For the three chemical-based transfections, AD-MSC were plated into 24-well plates 
a day before transfection. Thereafter, 3µg of Mag01 plasmid was used to transfect the 
cells in the following day. For the nucleofection method, AD-MSC were collected 
from cell culture and directly transfected using the Amaxa™ Nucleofection kit. All of 
these transfections were undertaken on the same day. The transfected cells were then 
incubated at 37oC in 5% CO2 incubator for 2 days.  The cells were then collected and 
analysed by Flow cytometry. Untransfected cells from each group was used as a 
negative control. The experiment was repeated twice.  
As shown in the Table 4-1, the Flow cytometry result indicated that the percentage of 
GFP-positive cells were 59.6±1.9 %, 6.6±0.6 %, 15.5±3.9%, and 2.6±0.2% for Mag01-
transfected AD-MSC with Amaxa™ Nucleofection, Lipofectamine 3000®, X-
tremeGENE™ HP DNA, and FugeneHD® Transfection reagent, respectively.  It was 
observed that the use of Amaxa™ Nucleofection resulted in the highest percentage of 
AD-MSC positively expressing GFP-tag Mms6 protein with value of 59.6±1.9 %. This 
number was 3.8 times higher than the number of GFP positive cells from Mag01-
transfected cells using X-tremeGENE™ transfection reagent which was only 
15.5±3.9%. Compare to lipid-based transfection, Nuclofection techniques was 8.9 
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times more efficient than Lipofectamine 3000® in transfecting AD-MSC as 
Lipofectamine 3000® only generates 6.6±0.6% of GFP positive cells. The lowest 
transfection efficiency was 2.6±0.2% from Mag01-transfected AD-MSC using 
FugeneHD® Transfection Reagent, which was 22 times less efficient compared to 
Amaxa™ Nucleofection. Overall, Nucleofection technique improves the efficiency of 
AD-MSC transfection.  
 
Table 4-1: Percentage of GFP-positive cells after Mag01 transfection of AD-MSC 
using different transfection reagent. 
Method Percentage of GFP-positive cells 
Amaxa™ Nucleofection 59.6±1.9% 
Lipofectamine 3000® 6.6±0.6% 




4.6 MMS6 PROTEIN IS EXPRESSED IN AD-MSC AFTER 
NUCLEOFECTION. 
Following the above observations that transfection efficiency of AD-MSC was 
improved using Nucleofection, it was necessary to investigate Mms6 protein 
expression in AD-MSC after Nucleofection with each of MAGISTER plasmids to 
identify which, if any, resulted in maximal protein production. Flow cytometry, GFP 
imaging and Western blotting were used to assess Mms6 protein expression.  
For the Flow cytometry and GFP imaging, AD-MSC were transfected with each of the 
MAGISTER plasmid using Amaxa™ Nucleofection kit. As a positive control, AD-
MSC were transfected with pMax GFP plasmid. Untransfected cells were used as 
negative control. After 2 days of incubation, cells were either collected for Flow 




For the Western blot, AD-MSC were transfected with each of the MAGISTER plasmid 
using Amaxa™ Nucleofection kit. After 2 days of incubation, 20 µg of protein lysates 
from each sample were used for the Western blot assay. The non-transfected cells of 
both AD-MSC were considered as a negative control, while ß-actin was used as an 
internal control. The experiment was repeated three times. 
As shown in the Figure 4-4, the Flow cytometry result shows that around 45–55% of 
AD-MSC from each group of MAG-trasfected AD-MSC were expressing GFP-tag 
Mms6 protein after the Nucleofection. The percentage of cells expressing GFP were 
47.3±4.1%, 49.4±3.5%, 53.9±1.2%, and 47.3±3.7% for cells nucleofected with 
MagWT, Mag01, Mag02 and Mag03, respectively. The percentage of GFP positive 
cells which transfected with pmaxGFP plasmid was 87.9±2.9%, which was 
significantly higher than cells nucleofected with MAGISTER plasmids. Overall, this 
result confirmed the previous result that nucleofection technique improves the 
efficiency of AD-MSC transfection. Moreover, all of transfected AD-MSC showed 
GFP-tag Mms6 protein expression in all samples which was the ultimate goal of the 
experiment.  
 
Figure 4-4: Flow cytometry analysis of positive MAGISTER-transfected AD-MSC 
expressing GFP.  No statistical difference in percentage of GFP positive MAGISTER-
transfected AD-MSC cell in all samples but pmaxGFP-transfected AD-MSC. Values are 





Figure 4-5 shows the results for GFP imaging assay. Cells expressing green 
fluorescence were found in nucleofected-AD-MSC with each of MAGISTER plasmids 
and pmaxGFP plasmid. This result agrees with the previous Flow cytometry result, 




Figure 4-5: Image for GFP imaging analysis for GFP-tag Mms6 protein 
expression in AD-MSC at 2 days after nucleofection. All MAG-transfected AD-MSC 
samples successfully expressing GFP-tag Mms6 protein green following nucleofection.. A = 
MagWT-transfected AD-MSC; B = Mag01-transfected AD-MSC; C = Mag02-transfected AD-
MSC; D = Mag03-transfected AD-MSC; E = pmaxGFP-transfected AD-MSC /positive 
control; F = control/untransfected AD-MSC. Scale bar = 100 µm. N= 3 
Further experiment also confirmed the Mms6 protein expression in AD-MSC. As 
shown in Figure 4-6A, Westen blot result shows His-tag protein bands were identified 
around the expected size of interest (44 KDa) in each of MAG-transfected AD-MSC 
sample. The His-tag protein was absent in the negative controls, while ß-actin protein 
bands with the expected size (42 KDa) were shown in all samples. This result, finally, 
confirmed the expression of His-GFP-tag Mms6 protein in AD-MSC after 
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nucleofection. Figure 4-6B shows the deduced levels of His-tag Mms6 protein for 
each band, corrected by ß-actin. Although, it seems that the expression of His-tag 
Mms6 protein was found to be highest in AD-MSC transfected with Mag03 compared 




Figure 4-6: Western blot analysis for His-GFP-tag Mms6 protein expression in 
AD-MSC at 2 days after nucleofection. A) Image for western blot of three independent 
experiments. B) Protein levels of His-tag Mms6 from each of MAGISTER-transfected AD-
MSC were normalised by Actin. Values are presented as mean ± SD from three independent 
experiments.  N = 3 
 
4.7 DECREASED AD-MSC CELL VIABILITY AFTER NUCLEOFECTION 
The effect of nucleofection on the cell viability of AD-MSC was assessed by the 
AlamarBlue Cell Viability assay. For this, AD-MSC cell samples were transfected 
with either Mag03 or the pmaxGFP plasmid using Amaxa™ Nucleofection kit. The 
non-transfected cells were considered as a negative control. A day after nucleofection, 
cell viability determination was performed.   
The results are shown in Figure 4-7. AlamarBlue fluorescence intensity average was 
7040 ± 231% for cells nucleofected with Mag03, and 8627±373% for cells 
nucleofected with pmaxGFP, against mean fluorescence intensity of 10356±410 % for 
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control untransfected cells. The results are statistically significant (p<0.0001) for cells 
nucleofected with Mag03 and (p<0.01) for cells nucleofected with pmaxGFP plasmid. 
Cell viability percentage of transfected cells was calculated as a ratio between 
transfected and controls cells, and it is shown in considering controls as 100% viable. 
Results reveal that the viability of cells nucleofected with Mag03 was 66.2±2.5% of 
that of controls, while the viability of cells nucleofected with pmaxGFP was 
82.3±6.5% of that of controls 
 
 
Figure 4-7: Cell viability measurement of Mag03-transfected and pmaxGFP-
transfected AD-MSC by AlamarBlue Cell Viability Assay. AD-MSC nucelofected with 
Mag03 plasmid (light grey column), or with pmaxGFP plasmid (dark grey column), or not 
nucleofected (controls - black column). A = fluorescence intensity; B = Cell viability 
percentage of transfected cells against controls. Values are presented as mean ± SD from one 






4.8 DECREASED MMS6 PROTEIN PRODUCTION WITH TIME IN 
CULTURE 
Consistent with the known transient nature of plasmid-based transfection, transgene 
expression generally decreased rapidly over time, lasting usually 2 to 3 weeks. To 
assess the stability of Nucleofection-based transfection of the transfected His-GFP-tag 
mms6, the time course and level of expression were determined. For this analysis, 
nucleofected cells were analyzed and sorted for GFP expression from day 2 up to day 
21 after nucleofection. Specifically, on d 2, 7, 14, and 21, cells were trypsinized and 
reanalyzed for GFP-positive cells.  
As shown in Figure 4-8, the number of positive GFP-expressing cells dropped to 
29.3% by day 7 and to 4.6 % by day 14, then declined to only 0.6% by day 21, for 
MagWT nucleofected cells. For Mag01-nucleofected cells, the number of positive 
GFP-expressing cells dropped to 25.5% by day 7 and to 3.4 % by day 14, then went 
down to 0.2% by day 21. In Mag02-nucleofected cells, the number of positive GFP-
expressing cells also dropped to 24.7% by day 7 and to 4.3 % by day 14, then declined 
to only 0.3% by day 21. Similar result also observed in Mag03-nucleofected cells, as 
the number of positive GFP-expressing cells also dropped to 25.9% by day 7 and to 
4.1 % by day 14, then declined to only 1% by day 21.  Thus, nucleofection tecnhique 
exhibited a time course that declined over time, as would be expected for a transient 
transfection with no subsequent expression-based selection. However, it is noteworthy 
that a substantial level of His-GFP tag Mms6 expression was detected even after 7 









Figure 4-8: Flow cytometry analysis of GFP-positive MAG-transfected AD-MSC 
at different time point after nucleofection.  A) Image of percentages of positive cells 
for His-GFP-tag Mms6 protein expression at different time point:  I = 2 days; II = 7 days; III 
= 14 days; and IV = 21 days after nucleofection. B) His-GFP-tag Mms6 expression decreases 






4.9 LENTIVIRAL TRANSDUCED AD-MSC STABLY EXPRESSING mms6 
Having confirmed that Mms6 protein can be expressed in AD-MSC but only 
transiently, it was necessary to generate AD-MSC stably expressing mms6. For this, 
viral transduction was performed using lentivirus carrying codon optimized mms6 
(Mag01, without His-GFP tag). The mms6 sequence was cloned into pSicoR-Ef1α-
mCh-Puro lentiviral transfer plasmid. This vector has two important markers which 
were Puromycin selection marker and mCherry red fluorescence marker, allowing for 
selection of the transduced cells.  
For virus transduction, AD-MSC and HEK293T cells were seeded in into 24-well plate 
and grown overnight. HEK293T cell line were used as a positive control due to their 
feature as ‘easy to transfect’ cell line. A day after incubation, cells were then 
transduced with the virus particle. For HEK293T cells, MOI (multiplicity of infection) 
ratios of 5 and 10 were used, while MOI ratios of 10, 15 and 30 were used for AD-
MSC. 
After 2 days of incubation, the medium was refreshed with 2 µg/ml Puromycin 
selection medium to generate stable cells expressing the mms6 gene. The selection 
medium was changed every 3 days. The mCherry red fluorescence produced by cells 
was observed every 5-7 days during the selection process for three weeks. Moreover, 
mCherry red fluorescence imaging and end-point PCR assay were performed to 
confirm the mms6 expression. The successful cells stably expressing mCherry red 
fluorescence were then expanded for the later experiments. 
As shown in Figure 4-9, AD-MSC were expressing red fluorescence in all samples at 
1 week after lentiviral transduction. It seems that the higher the MOI ratio, the brighter 
the red fluorescence. Similar to this result, cells expressing red fluorescence was also 
observed in transduced HEK293T cells, as shown in Figure 4-10, suggesting the 




Figure 4-9: mCherry red fluorescence analysis of AD-MSC a week after lenti-
mms6 transduction. AD-MSC expressing mCherry red fluorescence after lenti-mms6 
transduction using three different MOI ratio. A = Magnification 5x, scale bar 500 µm. B = 
Magnification 10x, scale bar 100 µm. N = 3. 
 
Figure 4-10: mCherry red fluorescence analysis of HEK293T cells a week after 
lenti-mms6 transduction. HEK293T cells expressing mCherry red fluorescence after 
lenti-mms6 transduction with two different MOI ratio. A = Magnification 5x; B = 




Figure 4-11 shows transduced AD-MSC were expressing mCherry red fluorescence 
expression at 3 weeks after lenti-mms6 viral transduction. By visual inspection brighter 
red fluorescence signal was also observed in higher MOI used for the transduction. 
Overall, this result suggests that the lentiviral transduction approach was able to 
generate AD-MSC stably expressing mms6 gene as confirmed by the constant 
expression of mCherry red fluorescence. 
 
 
Figure 4-11: mCherry red fluorescence analysis for AD-MSC at three weeks after 
lenti-mms6 transduction. AD-MSC stably expressing mCherry red fluorescence at three 
weeks after lenti-mms6 transduction with three different MOI ratio. Scalebar 100 µm. N = 3 
 
To further confirm the mms6 expression, end-point PCR was also performed at 3 
weeks after transduction. To test this, a set of internal primers to obtain an amplicons 
length of 167 bp were used: 
 
Forward : 5’ GAA AGT GGT GGG CGG CAC 3’  
Reverse : 5’ CCA CTT CTT CAT CGC TCT GC 3’ 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers was used as an 
internal control. 
As shown in Figure 4-12, the DNA bands of mms6 were present in all transduced cell 
samples, as indicated by lane D, F and H for cells transduced with MOI 10, 15 and 30 
of lenti-mms6 viral titer, respectively. These DNA bands were found at position 
slightly above 150 bp of the PCR marker. This was found to be consistent in each 
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sample with the expected DNA band of 167 bp. No mms6 DNA bands was observed 
in untransfected cells, as indicated in lane B. As for the internal control, GAPDH DNA 
bands were also present both in all samples, both untransfected cells and in lenti-mms6 
transduced AD-MSC. These DNA bands were also found to be consistent for all 
samples with the expected size of 210 bp, confirming the validation of the experiment. 
Overall, the end-point PCR demonstrates the expression of mms6 mRNA in AD-MSC 
up to 3 weeks following the lentiviral transduction, suggesting the integration of viral 
DNA which carries mms6 into the host DNA of AD-MSC allowing the cells to to 




Figure 4-12: mms6 gene expression in AD-MSC at 3 weeks after lentiviral 
transduction. The end-point PCR demonstrates the expression of mms6 (Mag01) mRNA in 
AD-MSC following lenti-mms6 transduction. A-B = Control; C-D = MOI 10; E-F = MOI 30. 






The aims of the experiments detailed in this chapter were: 
1. To demonstrate mRNA expression of different codon optimised mms6 in AD-
MSC 
2. To demonstrate protein expression of different codon optimised mms6 in AD-
MSC 
3. To improve the transient transfection approach for Mms6 protein expression in 
AD-MSC using nonviral-based transfection. 
4. To develop AD-MSC stably expressing mms6 using Lentiviral transduction. 
Regarding the first aim, the end-point PCR results indicate that both non-codon 
optimised and codon optimised mms6 can be expressed in AD-MSC.  The mRNA of 
mms6 was constantly expressed in AD-MSC up to 21 days after the transfection with 
each of the MAG plasmid using X-tremeGENE™ DNA Transfection Reagent.  
Initially, it was hypothesised that certain codon optimised mms6 for mammalian cell 
expression might be more preferable than non-optimised mms6 by AD-MSC cell 
system for the protein expression. Indeed, codon optimization can affect protein 
conformation and function, thus the optimal codon usage patterns for a specific host 
organism can be used to enhance expression (Patterson et al., 2005; Mauro and 
Chappell, 2014).  
However, the initial Western blot result showed that the His-GFP-tag Mms6 protein 
expression was found to be absent in all samples after the transfection with X-
tremeGENE™ DNA Transfection Reagent. Nonetheles, the His-GFP-tag Mms6 
protein was observed to be expressed in HEK293T cells, as indicated by Western blot 
and GFP imaging assay. This result confirms that the absence of His-GFP-tag Mms6 
protein in all samples might not be related to the codon optimisation of the mms6. 
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Instead, this most likely as a consequence of low transfection effiency since AD-MSC 
has been known as difficult to transfect cells.  
It is also important to note that, as discussed in Chapter 3, there was also a high 
likelihood that the bands in end-point PCR result could reflect the plasmid DNA as 
contaminant, giving a false positive result. The high concentration of MAG plasmid 
DNA used in the transfection which was 3 µg may contaminate the RNA isolation and 
end-point PCR assays. Therefore, it is important to use DNAse during RNA isolation 
process to avoid this issue. Moreover, negative control should be also performed in the 
end-point PCR experiments, such as: 1) A no template control omits any DNA or RNA 
template from a reaction, and serves as a general control for extraneous nucleic acid 
contamination, and 2) A no reverse transcriptase control or minus reverse transcriptase 
control involves carrying out the reverse transcription step of a PCR experiment in the 
absence of reverse transcriptase. This control assesses the amount of DNA 
contamination present in an RNA preparation. 
In an attempt to improve the transient transfection efficiency of AD-MSC, several 
nonviral-based transfection approaches were investigated. Based on the Flow 
cytometry analysis, it was observed the electroporation method using Amaxa™ 
Nucleofection was able to generate 59.6±1.9% of GFP-positive cells at 2 days after 
transfection with Mag01 plasmid. This was the highest percentage of transfection 
efficiency compared to the previously used method using X-tremeGENE™ 
transfection reagent with only 15.5±3.9% GFP-positive cells. Other methods using 
Lipofectamine 3000® and FugeneHD® only generated relatively low transfection 
efficiency with only 6.6±0.6% and 2.6±0.2%, respectively. This low transfection 
efficiency result was in agreement with other report which suggests lipid and 
polymeric agents typically can transfect only 2–35% of MSC (Santos et al., 2011). 
Moreover, the conventional cationic liposome method was not effective for MSC 
transfection as it resulted in very low transfection efficiency even close to 0 % (Mun 
et al., 2016). In contrast, Haleem-smith and coworkers reported that the application of 
electroporation method using Amaxa™ Nucleofection was able to enhance the 
transfection efficiency of adult human MSC. With this method, transfection 
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efficiencies of 50 to 80% were achieved using two different GFP expression plasmid 
constructs (Haleem-Smith et al., 2005). Similar to this finding, my work also shows 
that nucleofection using Amaxa™ Nucleofection was able to produce high transfection 
efficiency, as the percentage of AD-MSC expressing GFP were 47.3±4.1%, 
49.4±3.5%, 53.9±1.2%, and 47.3±3.7% for cells nucleofected with MagWT, Mag01, 
Mag02 and Mag03, respectively. Other group also tried to overexpress CXCR4 in 
human MSC using mRNA nucleofection approach and obtained 90% expression of 
the surface receptor, suggesting high effectivity of nucleofection technique for 
modification of human MSC (Wiehe et al., 2013). 
The result of experiments described in this chapter confirm the protein expression of 
His-GFP-tag Mms6 protein in AD-MSC after electroporation. The GFP fluorescence 
expressed by AD-MSC evaluated by both Flow cytometry and GFP imaging analysis 
confirmed the success of expressing Mms6 protein in AD-MSC. This was also 
confirmed by Western blot analysis which shows the expression of His-GFP-tag 
protein in all cell samples nucleofected with MagWT, Mag01, Mag02 and Mag03 
plasmid. 
It was also hypothesized that different codon optimised mms6 may improve Mms6 
protein expression, hopefully resulting in increased MNP production. To test this 
hypothesis, a semi-quantitative protein quantification analysis was performed using 
western blot. Even though the result reveals the expression of His-GFP-tag Mms6 
protein was found to be highest in AD-MSC transfected with Mag01 and Mag03 
compared to the other two plasmids, statistically no significant variation of Mms6 
protein expression was observed. More replicates may be needed to measure whether 
there is a significant difference of Mms6 protein expression level due to certain codon 
optimisation of mms6.   
AD-MSC cell viability was found to be affected by electroporation which results in 
reducing its cell viability. AlamarBlue cell viability analysis reveals that the viability 
of cells nucleofected with Mag03 was significantly decreased to 66.2±2.5% against 
100% cell viability of control. This was expected as, generally, the disadvantage of 
using electroporation method is the tendency for high level of damaged cells (Kaestner 
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et al., 2015). In agreement with the finding in my study, Helledie et al. (2008) also had 
optimized the parameters of electroporation of human MSC (hMSC), using 
exponential decaying pulses. The result of the study indicated up to 90% stable 
transfection efficiency. However, the main disadvantage of this electroporation 
approach was that it decreased 50% cell viability, suggested that this technique is 
rather harsh and caused a high rate of cell mortality, especially in MSC (Helledie et 
al., 2008). The significant effect on cell viability following the electroporation may be 
due to the large surface area of the electrode (Halim et al., 2014). 
Moreover, it was also noticed that the Mms6 protein production was decreased over 
time in culture, which was expected for a transient transfection method. In general, 
transiently transfected genes are only expressed for a limited period of time. This most 
likely as a consequence of the transfected genetic material are not integrated into the 
genome and affected by cell division and environmental factors (Kim and Eberwine, 
2010). Moreover, the drop off in expression is also likely due to cytomegalovirus 
(CMV) promoter used in the plasmid. CMV promotor has been known its advantage 
to direct a high level of transient gene expression. However, a potential drawback of 
the CMV promoter is that it is prone to silencing over time after being introduced into 
the genome of host cells (Damdindorj et al., 2014). Previous study has demonstrated 
that the CMV promoter in plasmid vectors directs a prominently high level of transient 
gene expression, but such gene expression does not persist for a long period of time in 
human cell lines (Damdindorj et al., 2012). For long term expression, mammalian 
promoter such as elongation factor-1α(EF1α) may be a more suitable for this work as 
it offers more stable expression (Norrman et al., 2010).  
However, it is noteworthy that over 20% level of His-GFP tag Mms6 expression at 7 
days after transfection was observed in all nucleofected cell samples, suggesting high 
efficiency of the approach.  In agreement with this finding, a study also reported that 
following the MSC electroporation using Amaxa™ Nucleofection, a drop in the 
number of GFP expression cells was observed over time, corresponding to 21% at day 
13 and 12% at day 23, resulting a significant number of GFP- positive MSC cells 
remained by 3 weeks post transfection (Haleem-Smith et al., 2005) 
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The final aim of this chapter was to develop AD-MSC stably expressing mms6 using 
Lentiviral transduction. It has been well known that classical transfection methods are 
generally less efficient than viral-based techniques, in particular for AD-MSC 
transfection (Halim et al., 2014). Previous studies investigating human-periodontal-
ligament-stem-cell (hPDLSC) transfection using nonviral-based transfection method 
such Lipofectamine 3000® and X-tremeGENE DNA Transfection Reagent compared 
to lentiviral vectors harboring a green-fluorescent-protein gene indicated that 
transfection efficiency of nonviral-based transfection was unsatisfactory (<6%) 
compared to that of lentiviral vectors (95%) (Wang et al., 2015). Taken together all 
this evidence, it was then decided to clone the mms6 into a lentiviral vector in order to 
develop AD-MSC stably expressing mms6. In my study, I did not perform transfection 
efficiency measurement following the lentiviral transduction. Instead, I performed 
antibiotic selection started at day 2 after transduction and continuously for 2 weeks in 
order to obtain colony of AD-MSC expressing mms6.  
The results of lentiviral transduction experiment described in this chapter confirm that 
AD-MSC can be modified to stably expressing mms6 as shown by continuous mCherry 
red fluorescence protein marker expression and mms6 mRNA expression at 3 weeks 
after transduction. This was as expected due to the fact that viral vector has nature of 
integration into the host genome, providing high efficiency of gene transfection. The 
integrated viral DNA replicates as the host genome does. Consequently, it segregates 
into daughter cells, which enables sustainable transgene expression (Kim and 
Eberwine, 2010).  
In summary, nucleofection, although rather harsh and leading to excessive cell death, 
is highly effective for transient expression of Mms6 in AD-MSC. Morevor, viral-based 
transduction, using lentiviral carrying mms6, was also able to generate AD-MSC stably 
expressing mms6. These cells were utilized for the later MNHT experiments in the 
following chapter. Importantly, this chapter has succeeded to demonstrate expression 
of an MTB gene, mms6, in AD-MSC both in transcriptional and translational level 


























 THE EFFECT OF mms6 EXPRESSION ON THE AD-MSC 




In chapter 4, experiments successfully showed that it is possible to express a bacterial 
magnetic gene, mms6, in AD-MSC. However, the main aim of the research was to 
produce biogenic magnetic human AD-MSC which can be used for MNHT or MRI 
applications. Therefore, in this chapter, it was determined if the mms6 expression of 
AD-MSC could cause any detrimental effect on the nature characteristic of AD-MSC 
by investigating MSC stemness and its multipotency. Further investigations on 
magnetic nanoparticles produced in AD-MSC expressing mms6 was then assessed by 
Transmission Electron Microscopy (TEM) analysis. This work also involved 
investigations using commercial iron-based MNP for comparison of magnetic 
properties between AD-MSC expressing mms6 and iron-based nanoparticle labelled 
AD-MSC. 
To determine whether lenti-mms6 transduced AD-MSC could still be considered stem 
cells and have utility in the clinical setting, experiments were carried out to confirm 
MSC stemness and the ability of the cells to differentiate into the osteogenic and 
adipogenic lineage.  
For the iron-based nanoparticle-labelled AD-MSC studies, several commercial iron-
based MNP, NanoMAG-D-Spio, BNF-Dextran, FluigMAG-CT and Ferucarbotran 
nanoparticles, were used. The stability of these nanoparticles in culture medium as 
well as cell viability analysis of AD-MSC loaded with these nanoparticles were then 
performed. To look further on the nanoparticle uptake ability of MSC, Prussian blue 
staining and TEM analysis were performed.  
For the TEM analysis, AD-MSC expressing mms6 were cultured in a ferric quinate 
(FeQ) doped medium (3.4 µl FeQ/ml), following the standard protocol for the culture 
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of MTB, to provide non-magnetic iron necessary to create nanoparticle material. In 
this experiment, three group of AD-MSC expressing mms6 were used: lenti-mms6 
transduced-cells, Mag01-nucleofected cells, and Mag03-nucleofected cells. They were 
cultured in FeQ medium for 10 days, allowing incubation time for the cells to bind the 
iron. Furthermore, the magnetism of AD-MSC expressing mms6 and MNP labelled 
AD-MSC were evaluated by Superconducting Quantum Interference Device (SQUID) 
upon zero field cooling (ZFC) and field cooling (FC) magnetic measurement.  
 
5.2 AIMS 
The aims of the experiments detailed in this chapter were: 
1. To investigate the effect of mms6 expression in AD-MSC stemness and 
differentiation potential. 
2. To study magnetic nanoparticle production by AD-MSC expressing mms6 and 
commercial magnetic nanoparticle-labelled AD-MSC. 











5.3 ANALYSIS OF STEM CELL SURFACE MARKERS OF AD-MSC 
EXPRESSING mms6. 
In order to investigate whether AD-MSC expressing mms6 are still able to express 
typical mesenchymal stem cell surface markers, immunofluorescence analysis was 
performed. This was important to define whether the stable expression of mms6 could 
affect the ability of stem cells in maintaining their stemness and differentiation 
potential.  
Immunofluorescence was performed on lentiviral transduced AD-MSC expressing 
mms6 cell samples. Cells were stained with anti-CD44, anti-CD90, anti-CD14 and 
anti-CD19, followed by Alexa Fluor 488-conjugated goat anti-mouse IgG (green) 
secondary antibody. CD44 or homing cell adhesion molecule (HCAM) and CD90 are 
MSC positive surface markers, while CD14 (present on leukocytes) and CD19 (present 
on B-lymphocytes) are negative markers for MSC. The non-transfected or wild type 
AD-MSC were used as a positive control. The experiment was run in triplicates. 
As shown in Figure 5-1 A-B, both AD-MSC expressing mms6 and control cells stained 
with anti-CD44 or anti-CD-90 shows green fluorescence signal. On the other hand, the 
green fluorescence signal was not detected in both cell lines stained with anti-CD14 or 
anti-CD-19 (Figure 5-1 C-D). This result indicates the expression of MSC positive 
markers and the lack of negative markers expression on both AD-MSC expressing 
mms6 and control cells. This suggests that AD-MSC expressing mms6 are still able to 
express the typical mesenchymal stem cell surface markers, and the expression of 







Figure 5-1: Analysis of mesenchymal stem cell surface markers. 
Immunofluorescence image showing both AD-MSC expressing mms6 (left panel) and 
untransduced AD-MSC as control (right panel) stained with A) anti-CD44, B) anti-CD90, C) 
anti-CD14, and D) anti-CD19, followed by Alexa Fluor 488-conjugated goat anti-mouse IgG 
(green) secondary antibody. Cell nuclei is shown in blue (DAPI) and surface markers 
positivity is shown in green. Scale bar = 100 µm. N=3. 
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5.4 ASSESSMENT OF ADIPOGENIC AND OSTEOGENIC 
DIFFERENTIATION POTENTIAL OF AD-MSC EXPRESSING mms6. 
In order to evaluate whether stable expression of mms6 could cause any adverse effect 
on MSC pluripotency, in vitro functional differentiation experiments were carried out 
on AD-MSC expressing mms6 and wild-type AD-MSC. Both cells group were 
differentiated into the osteogenic and adipogenic lineage using the appropriate 
medium for each lineage. The results were then compared, using the wild-type AD-
MSC as a positive control. 
For osteogenic differentiation, AD-MSC expressing mms6 and control cells were 
incubated with osteogenic differentiation medium for 14 and 21 days. Cells grown in 
standard medium served as negative controls. At each time point, osteogenic 
differentiation of both cell lines was assessed by identification of calcium deposits 
stained by the Alizarin Red dye. The experiment was run in triplicates. 
For adipogenic differentiation, AD-MSC expressing mms6 and wild-type AD-MSC 
were incubated with adipogenic differentiation medium for 10 days. Cells grown in 
standard medium served as negative controls. Following the incubation, cells were 
fixed in 4% paraformaldehyde and stained by Oil Red O. Pictures of cells were taken 
in light microscopy and photographed using a coloured camera. The experiment was 
run in triplicates. 
As shown in Figure 5-2, following 14 days in osteogenic and standard culture medium 
calcium deposits were not detected in either AD-MSC expressing mms6 or wild-type 
AD-MSC. At 21 days AD-MSC expressing mms6 and wild-type AD-MSC in 
osteogenic media showed extensive calcium deposition whereas cells in control media 
did not show calcium deposition. The result indicates no difference was observed 
between AD-MSC expressing mms6 and wild-type AD-MSC both at 14 days and 21 
days incubation with osteogenic differentiation medium, indicating successful 
differentiation of both cell lines into osteoblasts and in vitro bone-formation. This 
result demonstrates the expression of mms6 did not affect the ability of AD-MSC in 




Figure 5-2: AD-MSC expressing mms6 differentiate into osteogenic lineage. 
Alizarin staining data showing both AD-MSC expressing mms6 (upper panel) and wild-type 
AD-MSC as control (lower panel) cultured for 14 days and 21 days in osteogenic medium (A 
& C) or in standard medium (B & D). N=3. 
 
After being cultured in adipogenic medium for 10 days, both AD-MSC expressing 
mms6 and wild-type AD-MSC began to form small intracellular translucent vacuoles, 
which then gradually filled the cytoplasm along the cell membrane, exhibiting 
adipogenic phenotype. As shown Figure 5-3, both cell lines show formation of 
intracellular lipid droplets, stained in bright red colour by Oil Red O. No formation of 
lipid droplets and morphological changes were noticed in both cell lines cultured in 
standard medium. Therefore, this result confirms the expression of mms6 did not affect 
the ability of AD-MSC in maintaining their adipogenic differentiation potential and 




Figure 5-3: AD-MSC expressing mms6 differentiate into adipogenic lineage. Oil 
Red O staining data showing both AD-MSC expressing mms6 (left panel) and control cells 
(right panel) cultured for 10 days in adipogenic medium (A-B) or in standard medium (C-D). 
Scale bar = 100 µm. N=3. 
 
5.5 ASSESSMENT OF COMMERCIAL IRON-BASED MNP STABILITY IN 
THE CULTURE MEDIUM. 
In vitro studies using chemically synthesized MNP were also performed. The 
experiment aimed to find the best candidate of MNP for MNP-loaded AD-MSC. This 
will allow a comparison study of MNP-loaded AD-MSC and AD-MSC expressing 
mms6 being able to self-produce nanoparticles. For this purpose, fully synthetic 
commercial iron oxide-based MNP were investigated: NanoMAG D-Spio, BNF-
Dextran, FluigMAG-CT and Ferucarbotran nanoparticle.  
Since MNP colloidal stability in culture medium is a crucial factor in in vitro assay, 
the colloidal stability of each of these MNP was measured. Colloidal stability of MNP 
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in medium is indicated by consistent turbidity over time. Therefore, turbidity 
measurement of these nanoparticles in culture medium was performed to assess their 
colloidal stability. For this analysis, a turbidity assay was monitored over a period up 
to 24 h, namely 0, 2 h, 16 h and 24 h, with MNP concentration of 500 µg/ml. MNP 
were suspended in culture medium or in PBS. The turbidity of MNP suspension was 
measured at 450 nm using a microplate reader. The experiment was conducted in 
quadruplicates and repeated twice. 
 
Figure 5-4: Spectroscopy of 450 nm of iron-based MNP in PBS and in basic 
culture medium. Turbidity analysis data showing absorbance value of A) NanoMAG D-
Spio in culture medium and PBS; B) BNF-Dextran in culture medium and PBS; C) FluidMAG-
CT in culture medium and PBS; D) Ferucarbotran in culture medium and PBS.   Values are 
presented as mean ± SD. N = 4. 
As shown in Figure 5-4, both NanoMAG D-Spio and BNF-Dextran showed increasing 
absorbance value in culture medium over period of 24 hours, suggesting the turbidity 
of the nanoparticle was increased or not stable in the medium. This was also confirmed 
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with debris formation at the bottom of culture plate after 16 hours of incubation by 
visual inspection. On the other hand, despite increased turbidity over time in PBS, 
FluidMAG-CT showed consistent turbidity in culture medium over period of 24 hours. 
Meanwhile, the turbidity measurement of Ferucabotran nanoparticles in both PBS and 
culture medium showed consistent values over 24 hours, indicating Ferucarbotran 
nanoparticles were the only colloidally stable MNP in both PBS and the culture 
medium. Based on these results, FluidMAG-CT and Ferucabotran nanoparticles were 
the most stable MNP in culture medium suspension among those four MNP, thus they 
were chosen for the later in vitro experiment.  
 
5.6 CELL VIABILITY OF MNP-LOADED AD-MSC 
Cellular viability of AD-MSC loaded with Ferucarbotran or FluigMAG-CT 
nanoparticles was assessed to investigate whether these iron-based MNP had cytotoxic 
effect on AD-MSC. For this, cells were seeded in 48-well plates (5 x 104 cells/well in 
500 µl medium) for 24 hours after which they were loaded with 25, 50, 100, 250, 500 
or 1000 µg/ml nanoparticles. Cells without MNP added were used as control. 
Following 24 hours of incubation, cell viability determination was performed using an 
AlamarBlue assay. The experiment was run in triplicates and repeated three times. 
As shown in Figure 5-5, AlamarBlue fluorescence intensity average decreased with 
increasing FluidMAG nanoparticle concentration. The fluorescence intensity average 
values were 6364±414, 5974±389, 5528±340, 4727±182, 4365±657, and 3381±245 
for cells incubated with 25, 50, 100, 250, 500 and 1000 µg/ml nanoparticle 
concentration, respectively, against average fluorescence intensity of 6940±548.99 for 
control cells. The fluorescence intensity was found to be statistically significant against 
control with value (p<0.01) for cells incubated with 100 µg/ml, (p<0.001) for cells 
incubated with 250 µg/ml, and (p<0.0001) for cells incubated with 500 and 1000 
µg/ml. This suggests that FluidMAG-CT nanoparticles are toxic for AD-MSC at MNP 




Figure 5-5: Cell Viability of MNP-loaded AD-MSC. AlamarBlue data showing 
fluorescence intensity of A) AD-MSC loaded with FluigMAG nanoparticles, and B) AD-MSC 
loaded with Ferucarbotran nanoparticles, cultured for 24 hours in standard medium. Values 
are presented as mean ± SD. *p≤0.05, **p≤0.01, *** p≤0.001, **** p≤0.0001 from control. 
N=3 
AlamarBlue fluorescence intensity average values were 9878±302, 9189±288, 
8488±209, 8037±43, 7903±20, and 7653±220 for cells incubated with 25, 50, 100, 
250, 500 and 1000 µg/ml Ferucarbotran nanoparticle concentration, respectively, 
against average fluorescence intensity of 9115.33±858.53 for control cells. The 
fluorescence intensity was found to be statistically significant against control with 





500 µg/ml, and (p<0.001) for cells incubated with 1000 µg/ml Ferucarbotran 
nanoparticle. This result indicated that Ferucarbotran nanoparticles are toxic for AD-
MSC at MNP concentration higher than 250 µg/ml. In addition, it was noticed the 
reduction in cell viability of AD-MSC incubated with Ferucarbotran nanoparticles was 
less dramatic than that of AD-MSC incubated with FluidMAG-CT nanoparticles. 
Overall, Ferucarbotran nanoparticles appeared to be less toxic compared to 
FluidMAG-CT nanoparticles. Therefore, Ferucarbotran nanoparticles were chosen for 
subsequent experiments.  
 
5.7 ASSESSMENT OF FERUCARBOTRAN NANOPARTICLE UPTAKE BY 
AD-MSC 
Cellular labeling was evaluated using Prussian blue staining for iron assessment.  This 
was important to assess the ability of MNP uptake by AD-MSC. Successful AD-MSC 
cellular labeling is necessary for comparative studies with AD-MSC expressing mms6. 
For Prussian blue staining, cells were seeded in 12-well plate (5 x 104 cells/well) and 
grown overnight. A day after, cells were loaded with 200 µg/ml Ferucarbotran 
nanoparticle in 500 µl medium. Cells without MNP served as control. Following 
overnight incubation, cells were fixed with formaldehyde and stained with Prussian 






Figure 5-6: Ferucarbotran nanoparticles uptake by AD-MSC. Prussian blue data 
showing A) AD-MSC control, and B) AD-MSC loaded with 100 µg/ml Ferucarbotran 
nanoparticles stained with Prussian blue. Both cells cultured in standard medium for 24 
hours; the colour blue indicates the presence of iron; arrows indicate representative 
intracellular iron accumulation. Scale bar = 100 µm. N =3.  
As shown in Figure 5-6, under light microscopy blue-colored granules are identifiable 
distributed along the cell cytoplasm, indicating the presence of iron in Ferucarbotran-
loaded AD-MSC. These blue granules were not detected in control cells. This result 
shows the successful of AD-MSC cellular labeling with Ferucarbotran MNP, 
confirming the ability of iron uptake by AD-MSC after overnight incubation of AD-
MSC with Ferucarbotran nanoparticles. 
 
5.8 TRANSMISSION ELECTRON MICROSCOPY ANALYSIS OF AD-MSC 
EXPRESSING mms6 AND FERUCARBOTRAN-LOADED AD-MSC. 
To evaluate whether the expression of mms6 could induce AD-MSC to produce 
intracellular biogenic MNP, electron micrographs were acquired. This was also 
important to further evaluate the location and distribution of the Ferucarbotran 
nanoparticles within cells for comparative purposes.  
Mag01-nucleofected AD-MSC, Mag03-nucleofected AD-MSC, and lenti-mms6 
transduced AD-MSC were cultured in medium doped with FeQ (34 µM) for 10 days. 
Untransfected AD-MSC cultured in medium doped with FeQ (34 µM) for 10 days 
were used as a control. AD-MSC cultured with Ferucarbotran (100 µg/ml) for 24 hours 
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were also assessed by TEM. Following 10 days incubation, cells were dehydrated and 
embedded in Eponate resin. Thereafter, ultrathin sections of samples were produced 
and viewed on a transmission electron microscope. 
As shown in Figure 5-7, dispersed electron dense nanocrystal-like structures are 
present in the cytoplasm of all transfected cells samples, both MAG-nucleofected cells 
(Figure 5-7 B & C) and lenti-mms6-transduced cells (Figure 5-7 D). The nanocrystals 
appear homogenous in size. The vesicles size varies from 100 nm to more than 1 µm. 
No electron dense intracytoplasmic particles are present in untransfected AD-MSC 
(Figure 5-7 A). It was also noticed some nanocrystals appear to form clusters within 
the vesicle. The nanoparticle clusters look denser in AD-MSC stably expressing mms6 
compared to Mag01- and Mag03- nucleofected AD-MSC. Similar to this result, the 
same nanocrystal materials within vesicles were also found in AD-MSC incubated 
with Ferucarbotran nanoparticles, as indicated in Figure 5-7 E.  Overall, the TEM 
analysis demonstrates that AD-MSC expressing mms6 could induce iron binding to 








Figure 5-7: TEM Analysis of AD-MSC. Representative TEM pictures of A1-A2) AD-MSC 
control cells; B1-B2) Mag01-nucleofected AD-MSC; C1-C2) Mag03-nucleofected D1-D2) 
Lenti-mms6—transduced AD-MSC; E1-E3) Ferucarbotran-loaded AD-MSC. Scale bar = 100 
µm (A1-E1); 500nm (E2); 100 nm (E3). N = 2. 
 
5.9 MAGNETISATION ANALYSIS OF AD-MSC EXPRESSING mms6 AND 
FERUCARBOTRAN-LOADED AD-MSC 
The magnetization of AD-MSC expressing mms6 and Ferucarbotran-loaded AD-MSC 
was measured upon zero field cooling (ZFC) and field cooling (FC) in magnetic fields 
by Superconducting Quantum Interference Device magnetometer (SQUID) 
magnetometry. This was important to evaluate the magnetism of both AD-MSC 
expressing mms6 and Ferucarbotran-loaded AD-MSC. 
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For AD-MSC expressing mms6 cell magnetization analysis, 3 x 106 cells were 
incubated for 10 days in culture medium doped with FeQ (3.4 µl FeQ/ml). Wild-type 
AD-MSC incubated under identical conditions were used as a control. For 
Ferucarbotran-loaded AD-MSC, 3 x 106 cells were incubated with Ferucarbotran (100 
µg/ml) for 24 hours. Following the incubation time, cells were collected in a pellet 
form then air-dried and transferred into SQUID capsule for the measurement.  
The zero-field-cooled (ZFC) and field-cooled (FC) measurements were performed 
under an applied field of 100 Oe between 5 up to 400 K. Firstly, the sample was cooled 
down to the lowest temperature (5K) in zero magnetic field, so that the nanoparticles 
were randomly oriented. Then, at 5K, a very low field was applied (100 Oe) and the 
recording started. In the second run, the measurement was taken under FC condition. 
Figure 5-8 shows the temperature dependence of magnetization plot, at an applied 
field of 100 Oe, measured for the Ferucarbotran-loaded AD-MSC. The resulting plot 
shows a lower branch (ZFC) and an upper branch (FC). It can be clearly seen from the 
ZFC branch, raising temperature increases the magnetisation of the sample. However, 
above a certain temperature (around 135 K), the magnetization was decreasing. This 
transition shows a ferromagnetic behavior at low temperatures and 
superparamagnetism at higher temperature. The transition at low temperature named 
the blocking temperature Tb that appear in the ZFC curve is a typical characteristic of 
superparamagnetic nanoparticles. At low temperatures, the nanoparticles are 
disoriented and frozen. Then the heating makes the nanoparticles more mobile, so they 
tend to orient themselves in the field, and reaching the maximum at the blocking 
temperature (Tb). Upon further heating of the sample, the Brownian motion brings so 
much disorder that the nanoparticles start to move randomly and they disorient again, 
causing the magnetisation decreasing. Further, in cooling in a 100 Oe magnetic field, 
the magnetic moment of the sample will permanently increase, as shown by FC curve. 
Overall, this result demonstrates superparamagnetic behavior of Ferucarbotran-loaded 
AD-MSC at room temperature, suggesting AD-MSC were succesfully labelled with 





Figure 5-8. The M-T measurements in ZFC & FC mode under the field of 100 Oe 
in temperature range 5 K-300 K for Ferucarbotran-loaded AD-MSC sample. The 
resulting plot displays a lower branch (ZFC) and an upper branch (FC) which indicates 
blocking temperature (Tb) reached at around 135 K. This transition at Tb demonstrates that 
Ferucarbotran-loaded AD-MSC has superparamagnetic behavior at higher temperature.  
 
Figure 5-9 shows the temperature dependence of magnetisation plot, at an applied 
field of 100 Oe, measured for the AD-MSC expressing mms6 (blue lines) and wild-
type AD-MSC as control (red lines). ZFC curves of both samples show no blocking 
temperature in the range of 5 to 400 K, confirming no superparamagnetic behavior 
detected on both samples. However, it can be seen that the magnetization of AD-MSC 
expressing mms6 is higher than control, as indicated by higher position of the curve of 
AD-MSC expressing mms6 (blue) compared to wild-type AD-MSC (red). 
When cooling down from 400 K, both the ZFC and FC data follow similar trend, that 

























FC curves from both samples are separated and continue to persist up to room 
temperature, indicating that the Curie temperature of the sample is expected to exceed 
300 K. Note that the ZFC-FC curve separation gap of AD-MSC expressing mms6 is a 
consequence of the large distribution of energy barriers, which can be associated with the 
particle size distribution. Most importantly, it can be clearly seen that the temperature-
dependent magnetisation of AD-MSC expressing mms6 (blue curve) is stronger than 
that of wild-type AD-MSC (red curve). 
 
Figure 5-9:The M-T measurements in ZFC & FC mode under the field of 100 Oe 
in temperature range 5 K-400 K for AD-MSC expressing mms6 (blue) and wild-
type AD-MSC (red).  Blocking temperature in the range of 5 to 400 K was not detected on 
both AD-MSC expressing mms6 and control cells, confirming no superparamagnetic behavior 
observed on AD-MSC expressing mms6. 
Overall, the magnetic measurement based on ZFC-FC indicate two important results: 
1) the existence of room temperature ferromagnetism of both AD-MSC expressing 
mms6 and control cells. This is likely to be due to the incubation of both cell samples 
in FeQ doped medium 2) The temperature-dependent magnetisation of AD-MSC 
expressing mms6 is stronger than that of wild-type AD-MSC, revealing the expression 
of mms6 may improve iron binding ability of the cells, which then increased the 

























In this chapter, it was determined if:  
1. The mms6 expression of AD-MSC could cause any detrimental effect on the 
cells by investigating MSC stemness and MSC differentiation potential. 
2. The mms6 expression of AD-MSC could promote iron binding in order to 
produce magnetic nanoparticles inside the cells.   
3. The mms6 expression of AD-MSC could generate a magnetic behavior similar 
to commercial MNP or magnetosomes in MTB. 
Regarding the point 1, immunofluorescence experiments revealed no observable 
difference between AD-MSC expressing mms6 and control cells. It was observed the 
expression of mms6 did not alter the presentation of typical surface antigens on human 
MSC. Both cell groups were positive for the typical MSC markers CD44 and CD90, 
and negative for CD14 and CD19. In addition, both AD-MSC expressing mms6 and 
control cells showed a similar differentiation capacity into adipogenic and osteogenic 
lineages. Adipogenesis was demonstrated by the accumulation of lipid vacuoles after 
10 days of adipogenesis induction, indicated by a positive Oil Red O staining. In 
addition, Alizarin red staining also confirmed osteogenic differentiation after 21 days 
of osteogenic induction.  
A previous study has shown that differentiation of MSC is affected with increasing 
MNP dose (Henning et al., 2009). Confirming this finding, a study using Citrate 
SPIONs for magnetic labeling of human MSC bu Andreas and coworkers (2012) 
indicated that the nanoparticle labeling did not affect cell proliferation, presentation of 
typical cell surface marker antigens and differentiation into the adipogenic and 
osteogenic lineages. However, chondrogenic differentiation and chemotaxis were 
significantly impaired with increasing SPIONs incorporation (Andreas et al., 2012). 
Hence, in this chapter, the investigation of MSC stemness and differentiation potential 
was also crucial to assess whether such genetic modification for inducing magnetic 
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nanoparticles synthesize in AD-MSC could alter the functionality of cells. Overall, the 
results show that the MSC stemness and multipotency are unaffected by the expression 
of this magnetobacterial genes  
Regarding point 2, a separate investigation on iron-based MNP was also performed 
before performing TEM analysis for both AD-MSC expressing mms6 and iron-based 
MNP-loaded AD-MSC. A prior study by Kasten et al (2014) has suggested AD-MSC 
can be labelled with iron-based MNP. In their study, AD-MSC were loaded with 
bionized nanoferrite (BNF) starch and Nanomag®-D-spio and differentiated into 
adipogenic lineage. The result showed the successful in vivo MRI visualization of 
magnetically labeled AD-MSC seeded onto collagen scaffolds for adipose tissue 
engineering in a SCID mice model (Kasten et al., 2014).  
A further study looking at potential use of MSC as cellular therapy for vascular injury 
also showed successful MSC labelling with FluidMAG and Ferucarbotran 
nanoparticles (Riegler et al., 2013). The study revealed that MSC labelled with MNP 
increased cell retention after balloon angioplasty leading to reduced restenosis in a 
rabbit model. A recent study by Kalber et al (2016) also demonstrated that MSC can 
be used as carriers of Ferucarbotran MNP, that following an injection into tumour in a 
mouse model, these labeled MSC can be retained in the tumour tissue over a matter of 
weeks before a magnetic hyperthermia treatment. Indeed, Ferucarbotran has recently 
been used in a number of hyperthermia studies (Araya, T, 2013; Kalber et al., 2016; 
Sato, I., 2014). Most importantly, a study by Kallumadil et al. (2009) in investigating 
a number of commercial colloids for magnetic hyperthermia also suggested three best 
magnetic fluids in terms of magnetic heating capability, which were Nanomag-D-Spio 
100 nm, FluidMAG-D 50 nm and Resovist Carboxydextran or Ferucarbotran 
(Kallumadil et al., 2009).  
Taken together all the evidence above, several commercial iron-based MNP 
NanoMAG-D-Spio, BNF-Dextran, FluigMAG-CT and Ferucarbotran nanoparticles 
were investigated in this study. Firstly, since their stability in culture medium is a 
crucial factor affecting their further use, the colloidal stability of each of these MNP 
was measured. Turbidity measurement revealed only Ferucabotran and FluidMAG-
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CT were stable over 24 hours. In contrast, Nanomag-D-Spio and BNF-Dextran showed 
an increase of turbidity of the medium, suggesting they are not colloidally stable in the 
medium culture. The use of both MNP also raised technical issue during MNP-loaded 
AD-MSC experiments. There is a high likelihood that the increasing turbidity over 
time was due to MNP in contract with FBS or protein-containing media. This 
interaction could generate protein corona and form larger aggregates of MNP, as 
opposed to in PBS (Gorshkov et al., 2019). Therefore, Feruarbotran and FluigMAG-
CT were then used in the later experiments. 
The cell viability analysis was performed on FluidMAG-CT-loaded and Ferucabotran-
loaded AD-MSC. The result indicated that AD-MSC cell viability was dramatically 
lower with increasing FluidMAG nanoparticle concentration. Despite the result 
showing that Ferucarbotran nanoparticles at concentration higher than 250 µg/ml was 
statistically affected the cell viability, only slight decrease was observed even up to 
1000 µg/ml concentration compared to the FluidMAG-CT sample. In good agreement 
with this result, a previous report suggested that the amount of iron in living cells is 
remarkably increased by increasing the concentration of carboxy-dextran MNP in the 
cell culture media and no toxicity was noticed up to 250 µg Fe/ml (Mahmoudi et al., 
2011). In contrast, a contradictive study has shown that the labeling of Ferucarotran 
nanoparticles is advantageous to stem cell growth. The study showed that instead of 
inducing cellular toxicity, the Ferucarbotran can accelerate cell cycle progression and 
promote cell growth which likely due to its ability to diminish intracellular H2O2 
through intrinsic peroxidase-like activity (Huang et al., 2009). For this reason, 
Ferucarbotran nanoparticles were chosen for subsequent experiments as it was 
expected that the MNP should be non-toxic and can be retained within cells before 
magnetic hyperthermia treatment. 
Ferucarbotran MNP used in this study is similar to the dextran-coated Endorem and 
carboxydextran-coated Resovist MNP, which are the most commonly used MNP as 
MRI contrast agent and are clinically applied for liver and spleen imaging by MRI. 
These nanoparticles have range of 50-200 nm size, which are easily phagocyted by 
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Kupffer cells of the reticuloendothelial system (RES) upon intravenous administration 
(Reimer and Balzer, 2003).  
To investigate the Ferucarbotran nanoparticles uptake of AD-MSC, Prussian blue 
staining was conducted. The result showed blue-colored granules inside the cells, 
revealing the presence of iron and the ability of nanoparticle internalisation by AD-
MSC.  This result agrees with a numerous studies that showed MSC can be labelled 
with Ferucarbotran after overnight incubation without the need of transfection reagent, 
and can be visually detected by Prussian blue staining (Mailänder et al., 2008; Bauer 
et al., 2009; Henning et al., 2009; Yang et al., 2009; Kalber et al., 2016). The presence 
of carboxyl groups in Ferucarbotran structure was known increases the cellular uptake 
as compared with non-functionalized MNP (Mahmoudi et al., 2011).  
Further investigation on nanoparticles cellular uptake of Ferucarbotran-loaded AD-
MSC showed accumulation of membrane-bound, intracytoplasmic electron-dense 
nanoparticles identified by TEM. Similar electro-dense material was also found in both 
AD-MSC stably expressing mms6 after lentiviral transduction and AD-MSC 
transiently expressing mms6 after nucleofection with Mag01 or Mag03. Although the 
number of nanoparticles formed inside the cells were not deeply quantified or analysed 
in this study, by visual inspection the electro-dense material in AD-MSC stably 
expressing mms6 appeared to look denser than the nucleofected ones. This may be 
possible due to the stable expression of mms6 which may induce more iron binding 
during 10 days of cell incubation with FeQ doped medium.  
In agreement with this result, a previous study by Elfick et al. (2017) has shown that 
bone marrow-derived MSC expressing mms6 and mmsF genes contain vesicles filled 
with both dispersed and larger electron-dense material. Image analysis studies show 
an increase in the amount of electron-dense material within cytoplasmic vesicles of 
mms6 transfected cells from day 10 to day 15 (Elfick et al., 2017). In addition, Zhang 
et al (2014), using a gliosarcoma cell line stably expressing mms6, showed 3 types 
nanoparticle distribution within cells after 3 days incubation in ferric citrate doped 
medium: 1) Some clusters of nanoparticles within membrane-enclosed structures, 2) 
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few clusters of nanoparticles without membrane enclosures, and 3) few scattered 
nanoparticles throughout the cytoplasm.  
Although the mechanism of formation those nanoparticle clusters remains unclear, the 
intracellular membrane-enclosed structures are likely endosomes or lysosomes in 
which waste materials are disposed (Pieber et al., 2009). Furthermore, the distribution 
of nanoparticle clusters formed in AD-MSC expressing mms6 appeared to look the 
same as the AD-MSC loaded with Ferucarbotran. Studies using carboxydextran 
Resovist demonstrated that the nanoparticle clusters were not found in the cell core, 
Golgi or mitochondria, and were found only localized in intracellular compartments 
resembling endosomes of MSC (Mailänder et al., 2008). Other TEM analysis of 
human MSC loaded with Citrate SPIONs study also displayed internalization into 
endosomes suggesting an endocytotic uptake mechanism (Andreas et al., 2012).  
Regarding point 3, the magnetic measurement based on ZFC-FC demonstrated a strong 
ferromagnetic behavior of AD-MSC expressing mms6. The temperature-dependent 
magnetisation of AD-MSC expressing mms6 was stronger than that of untransfected 
AD-MSC control cells, indicating the expression of mms6 may promote iron binding 
ability of the cells, which then increased the ferromagnetism of the cells. In contrast, 
the magnetic measurement on Ferucarbotran-loaded AD-MSC displayed a 
superparamagnetic behavior, confirming different magnetic properties between AD-
MSC expressing mms6 and Ferucabotran-loaded AD-MSC.   
A study comparing the magnetic properties of MNP modified with amino silane with 
bacterial magnetosomes revealed that synthetic MNP show superparamagnetic 
characteristics while magnetosomes are ferromagnetic. The study suggested that the 
different magnetic properties of magnetosomes and MNP may be largely due to their 
different size (R.-T. Liu et al., 2012). The large sizes of magnetosome result in a 
ferromagnetic behavior at physiological temperature, while the SPION of sizes below 
20 nm are superparamagnetic at this temperature. (Arakaki et al., 2008; Alphandéry et 
al., 2010). The ferromagnetic behaviour displayed by AD-MSC expressing mms6 
could mean that the Mms6 protein binds iron and form a bigger nanocrystal aggregates, 
instead of smaller superparamagnetic nanocrystal. It should be also underlined that the 
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Mms6 alone would not be able to synthesise ferromagnetic magnetosome structure 
similar to the one in MTB.  
Despite the ferromagnetic properties of bacterial magnetosomes, numerous studies 
have attempted to synthesize superparamagnetic nanoparticle using Mms6 protein 
(Prozorov et al., 2007; Wang et al., 2012; Feng et al., 2013). It was demonstrated that 
Mms6 binds iron in order to form superparamagentic nanoparticles in vitro (Wang et 
al., 2012).  The high affinity for iron ions and negative charges of the Mms6 protein 
was believed give the protein a unique ability to self-assemble, making it a key 
regulator of crystal size and morphology (Arakaki et al., 2010, 2014).  
A study by Prozorov et al. showed the Mms6 protein-mediated nanoparticle synthesis 
was found to be able to promote shape-selective formation of uniform 
superparamagnetic nanocrystals. In their study, recombinant Mms6 facilitates 
formation of single-domain, uniform magnetite nanocrystals in solution, as confirmed 
by using TEM and magnetization analysis. In contrast, the nanoparticles formed in the 
presence of iron binding protein such as mammalian ferritin, lipocalin, and bovine 
serum albumin, do not exhibit the uniform sizes and shapes observed for those formed 
in the presence of Mms6. Most importantly, Mms6 protein-mediated synthesis 
magnetite nanoparticles displayed the largest magnetization values above the blocking 
temperature, as well as the largest magnetic susceptibility compared to those of the 
nanomaterials synthesized with other proteins (Prozorov et al., 2007).  
It should be underlined that MNP for the use in biomedical applications are preferable 
to have superparamagnetic properties (SPIONs) (Corot et al., 2006; Markides et al., 
2012; Ludwig et al., 2014b). SPIONs are typically small particles composed of either 
a magnetite (Fe3O4) or maghemite (γ-Fe2O3) core coated with a biocompatible 
organic/inorganic polymer (Pardoe et al., 2001; Mahmoudi et al., 2010). Both 
maghemite and magnetite are commonly ferromagnetic in nature. However, they lose 
their permanent magnetism and become superparamagnetic when they decrease in size 
to 30nm or smaller (Mahmoudi et al., 2011). For biomedical application, it was 
suggested that the superparamagnetic properties may prevent the nanoparticles to not 
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be attracted each other, thus the risk of agglomeration in a its medical use could be 
avoided (Markides et al., 2012). 
The mechanism by which mms6, as a single gene, is able to provide the human AD-
MSC with magnetic properties is still not well understood. However, there are some 
specific properties of the Mms6 protein which could justify its ability to confer such 
fascinating properties to the cells. Mms6 was described as a protein able to bind iron 
and generate uniform magnetic crystals with a high affinity for iron ions and bearing 
negative charges which give to the protein the peculiar ability to self-assemble  
(Prozorov et al., 2007). Moreover, Mms6 is not the only protein able to generate 
magnetic properties to mammalian cells. Previous work expressing MagA in 
mammalian cells also showed the ability to increase the iron retention and to create 
magnetic structures inside mouse and human cancer cells, as well as in human 
embryonal kidney cell line. The magnetic structures generated by MagA in the cells 
produced contrast at MRI of 11T, suggesting the gene has a potential use as reporter 
gene for MRI applications (Zurkiya et al., 2008; Goldhawk et al., 2009). Therefore, 
all of these evidence support the idea that a single gene could be sufficient to generate 
magnetic properties to mammalian cells. 
In summary, this chapter have demonstrated that the expression mms6 gene could 
promote the intracytoplasmic vesicles formation in AD-MSC, which contain magnetic 
nanocrystal material. Most importantly, the expression of this bacterial gene does not 
affect cells stemness, proliferation and differentiation ability. Morever, the nanocrystal 
in AD-MSC expressing mms6 appeared to showed a ferromagnetic behaviour. In 
addition, AD-MSC was also successfully labelled with commercial iron-based 
Ferucarbotran-loaded AD-MSC, and showed a superparamagnetic characteristic. 
Further investigation in the use of these cells in MRI and MNHT application will be 




























 IN VITRO APPLICATION OF ALTERNATING MAGNETIC FIELD 
ON AD-MSC EXPRESSING mms6. 
6.1 SUMMARY 
The hypothesis underlying this study was that the nanoparticles produced inside AD-
MSC expressing mms6 could induce cell cytotoxicity or cell death when the cells are 
exposed to an alternating magnetic field (AMF). It is expected that in its biomedical 
application, when the AD-MSC have successfully homed to tumours, the magnetic 
hyperthermia application would activate the nanoparticle-mediated cell death 
mechanism. Hence it could cause the death of the neighbouring cancer cells or induce 
an antitumour immune response.  
To test this concept, this chapter is focusing on in vitro application of an alternating 
magnetic field (AMF) to AD-MSC expressing mms6. To conduct this study, a 
MagneThermTM device was used to create an in vitro model of magnetic hyperthermia 
application. The device is specifically designed for nanoparticle heating applications, 
operating within with a wide frequency range from 100 kHz to 1MHz.  
In this chapter, the two important questions I address are the following: 1) could the 
interaction between nanoparticles produced inside the AD-MSC expressing mms6 and 
AMF application have a magnetic hyperthermia effect? 2) Can I achieve the desired 
magnetic hyperthermia effect at three different AMF frequencies of 178.3 kHz (23.89 
mT), 540 kHz (24.87 mT), and 1030 kHz (13.37 mT). To answer these questions, AD-
MSC cell viability, cell apoptosis and HSP70 expression following the AMF 
application were investigated.  
In chapter 5, it was observed that Ferucarbotran-loaded AD-MSC have 
superparamagnetic behavior, while AD-MSC expressing mms6 has Feromagnetic 
behavior. Therefore, the magnetic hyperthermia effect of AMF application on 
Ferucarbotran-loaded AD-MSC was also determined. This was important since the 
heating capacity of magnetic nanoparticles will vary, depending on size, shape and 
material properties (Ludwig et al., 2014a; Patsula et al., 2016). 
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The magnetic hyperthermia effect of the AMF on cell viability was assessed using the 
AlamarBlue Cell Viability assay. For this, cells were arranged in two experimental 
designs: 1) AMF application on cells in 2-D monolayer model as cells arranged in a 
Petri dish, 2) in attempt to create an in vitro model of an in vivo situation, AMF 
application on cells in a 3-D model were performed. Furthermore, to determine the 
AMF effect on cell apoptosis, In Situ Apoptosis Detection was conducted using The 
Click-iT Plus TUNEL assay. For HSP70 expression analysis, a western blot assay was 
conducted.  
In order to investigate whether the nanoparticles created in AD-MSC expressing mms6 
could be utilized as contrast agent for magnetic resonance imaging (MRI), an in vitro 
model of MRI experiment was also performed.  In this experiment, the following AD-
MSC were used for the MRI analyses: 1) Mag01-transfected AD-MSC, 2) Mag03-
transfected AD-MSC 3) lentiviral-mms6 tranduced AD-MSC and 4) Ferucarbotran-
loaded AD-MSC. This experiment may elucidate the future potential use of cells 
expressing mms6 for MRI detection or cell tracking.  
 
6.2 AIMS 
The aims of the experiments detailed in this chapter were: 
1. To investigate the effect of AMF on cell viability of AD-MSC expressing mms6 
and Ferucarbotran-loaded AD-MSC arranged in 2-D and 3-D culture. 
2. To investigate the effect of AMF application on cell apoptosis and HSP70 
expression of AD-MSC expressing mms6. 
3. To demonstrate the potential use of AD-MSC expressing mms6 in magnetic 




6.3 HEATING CAPACITY OF FERUCARBOTRAN NANOPARTICLE. 
In this study, the heating capacity of free Ferucabotran nanoparticles in colloid under 
different frequencies of AMF was performed. Previous report has shown 
Ferucarbotran MNP (Resovist) have higher magnetic heating capability compared to 
several MNP manufactured by Chemicell and Micromod. Intrinsic loss power (ILP) 
measurement of 28 mg/mL Fe concentration of Ferucarbotran (60nm) showed ILP 
value of 3.1 nHm2/kg (Kallumadil et al., 2009). Furthermore, specific absorption rate 
(SAR) measurement, which is dependent on the field amplitude and frequency, 
indicated Ferucarbotran have 90 W/g SAR value under 5.7 kA/m field amplitude and 
900 kHz frequency (Blanco-Andujar et al., 2016).  
The main goal of this experiment was to demonstrate the interaction between AMF 
and free Ferucabotran nanoparticles in rising the temperature of nanoparticle 
suspension. This was also important particularly to test whether the MagneThermTM 
device is suitable for this in vitro magnetic hyperthermia (MH) experiment in this 
study and to provide a positive control for future experiments with mms-6 expressing 
cells.  
For this, three group samples of Ferucarbotran nanoparticle suspensions were prepared 
in microcentrifuge tubes. Each tube contains 5 mg/ml of Ferucarbotran nanoparticle in 
500 µl sterile water. Each sample was then exposed for 50 minutes, each with three 
different frequencies of AMF: 178.3 kHz (23.89 mT), 540 kHz (24.87 mT), and 1030 
kHz (13.37 mT). The samples were exposed under AMF for 40 minutes then allowed 
to rest in the MagneThermTM device without AMF for a further 10 minutes. The 
temperature changes during the experiment were recorded every 5 minutes using a 
Fibre Optic Probe and USB data logging Temperature sensor (MagneThermTM) 
allowing data capture of the sample temperature. The experiment was repeated three 
times.  
As shown in Figure 6-1, all samples showed temperature increase as soon as samples 
were exposed to AMF. In Ferucarbotran suspension exposed under 178.3 kHz AMF, 
the temperature goes up from 25.8±1.2 °C to 38.5±1.0 °C in 20 minutes. The maximum 
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temperature hits 40.2±0.8 at 40 minutes before going down to 33.8±1.5 after the AMF 
was turned off. Similar temperature profile was also shown in sample exposed to 1030 
kHz, which showed temperature raising from 26.2±0.6 °C to 39.8±0.3 °C in just 10 
minutes. The maximum temperature hits 43.5±0.9 °C at 35 minutes time point before 
going down to 34±0.9 °C when the AMF exposure has stopped. For 540 kHz AMF, 
the Ferucarbotran nanoparticles generates a temperature rise from 26.2±3.1 °C to 
51.7±31.9 °C in just 5 minutes. Afterwards, the temperature continues to rise up to 
67.5±1.3 °C at 40 minutes, then goes down to 49.5±2.8 °C in the end.  
 
 
Figure 6-1: Temperature profile of Ferucarbotran nanoparticle. Temperature 
measurement analysis showing the temperature increase of Ferucarbotran nanoparticle 
suspension over 40 minutes of AMF exposure. Ferucarbotran suspension samples were 
exposed to 178.3 kHz (green line), 540 kHz (blue line), and 1030 kHz (red line). Values are 
presented as mean ± SD. N=3 
In general, the experiment successfully demonstrated the heating capacity of free 
Ferucarbotran nanoparticles under AMF application in the MagneThermTM device. 
The result was important to demonstrate that the MagneThermTM device was suitable 
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to be used in this in vitro magnetic hyperthermia (MH) study. All the samples showed 
the temperature rise above physiological temperature when they were exposed to 178.3 
kHz, 540 kHz, and 1030 kHz of AMF. 
The highest temperature was shown in sample exposed to 540 kHz AMF with a 
temperature value over 60 °C for less than an hour of AMF exposure. This was likely 
due to this particular setting generate the highest magnetic field which was 24.87 mT, 
compared to 23.89 mT and 13.37 mT generated by 178.3 kHz and 1030 kHz setting, 
respectively. 
However, the ultimate aim of the study was to use the AD-MSC as a cell delivery 
system to deliver magnetic nanoparticles instead of using free magnetic nanoparticles. 
Therefore, it was still not clear whether the nanoparticles inside the cells would give 
similar heating capacity as the free nanoparticle in colloid suspension. Indeed, it would 
have been better to measure the temperature of Ferucarbotran-loaded AD-MSC rather 
than the free Ferucarbotran nanoparticles. However, due to the lack of instrument 
specifically measuring cell temperature, the experiment was not possible to be done. 
 
6.4 THE EFFECT OF ALTERNATING MAGNETIC FIELD ON 
FERUCARBOTRAN-LOADED AD-MSC ARRANGED IN 2-D CULTURE. 
To determine the effect of AMF on Ferucarbotran-loaded AD-MSC arranged in 2-D 
monolayer culture, Ferucarbotran-loaded AD-MSC were exposed in three different 
frequency of AMF: 178.3 kHz (23.89 mT), 540 kHz (24.87 mT), and 1030 kHz (13.37 
mT). The effect of the AMF on AD-MSC cell viability was then determined with 
AlamarBlue Cell Viability Assay. 
 
6.4.1 Cell viability analysis of Ferucarbotran-loaded AD-MSC in 2-D 
culture following one-hour exposure of 178.3 kHz AMF. 
For 2-D monolayer culture, AD-MSC were seeded in Petri dishes and incubated 37 °C 
CO2 incubator for overnight. Cells were then loaded with 500 ug/ml Ferucarbotran in 
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culture medium and incubated overnight in 37 °C CO2 incubator. On the next day, the 
medium was then removed and replaced with fresh culture medium. Cells were then 
exposed to 178.3 kHz AMF for one hour. Ferucabotran-loaded AD-MSC exposed to 
0 kHz AMF (cells placed in MagneThermTM device without AMF) were used as 
control. After the exposure, cells were then incubated in 37°C CO2 incubator for 
overnight. The cell viability was then determined with Alamar Blue Cell Viability 
Assay. The experiment was run in triplicate and repeated three times. 
The result of this experiment is illustrated in Figure 6-2, where the fluorescence 
intensity average values registered for the exposed cells was 6114±365, while for 
control was 6181±360. Cell viability percentage of exposed cells was calculated as a 
ratio between AMF exposed cells and controls cells, and it is shown in considering 
controls as 100% viable. The result reveals that the viability of AMF exposed cells 
was 99.58±0.66% of that of controls and not statistically significant. This result 
confirmed that the 178.3 kHz of AMF application on the Ferucarbotran-loaded AD-
MSC arranged in a 2-D monolayer culture leads to no cytotoxicity effect. 
 
Figure 6-2: Cell Viability of Ferucarbotran-loaded AD-MSC in 2-D culture 
following one-hour exposure of 178.3 kHz AMF. Ferucarbotran-loaded AD-MSC 
cell were exposed to 178.3 kHz (grey column) or exposed to 0 kHz as control (black 
column). AlamarBlue data showing average of fluorescence intensity of cells following 
AMF exposure (left panel) and average of cell viability percentage of exposed cells 




6.4.2 Cell viability analysis of Ferucarbotran-loaded AD-MSC in 2-D 
culture following one-hour exposure of 540 kHz AMF. 
AD-MSC were seeded in Petri dishes and incubated 37 °C CO2 incubator for overnight. 
Cells were then loaded with 500 µg/ml Ferucarbotran nanoparticle in culture medium 
and incubated overnight in 37 °C CO2 incubator. On the next day, the medium was 
then removed and replaced with fresh culture medium. Cells were then exposed to 540 
kHz AMF for one hour. Ferucabotran-loaded AD-MSC placed in MagneThermTM 
device without AMF application for one hour were used as control. After the exposure, 
cells were then incubated in 37 °C CO2 incubator for overnight. The cell viability was 
then determined with AlamarBlue Cell Viability Assay. The experiment was run in 
triplicate and repeated at least three times. 
 
Figure 6-3: Cell viability of Ferucarbotran-loaded AD-MSC in 2-D culture 
following one-hour exposure of 540 kHz AMF. Ferucarbotran-loaded AD-MSC cell 
were exposed to 540 kHz (grey column) or exposed to 0 kHz as control (black column). 
AlamarBlue data showing average of fluorescence intensity of cells following AMF exposure 
(left panel) and average of cell viability percentage of exposed cells against controls (right 
panel). Values are presented as mean ± SD. N=3 
 
The result of this experiment is illustrated in Figure 6-3, where the fluorescence 
intensity average values registered for the exposed cells was 5665±235, while for 
control was 5984±153. Cell viability percentage of exposed cells was calculated as a 
ratio between AMF exposed cells and controls cells, and it is shown in considering 
controls as 100% viable. The result indicated that the viability of AMF exposed cells 
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was 94.65±2.03% of that of controls and not statistically significant. This result 
confirmed that the 540 kHz AMF exposure on the Ferucarbotran-loaded AD-MSC 
arranged in 2-D monolayer culture does not have an effect on AD-MSC cell viability. 
 
6.4.3 Cell viability analysis of Ferucarbotran-loaded AD-MSC in 2-D 
culture following one-hour exposure 1030 kHz AMF. 
AD-MSC were seeded in Petri dishes and incubated 37 °C CO2 incubator for overnight. 
Cells were then loaded with 500 ug/ml Ferucarbotran nanoparticle in culture medium 
and incubated overnight in 37 °C CO2 incubator. On the next day, the medium was 
then removed and replaced with fresh culture medium. Cells were then exposed to 
1030 kHz AMF for one hour. Ferucabotran-loaded AD-MSC exposed to 0 kHz AMF 
for one hour were used as control. After the exposure, cells were then incubated in 
37°C CO2 incubator for overnight. The cell viability was then determined with Alamar 




Figure 6-4: Cell viability of Ferucarbotran-loaded AD-MSC in 2-D culture 
following one-hour exposure of 1030 kHz AMF. Ferucarbotran-loaded AD-MSC cell 
were exposed to 1030 kHz (grey column) or exposed to 0 kHz as control (black column). 
AlamarBlue data showing average of fluorescence intensity of cells following AMF exposure 
(left panel) and average of cell viability percentage of exposed cells against controls (right 
panel). Values are presented as mean ± SD. N=3 
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The result of this experiment is illustrated in Figure 6-4, where the fluorescence 
intensity average values registered for the exposed cells is 6120±406, while for control 
is 6397±133. Cell viability percentage of exposed cells was calculated as a ratio 
between AMF exposed cells and controls cells, and it is shown in considering controls 
as 100% viable. This result demonstrated that the viability of AMF exposed cells was 
95.5±4.4% of that of controls and not statistically significant. The experiment failed 
to show a magnetic hyperthermia effect on cell viability even using a higher frequency 
(1030 kHz) of AMF on Ferucarbotran-loaded AD-MSC. 
 
6.5 THE EFFECT OF ALTERNATING MAGNETIC FIELD ON AD-MSC 
EXPRESSING mms6 IN 2-D CULTURE. 
To determine the effect of AMF on AD-MSC expressing mms6 arranged in 2-D 
monolayer culture, three group of cells were exposed in three different frequencies of 
AMF: 178.3 kHz (23.89 mT), 540 kHz (24.87 mT), and 1030 kHz (13.37 mT). The 
effect of the AMF on cell viability was then determined with AlamarBlue Cell 
Viability Assay. 
 
6.5.1 Cell viability analysis of AD-MSC expressing mms6 in 2-D culture 
following one-hour exposure of 178 kHz AMF. 
AD-MSC expressing mms6 were cultured in medium doped with FeQ (34 µM) for 10 
days in cell culture flask. Afterwards, the cells were then collected and seeded in Petri 
dishes in a 2-D monolayer culture and incubated in 37°C CO2 incubator for overnight. 
In the following day, cells in the Petri dishes were exposed under 178 kHz of AMF for 
one hour. AD-MSC expressing mms6 exposed to 0 kHz AMF for one hour were used 
as control. After the AMF application, cells were then incubated in 37°C CO2 
incubator for overnight. In the next day, the cell viability was then determined using 
AlamarBlue Cell Viability Assay.   
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The result of the experiment is illustrated in Figure 6-5, where the fluorescence 
intensity average values registered for the exposed cells is 6591±523, while for control 
is 7063±315. Cell viability percentage of exposed cells was calculated as a ratio 
between AMF exposed cells and controls cells, and it is shown in considering controls 
as 100% viable. The result reveals that the viability of AMF exposed cells was 
93.24±3.79% of that of controls and not statistically significant. This result confirms 
that the low frequency (178.3 kHz) of AMF application on the AD-MSC expressing 




Figure 6-5: Cell viability of AD-MSC expressing mms6 in 2-D culture following 
one-hour exposure of 178.3 kHz AMF. AD-MSC expressing mms6 cell were exposed to 
178.3 kHz (grey column) or exposed to 0 kHz as control (black column). AlamarBlue data 
showing average of fluorescence intensity of cells following AMF exposure (left panel) and 
average of cell viability percentage of exposed cells against controls (right panel). Values are 
presented as mean ± SD. N=3 
 
6.5.2 Cell viability analysis of AD-MSC expressing mms6 in 2-D culture 
following one-hour exposure of 540 kHz AMF. 
 AD-MSC expressing mms6 were cultured in medium doped with FeQ (34 µM) for 10 
days in cell culture flask. The cells were then collected and seeded in Petri dishes in a 
2-D monolayer culture and incubated in 37°C CO2 incubator for overnight. In the 
following day, cells were exposed with 540 kHz AMF for one hour. AD-MSC 
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expressing mms6 exposed to 0 kHz AMF for one hour were used as control. After the 
exposure, cells were then incubated in 37°C CO2 incubator. In the following day, the 
cell viability was then determined with AlamarBlue Cell Viability Assay.   
 
Figure 6-6: Cell viability of AD-MSC expressing mms6 in 2-D culture following 
one-hour exposure of 540 kHz AMF. AD-MSC expressing mms6 cell were exposed to 
540 kHz (grey column) or exposed to 0 kHz as control (black column). AlamarBlue data 
showing average of fluorescence intensity of cells following AMF exposure (left panel) and 
average of cell viability percentage of exposed cells against controls (right panel). Values are 
presented as mean ± SD. N=3 
 
The result of this experiment is illustrated in Figure 6-6, where the fluorescence 
intensity average values registered for the exposed cells is 6334±158, while for control 
is 6489±39. Cell viability percentage of exposed cells was calculated as a ratio between 
AMF exposed cells and controls cells, and it is shown in considering controls as 100% 
viable. It was noticed that the viability of AMF exposed cells was 97.62±2.79% of that 
of controls. No significance difference was observed between exposed and control 
group. Thus, this result confirmed that 540 kHz AMF application does not generate 




6.5.3 Cell viability analysis of AD-MSC expressing mms6 in 2-D culture 
following one-hour exposure of 1030 kHz AMF. 
 AD-MSC expressing mms6 were cultured in medium doped with FeQ (34 µM) for 10 
days in cell culture flask. The cells were then collected and seeded in Petri dishes in a 
2-D monolayer culture and incubated in 37°C CO2 incubator for overnight. In the 
following day, cells were exposed at low frequency of AMF (1030 kHz) for one hour. 
AD-MSC expressing mms6 exposed to 0 kHz AMF for one hour were used as control. 
After the exposure, cells were then incubated in 37°C CO2 incubator. Following one 
day of incubation, the cell viability was then determined with AlamarBlue Cell 
Viability Assay.   
 
 
Figure 6-7: Cell viability of AD-MSC expressing mms6 in 2-D culture following 
one-hour exposure of 1030 kHz AMF. AD-MSC expressing mms6 cell were exposed to 
1030 kHz (grey column) or exposed to 0 kHz as control (black column). AlamarBlue data 
showing average of fluorescence intensity of cells following AMF exposure (left panel) and 
average of cell viability percentage of exposed cells against controls (right panel). Values are 
presented as mean ± SD. N=3 
The result of the experiment is illustrated in Figure 6-7, where the fluorescence 
intensity average values registered for the exposed cells is 6968±77, while for control 
is 7131±208. Cell viability percentage of exposed cells was calculated as a ratio 
between AMF exposed cells and controls cells, and it is shown in considering controls 
as 100% viable. The result revealed that the viability of AMF exposed cells was 
97.75±1.79% of that of controls and not statistically significant. In summary, the 
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experiment failed to show a significance difference on cell viability of AD-MSC 
expressing mms6 even using 1030 kHz of AMF. 
 
6.6 THE EFFECT OF ALTERNATING MAGNETIC FIELD ON 
FERUCARBOTRAN-LOADED AD-MSC IN 3-D CULTURE. 
AD-MSC were loaded with 500 µg/ml Ferucarbotran nanoparticle and incubated in 37 
°C CO2 incubator for overnight. On the next day, the cells were washed three times, 
then pelleted in microcentrifuge tube in 100 µl medium. The cells were then exposed 
to 540 kHz AMF for two hours. Ferucabotran-loaded AD-MSC exposed to 0 kHz AMF 
for two hours were used as control. AD-MSC exposed in 45 °C in block heater for 2 
hours were used as positive control. After the exposure, cells were then incubated in 
37 °C CO2 incubator for overnight. The cell viability was then determined with Alamar 




Figure 6-8: Cell viability of Ferucarbotran-loaded AD-MSC in 3-D culture 
following two-hour exposure of 540 kHz AMF. Ferucarbotran-loaded AD-MSC cell 
were exposed to 540 kHz (light grey column) or exposed to 0 kHz as negative control (black 
column) or exposed to 45 °C in block heater as positive control (dark grey column). 
AlamarBlue data showing average of fluorescence intensity of cells following AMF exposure 
(left panel) and average of cell viability percentage of exposed cells against controls (right 




The result of the experiment is illustrated in Figure 6-8, where the fluorescence 
intensity average values registered for the exposed cells is 45999±1406, while for 
negative control and positive control are 47751±2386 and 106±35, respectively. Cell 
viability percentage of exposed cells was calculated as a ratio between AMF exposed 
cells and controls cells, and it is shown in considering controls as 100% viable. The 
result revealed that the viability of AMF exposed cells was 96.09±3.76% of that of 
controls. The experiment failed to show any significant difference on cell viability of 
Ferucarbotran-loaded AD-MSC arranged in 3-D culture following the 540 kHz AMF 
application.  
 
6.7 THE EFFECT OF ALTERNATING MAGNETIC FIELD ON AD-MSC 
EXPRESSING mms6 IN 3-D CULTURE. 
The effect of alternating magnetic field on AD-MSC expressing mms6 in 3-D culture 
were determined using 3 different assays: 1) AlamarBlue Cell Viability assay, 2) 
Apoptosis assay, and 3) HSP70 expression analysis.  
 
6.7.1 Cell viability analysis of AD-MSC expressing mms6 in 3-D culture 
following two-hour exposure of 540 kHz AMF. 
AD-MSC expressing mms6 were cultured in medium doped with FeQ (34 µM) for 10 
days. The cells were washed three times, then pelleted in microcentrifuge tube in 100 
µl medium. The cells were then exposed to 540 kHz AMF for two hours. AD-MSC 
expressing mms6 exposed to 0 kHz AMF for two hours were used as control. AD-
MSC exposed in 45 °C in block heater for 2 hours were used as positive control. After 
the exposure, cells were then incubated in 37 °C CO2 incubator for overnight. The cell 
viability was then determined with Alamar Blue Cell Viability Assay. The experiment 
was run in triplicate and repeated three times. 
188 
 
The results of the experiments are illustrated in Figure 6-9, where the fluorescence 
intensity average values registered for the exposed cells is 44434±702, while for 
negative control and positive control are 45307±1074 and 411±239, respectively. Cell 
viability percentage of exposed cells was calculated as a ratio between AMF exposed 
cells and controls cells, and it is shown in considering controls as 100% viable. The 
result reveals that the viability of AMF exposed cells was 97.42±2.25% of that of 
controls and not statistically significant. This result confirms that the 540 kHz AMF 




Figure 6-9: Cell viability of AD-MSC expressing mms6 in 3-D culture following 
one-hour exposure of 1030 kHz AMF. AD-MSC expressing mms6 cell were exposed to 
to 540 kHz (light grey column) or exposed to 0 kHz as negative control (black column) or 
exposed to 45 °C in block heater as positive control (dark grey column). AlamarBlue data 
showing average of fluorescence intensity of cells following AMF exposure (left panel) and 
average of cell viability percentage of exposed cells against controls (right panel). Values are 
presented as mean ± SD. N=3 
 
6.7.2 Cell apoptosis analysis of AD-MSC expressing mms6 in 3-D 
culture following two-hour exposure of 540 kHz AMF. 
AD-MSC expressing mms6 were cultured in medium doped with FeQ (34 µM) for 10 
days. The cells were washed three times, then pelleted in microcentrifuge tube in 100 
µl medium. The cells were then exposed to 540 kHz AMF for two hours. AD-MSC 
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expressing mms6 exposed to 0 kHz AMF for two hours were used as control. After the 
exposure, cells were then seeded in Petri dish and incubated in 37 °C CO2 incubator 
for overnight. The cell apoptosis was then determined with Click-iT™ Plus TUNEL 
Assay for in situ apoptosis detection with Alexa Fluor™ 488 dye. AD-MSC treated 
with DNase I were used as positive control. The experiment was run in triplicate and 
the experiment was only done once. 
From the visual inspection of fluorescent microscopy as shown in Figure 6-10, the 
green fluorescent signal was clearly noticed in the positive control cells confirming the 
apoptosis mechanism by DNA strand breaks from DNAse treatment. Meanwhile, 
green fluorescent signals were not found on the cells exposed to 0 kHz AMF. For the 
cells exposed to 540 kHz AMF, only a few numbers of cells showing the green 
fluorescence. Moreover, it was not clear whether the green fluorescence was the result 
of DNA strand break or autofluorescence. This result confirmed that the two-hour 540 
kHz AMF exposure on the AD-MSC may not induce cell apoptosis. It was also 
important to note that due to limited time and money, the experiment was only done 
once. Therefore, a further investigation using this method or other different methods 





Figure 6-10: Cell apoptosis analysis of AD-MSC expressing mms6. Click-iT™ Plus 
TUNEL Assay analysis showing cell apoptosis detection of AD-MSC expressing mms6 after 
two-hour of 540 kHz AMF exposure. Alexa Fluor™ 488 dye was utilized to detect the fragment 
DNA (green). DAPI was used to stain the cell nuclei (blue). Scale bar = 100 µm. N=3. 
 
6.7.3 HSP70 analysis of AD-MSC expressing mms6 in 3-D culture 
following two-hour exposure of 540 kHz AMF. 
AD-MSC expressing mms6 were cultured in medium doped with FeQ (34 µM) for 10 
days. The cells were washed three times, then pelleted in microcentrifuge tube in 100 
µl medium. The cells were then exposed to 540 kHz AMF for two hours. AD-MSC 
191 
 
expressing mms6 exposed to 0 kHz AMF for two hours were used as control. After the 
AMF treatment, cells were incubated in 37 °C CO2 incubator for overnight. 
Afterwards, cells were collected and 20 µg of protein lysates from each sample were 
used for the western blot. ß-actin was used as an internal control. The experiment was 
repeated three times. 
 
Figure 6-11: HSP70 expression of AD-MSC expressing mms6.  
A) Representative image of western blot analysis showing HSP70 expression in AD-MSC 
expressing mms6 following two-hour of 540 kHz exposure. B) Protein level of HSP70 of 
AMF exposed AD-MSC expressing mms6 against control normalised by ß-actin. 
Values are presented as mean ± SD from three independent experiments N=3.  
 
Based on the western blot result as shown in Figure 6-11, HSP70 protein band was 
found around the expected size of interest 70 KDa both in the AMF exposed cells and 
in the control cells. Meanwhile ß-actin protein bands with the expected size (42 KDa) 
were shown in both samples, confirming the validation of the experiment. From a 
visual inspection, it can be seen that the thickness of HSP70 protein band on both 
samples were similar without a clear difference. Using a semi quantitative method 
measuring the average expression of HSP70 normalised by ß-actin expression, it was 
found that the average expression of AMF exposed was 0.416±0.179 against 
0.414±0.128 for control. This result confirms that the 540 kHz AMF exposure for two 




6.8 IN VITRO MAGNETIC RESONANCE IMAGING ANALYSIS OF AD-MSC 
EXPRESSING mms6 
To determine whether AD-MSC expressing mms6 would enhance MR contrast, 
magnetic resonance imaging experiment was performed. For this, following AD-MSC 
were prepared for the experiment: 1) Mag01-transfected AD-MSC, 2) Mag03-
transfected AD-MSC 3) lentiviral-mms6 tranduced AD-MSC and 4) Ferucarbotran-
loaded AD-MSC. 
Transfected cells or AD-MSC expressing mms6 were cultured in medium doped with 
FeQ (34 µM) for 10 days. For Ferucarbotran-loaded AD-MSC, cells were incubated 
in 500 µg/ml Ferucarbotran for overnight. The cells were then harvested and fixed in 
1% agarose gel in 50 ml falcon tubes. The tubes were then arranged in imaging 
phantoms and were suspended in a water container to reduce artefact. Multi-gradient-
echo T2* acquisitions were acquired to generate T2* values (ms) using a standard 




Figure 6-12: AD-MSC expressing mms6 produce intracellular nanoparticles 
which are identifiable by magnetic resonance imaging (MRI). MRI analysis showing 
untransfected AD-MSC as control (A), Mag01-transfected AD-MSC (B), Mag03-transfected 
AD-MSC (C), Lenti-mms6 transduced AD-MSC (D), and Ferucarbotran-loaded AD-MSC (E). 
As shown Figure 6-12, all the AD-MSC expressing mms6 samples: Mag-01 
transfected (Tube B), Mag-03 transfected (Tube C), and Lenti-mms6 transduced (Tube 
D) cells produced visually detectable changes at 3 T compared to control (Tube A). 
Meanwhile, Ferucarbotran-loaded AD-MSC (Tube E) cells produced the strongest 
contrast compared to all samples. This result confirms that the approach to magnetize 
AD-MSC using mms6 gene has been successful and could be potentially useful in MRI 
application. However, it was clear that the use of chemically synthesized nanoparticle 




The discussion in this chapter is focusing on cell delivered nanoparticle-mediated 
magnetic hyperthermia as an alternative to conventional hyperthermia. The basic 
concept of hyperthermia therapy is relying on targeting temperatures above 43°C 
which can cause necrosis of cancer cells.  However, the main drawback of this 
approach is that adjacent normal tissues are also severely damaged under this 
conventional hyperthermia treatment. Thus several groups have attempted to use 
magnetic-nanoparticle-mediated hyperthermia which has the potential to overcome 
these shortcomings (Armijo et al., 2012; Lemine et al., 2014; Moros et al., 2015; 
Blanco-Andujar et al., 2016) 
While much work on developing magnetic nanoparticle for hyperthermia are 
promising, MNP as a foreign material also have potential side effects in their clinical 
application (Huang et al., 2017). Moreover, the previous approaches are still afflicted 
by the difficulty of delivering the magnetic nanoparticles to the tumour site in vivo 
(Gao et al., 2013; Huang and Hainfeld, 2013). As such, there is a need for more 
selective hyperthermia agents, prevention of the necrosis of normal tissues and better 
nanoparticle delivery systems. To overcome this challenge, the ultimate purpose of 
this chapter was to investigate the potential use of engineered-MSC cells for cancer 
treatment via intracellular magnetic hyperthermia. Therefore, two group of cells were 
used in this in vitro magnetic hyperthermia study: 1) AD-MSC expressing mms6 
cultured in medium doped with FeQ (34 µM) for 10 days, 2) AD-MSC loaded with 
Ferucarbotran nanoparticle for overnight.  
In this chapter, experiments were aimed to test the hypothesis that the nanoparticle 
produced inside AD-MSC expressing mms6 could generate a magnetic hyperthermia 
effect by applying AMF into the cells. Cell viability, cell apoptosis and HSP70 
expression were investigated as the parameter of magnetic hyperthermia effect. 
Furthermore, the experiment also aimed to demonstrate the potential use of AD-MSC 
expressing mms6 as a contrast agent for MRI.  
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Regarding the magnetic hyperthermia experiment, the heating capacity of 
Ferucarbotran nanoparticle in water suspension were investigated. The experiment 
was conducted simply to measure the temperature increase of free nanoparticle in 
colloid. The nanoparticles were exposed under AMF each with three different 
frequency: 178.3 kHz (23.89 mT), 540 kHz (24.87 mT), and 1030 kHz (13.37 mT). 
Afterwards, the same AMF frequencies were used to evaluate the effect of AMF 
exposure on single layer of Ferucabotran-loaded AD-MSC and AD-MSC expressing 
mms6. 
The three different frequencies above were considerably low to medium range radio 
frequencies. The different identifications of radio frequency sub-regions in terms of 
their frequency can be seen at Table 6-1. In magnetic hyperthermia, the heat generation 
involves the interaction between the magnetic moment of the MNP and the magnetic 
component of the applied electromagnetic wave.  
As for the interaction between electromagnetic fields and the exposed cells, it is known 
that living organisms are mostly composed of molecules with a dipolar electric 
moment, and therefore can interact with the electric component of the radio frequency 
radiation. This interaction at a molecular level depends on the characteristic energy 
levels that can be excited at certain frequency range of the electromagnetic spectrum 
(Silver et al., 1964; Goya et al., 2013). As an example, conventional hyperthermia 
treatment based on microwave ranges for deep tumour treatment, is using dielectric 
heating at higher frequency (Silver et al., 1964). In magnetic hyperthermia, however, 
the low RF frequency range (from approximately 100 kHz to 1 MHz) is commonly 
used. At his range, the interaction of both the electrical and magnetic components of 






Table 6-1: The different identifications of the RF sub-regions in terms of their 
frequency. Adapted from Radiation Advisory Group on Non-ionising Radiation. 
Frequency Wavelength Designation 
3–30 kHz 100–10km Very low frequency 
30–300 kHz 10–1km Low frequency 
300 kHz–3MHz 1 km–100m Medium frequency 
3–30MHz 100–10m High frequency 
30–300MHz 10–1m Very high frequency 
300 MHz–3GHz 1 m–10cm Ultra high frequency 
3–30GHz 10–1 cm Super high frequency 
30–300GHz 1 cm–1mm Extremely high frequency 
300 GHz–3000GHz 1 mm–0.1 mm Tremendously high frequency 
 
The result of the heating capacity of free Ferucarbotran nanoparticle experiment 
successfully showed that the temperature of the sample suspension was raised above 
physiological temperature when they were exposed under three different RF of AMF: 
178.3 kHz, 540 kHz, and 1030 kHz. The highest temperature was shown in sample 
exposed to 540 kHz AMF with temperature value over 60 °C for less than an hour of 
AMF exposure. However, this result does not represent the real condition once the 
nanoparticles enter the cells. In addition, the concentration used in this experiment was 
5 mg/ml which was too high and may not suitable for this in vitro intracellular 
magnetic hyperthermia experiment. 
Although many studies have been demonstrating the heating mechanism of MNP when 
submitted to AC magnetic field, the translation of these theoretical model into in vitro 
MH is still lacking. Factors such hydrodynamic size, intracellular distribution and the 
degree of agglomeration once the nanoparticles enter the cells are important in in vitro 
magnetic hyperthermia study. A study by Ge and coworkers in 2009, investigating the 
effect of surface charge and agglomerate degree of MNP on Oral Squamous 
Carcinoma Cell KB as an in vitro model revealed that cellular uptake of MNP by KB 
cells was dependent on incubation time, nanoparticle concentration and properties (Ge 
et al., 2009).  In addition, another problem related to in vitro MH is the complex nature 
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of the interaction between nanoparticles and the biological media in in vitro MH. 
Therefore, the in vitro MH greatly depends on the cell type, nanoparticle design and 
the biological set up in the experiment.  
The novelty of the present study is the use of engineered-AD-MSC as a potential cell 
delivery system and agent to induce magnetic hyperthermia. A similar approach was 
undertaken in an in vitro study reported by Asin and coworkers in 2013. The study 
was investigating the potential use of dendritic cells as cells to target tumours for 
magnetic hyperthermia. Interestingly, the study showed that cell death was observed 
following AMF exposure specifically to MNP-loaded dendritic cells (DCs) in culture 
and that this was caused by the release of unknown toxic agents into the cell culture 
supernatants without a significant temperature increase in the medium (Asín et al., 
2013). 
Other studies using synthesized MNP which were incorporated into human breast 
cancer cells (MCF-7) showed cellular death following an AMF exposure (4 kW, 250 
kHz, 20 minutes), achieving temperatures as high as 46 °C (Baba et al., 2012).  
Another type of cells which has been tested for magnetic hyperthermia was caco-2 
(human epithelial colorectal adenocarcinoma) cells. This study demonstrated that 
MNHT treatment (magnetic field of 20 kA/m; 237 kHz; for 30 minutes) significantly 
increases cell membrane fluidity which was believed to have contributing factor to the 
increase of cisplatin uptake in magnetic fluid hyperthermia-treated Caco-2 cells and 
enhance cytotoxic effect of the chemotherapeutic agent (Alvarez-Berríos et al., 2013).  
Rodríguez-Luccioni and coworkers also showed a significant decrease in MCF-7 cell 
viability when the cells loaded with carboxymenthyl dextran iron oxide nanoparticles 
and exposed to a magnetic field amplitude (20 kA/m; 238 kHz for 120 minutes. 
Interestingly, cell viability decreased with time after a single application of AMF 
indicating possible secondary effects on cell viability which are seen after only a 
further period of culture (Rodríguez-Luccioni et al., 2011). Other cells types, A549 
(human lung adenocarcinoma) and MDA-MB-231 (human mammary 
adenocarcinoma) cells have also been tested in in vitro MNHT. The study showed that 
magnetic hyperthermia application (6 kA/m and frequency of 386 kHz) for 30 minutes 
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using custom design SPIO nanoparticles prepared from iron chlorides can induce cell 
death 88% in A549 and 90% in MDA-MB-231 cells (Sadhukha, Niu, et al., 2013). The 
previous studies have shown promising potential in in vitro work of intracellular MH 
using various tumour cell lines however it may be that a significant component of the 
hyperthermia effect may be due to the presence of extracellular nanoparticles. The use 
of AD-MSC in the present work was found to be challenging for intracellular 
hyperthermia as the experiments failed to show any significant difference on the AMF 
treated and control group.  
For the AMF application on 2-D monolayer culture experiment, no observable 
difference was seen in cell viability of Ferucarbotran-loaded AD-MSC following the 
AMF application. It was observed that the viability of AMF exposed cells were 
99.58±0.66%, 94.65±2.03%, and 95.5±4.4% against controls after the cells were 
exposed to 178.3 kHz, 540 kHz and 1030 kHz of AMF, respectively (Figure 6-2, 
Figure 6-3, Figure 6-4). Therefore, the interaction of Ferucarbotran nanoparticles and 
considerably low frequency of AMF has not been found to influence cell viability of 
AD-MSC.  
In contrast to this finding, a study by Kalber and coworkers indicated that human MSC 
can be used as cell delivery system of Ferucarbotran. In the in vivo test using a mouse 
model, the internalized Ferucarbotran was found to induce heating at 2 weeks after the 
Ferucarbotran-loaded MSC cells(60 pg/cell) Ferucarbotran were injected into 
OVCAR-3 tumour tissue and AMF of 10 mT at 1.05 MHz applied. Interestingly, 
despite the 4.3°C rise was observed in surface temperature of the tumour, the AMF 
application did not result in measurable retardation of tumour growth (Kalber et al., 
2016). The study, however, did not test the effect of AMF on MSC viability in vitro. 
In another in vivo study by Araya and coworkers, Ferucarbotran nanoparticles (150 µl 
dose; 7.5 ml/kg) were injected into lung cancer xenografts in nude mice. The result 
revealed that the intratumour temperature rose rapidly and was maintained at 43 °C – 
45 °C for 20 minutes under AMF (20 – 24 mT; 142 kHz), which significantly 
suppressed tumour size by necrosis (Araya et al., 2013). However, the finding on this 
study is not relevant to the present study since the approach that they used was injecting 
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the Ferucabotran directly into the tumour site without using vector cells to deliver the 
Ferucarbotran nanoparticles. In addition, the study also declared its drawback which 
was the surface of the induction heating applicator was set at 2 cm from tumour site, 
thus it does not represent AMF application on deep organ cancers in clinical practice.  
Regarding the experiment on AD-MSC expressing mms6, it was observed that the 
viability of AMF exposed cells was 93.24±3.79%, 97.62±2.79%, and 97.75±1.79% 
against controls after the cells were exposed under 178.3 kHz, 540 kHz and 1030 kHz 
of AMF, respectively. Therefore, the interaction of nanoparticles created in AD-MSC 
expressing cells and the AMF has not been found to influence cell viability of AD-
MSC.  
A previous report investigating the potential use of magnetosomes isolated from 
Magnetospirillum magneticum strain AMB-1 magnetotactic bacteria for extracellular 
MNHT indicated an efficient magnetic hyperthermia treatment of tumour cells 
(Alphandéry et al., 2012). The study used two different approaches to treat the cancer 
cells: 1) addition of chains of magnetosomes to the cells, and 2) using individual 
separated magnetosomes to treat the MDA-MB-231 breast cancer cells. When the 
chain of magnetosomes (1 mg/ml) were incubated in the presence of cancer cells and 
exposed to AMF (~20 mT; 198 kHz; 5 – 20 min), they generate heat as indicated by 
increased SAR value and produce efficient inhibition of cancer cell proliferation, 
showing the percentage of inhibition increased by factor ~7 – 16 as indicated by MTT 
viability assay. By contrast, when the chain of magnetosomes were separated into 
individual magnetosomes, they were prone to aggregation, and did not produce 
efficient inhibition of cancer cell proliferation under application of AMF (Alphandéry 
et al., 2012). In a further study, the chain of magnetosomes nanoparticles were injected 
into mice bearing intracranial U87-Luc glioma tumour. After 12 to 15 cycles of 30 min 
AMF (30 mT; 200 kHz) application, the experiment showed full tumour disappearance 
in 40% of mice. The study identified that the tumour destruction by the chain of 
magnetosome could be explained by extracelluar MH by a larger production of heat 
and possibly endotoxins released following cell death under alternating magnetic field 
application (Alphandéry et al., 2017a). 
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Indeed, the use of mms6 in the present work was not aimed to create the complete 
structure of magnetosomes inside AD-MSC. In fact, the use of mms6 alone will not be 
able to create the complex natural structure of magnetosomes. Therefore, the use of 
magnetosomes for magnetic hyperthermia both in vitro and in vivo study as discussed 
above is not comparable to the magnetic hyperthermia results in the present study as 
they were aimed at comparing the utility of naturally produced magnetic nanoparticles 
by bacteria as a potential for use for clinical magnetic hyperthermia in contrast to 
chemically synthesized nanoparticles. However, the studies clearly described the 
superior characteristic of magnetosomes as a heating capacity agent in magnetic 
hyperthermia is highly dependant on its chain structure. Thus, it may be possible that 
the lack of observable difference of effect betweenAMF exposed and non-exposed 
AD-MSC expressing mms6 could be due to the poor structure or shape of the 
synthesized nanoparticles, relatively low number of intracellular nanoparticles which 
results in insufficient heating capacity. 
For the AMF application on 3-D model cells experiment, the result revealed that the 
viability of AMF exposed Ferucarbotran-loaded AD-MSC was 96.09±3.76% against 
controls. While the viability of AMF exposed AD-MSC expressing mms6 was 
97.42±2.25% against control. Consistent with the previous 2-D model experiment, 
both results showed no observable difference in AMF application effect on cell 
viability of Ferucarbotran-loaded AD-MSC and AD-MSC expressing mms6, 
suggesting no cell necrosis or cytoplasmic lysis following the 540 kHz AMF exposure. 
Furthermore, the investigation on cell apoptosis and HSP70 expression of AD-MSC 
expressing mms6 following the AMF application also showed no observable 
difference. Unfortunately, the experiment was only done once due to limited time and 
money. However, it can be concluded that the 540 kHz application of AMF on 3-D 
pellet of AD-MSC expressing mms6 does not induce cell apoptosis mechanism and 
does not increase the HSP70 expression.  
The 3-D model experiment was developed to mimic the in vivo condition. The 
experiment, however, did not use a proper 3-D cell culture system, such as 3-D well 
plate as culture plates could not be fitted into the MagneThermTM device for the AMF 
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application. For this reason, one million cells were simply collected, pelleted and 
placed inside a microcentrifuge tube. The tube was then placed at the center position 
of the coil of MagneThermTM device for the AMF application.The theoretical reason 
behind using a 3-D cell pellet experiment was also due to the hypothesis that a larger 
number of cells in close proximity is required for intracellular magnetic hyperthermia 
and triggering the hyperthermia effect. In 2013, a study by Hedayati and coworkers 
hypothesized that cytotoxicity increased with increasing cell number (Hedayati et al., 
2013). In their study, starch-coated magnetite (Fe3O4) core shell particles (Bionized 
NanoFerrite) or BNF were loaded into cultured DU145 prostate cancer cells. Then, the 
cell pellets of variable size were treated with AMF amplitude fixed at 1100 Oe for 30-
min duration. The study demonstrated that smallest cell pellet in which hyperthermia-
mediated cytotoxicity was observed contained 250,000 cells, revealing there is a 
minimum number of cells within a pellet required for cytotoxic hyperthermia. The 
study also concluded that the intracellular magnetic hyperthermia has the same scaling 
effect to the extracellular or macroscopic magnetic hyperthermia. As a result, the 
intracellular magnetic hyperthermia approach would be less effective for smaller cell 
pellets or heating micro-metastatic cancer in medical application (Hedayati et al., 
2013). In short, the smaller heating system will result in less magnetic heating effect. 
In agreement with the finding above, Wilhelm and coworkers (2007) investigated the 
relative cytotoxicity of maghemite anionic nanoparticles on human prostatic tumour 
cells. The study used 20 million cells of loose pellet and exposed to AMF (31 mT; 700 
kHz; 1 hour duration), and found that more than 80% of the cells were killed after 
being submitted twice to AMF. Interestingly, when magnetic cells coexist with non-
magnetic ones, the same proportion of cytotoxicity was found on both populations 
after the AMF application, suggesting the cytotoxic hyperthermia is a function of total 
iron particle content in the pellet (Wilhelm et al., 2007).  
As the studies above suggest, the negligible cytotoxicity associated with AMF 
treatment both on Ferucarbotran-loaded AD-MSC and AD-MSC expressing mms6 in 
this chapter is likely related to cell number or cell pellet size. The interpretation of this 
result is that the one million cells used in this experiment could be not sufficient to 
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achieve the AMF treatment scale for increasing the temperature. In this regard, how 
many Ferucarbotran particles each individual AD-MSC cell absorbs could determine 
the cytotoxicity following AMF application. It might be also possible that some cells 
at least take up only a few or none of the particles whereas others take up a large 
portion. While for AD-MSC expressing mms6, it could be possible that some cells 
produce Mms6 protein to a lesser degree than others which results in only limited 
nanoparticle in the cells. In summary, the experimental set-up in the present study 
might be inadequate to provide an in vitro environment to obtain a proper magnetic 
heating effect which result in no detectable changes in cell viability, cell apoptosis and 
HSP70 expression. 
Gordon et al. in in 1979 declared that intracellular hyperthermia is superior to 
extracellular hyperthermia by causing calamitous heating and triggering the 
intracellular space to reach higher temperatures. It is believed that the cell membrane 
may have a key role as a thermal insulator due to its low thermal conductivity, thus 
only intracellular heating can overcome this thermal barrier (Gordon et al., 1979). In 
2002, the hypothesis was rejected by Rabin and his co-workers who found that 
nanoscale heating effects are negligible in their study, suggesting a single magnetic 
nanoparticle does not have a practical effect on hyperthermia. Interestingly, the study 
also revealed that the heating generation in a single cell, which is loaded with a huge 
number of nanoparticles, is not sufficient to create the conditions for hyperthermia 
unless it is a part of a larger cellular structure of similar cells (Rabin, 2002). In short, 
macroscopic hyperthermia or extracellular hyperthermia is still superior to 
intracellular hyperthermia in the thermal sense, assuming that the same number of 
nanoparticles are present in both situations. 
Recent controversial reports also suggested that AMF can trigger cytotoxicity without 
any macroscopic temperature increase, which strongly suggest that cell death by AMF 
is not just a matter of temperature increase, but through other specific mechanism 
(Villanueva et al., 2010, Creixell, 2011). It is believed that the cell death is related 
either to chemical effects triggered by the presence of the nanoparticles, or mechanical 
damage caused to the cell by intracellular vibrations or movement of the nanoparticles. 
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Only 1 or 2 °C temperature increase was observed when nanoparticle-loaded dendritic 
cells (DCs) exposed under to AMF (260 kHz and 12.7 kA/m) for 15 min, yielding 
almost 100% of cell death (Asín et al., 2012). Interestingly, the toxicity of the 
supernatant of AMF-exposed cells was observed to have the potential to kill control 
cells  (Asín et al., 2013). It was explained that the MNP might generate the disruption 
of the endocytic vesicles/lysosomes membranes during AMF exposure, allowing the 
unknown toxic vesicle´s content to be released into the cytoplasmic region and 
triggering cell death (Asín et al., 2013). Another non-thermal explanation could be the 
disruption of cell membrane by the nanoparticles. It was suggested that the increasing 
cell membrane fluidity could trigger a heat shock protein response which may 
modulate positively or negatively apoptotic cell death (Csoboz et al., 2013). The fact 
that no observable difference in HSP70 expression in the present study suggesting that 
the AMF application does not have direct effect to membrane fluidity of AD-MSC 
expressing mms6. 
Work assessing cell apoptosis following AMF exposure needs to be optimised. An 
interesting observation comparing apoptotic effects of water-based hyperthermia 
(WH) and magnetic nanoparticle-mediated hyperthermia (MNHT) demonstrated that 
the apoptotic effect was slow and its effects on viability were not found until 48 hours 
after 2 hours of treatment. In contrast, an effect due to MNHT on cell viability was 
detected 24 hours after 2 hours of treatment (Rodríguez-Luccioni et al., 2011). As 
explained it may have been preferable that apoptosis was assessed in the present study 
at several time points after AMF application. In addition, several AMF cycles might 
be needed to obtain the magnetic hyperthermia effect. For example, 10-15 magnetic 
session for several days; 30 minutes per session. This was suggested in a previous 
report which used magnetosome-loaded tumour exposed to 12 to 15 cycles of 30 min 
AMF applications to achieve full tumour disappearance. (Alphandéry et al., 2017a). 
Regarding the MRI experiment, it was obvious that the use of Ferucarbotran-loaded 
AD-MSC was superior to AD-MSC expressing mms6 in terms of detectable magnetic 
signal, providing the same number of cells used in the experiment.  Having said that, 
the fact that MR contrast was detected in the transfected cells, the experiment 
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successfully demonstrated a promising potential of mms6 as a reporter gene. In 
agreement with this finding, a previous report using mms6 transfected gliosarcoma cell 
line showed detectable MR changes in both in vitro and in vivo experiments. Even 
more interesting, the study revealed that tumour cells stably expressing mms6 can 
produce MR contrast in the absence of iron supplementation by accumulating 
endogenous iron efficiently in the in vivo experiments (Zhang et al., 2014) in contrast 
to earlier reports which used iron supplementation  with cells transfected with magA, 
cloned from both MS-1 and AMB-1 species of MTB, to display increased MR contrast 
in stably transfected mammalian cells (Zurkiya et al., 2008; Goldhawk et al., 2009).  
In conclusion, this chapter successfully showed the potential use of mms6 as MR 
reporter gene for AD-MSC. However, future work both in vitro and in vivo is still 















 GENERAL DISCUSSION AND FUTURE PERSPECTIVE  
Due to their small size and high surface-to-volume ratio, magnetic nanoparticles 
(MNP) have attracted great interest for their potential biomedical applications either 
alone or through cell-based therapies (Gao et al., 2013).  One of the most promising 
approaches is magnetic nanoparticle-mediated hyperthermia (MNHT) for cancer 
treatment, where magnetic nanoparticles (MNP) absorb energy from alternating 
magnetic fields (AMF) and transform this energy into heat. While they are promising, 
MNP have disadvantages of variable uptake by cells and may have potential side 
effects in its clinical application (Huang et al., 2017). Another key challenge is the 
difficulty of delivering the magnetic nanoparticles to the tumour site due to their rapid 
removal from blood and biological barriers at tissue and cellular level (Gao et al., 
2013; Huang and Hainfeld, 2013). All these problems represent the need to find less 
toxic or more biocompatible nanoparticles and to improve strategies to deliver to and 
distribute nanoparticles within tumours for optimal MH treatment.   
To overcome these problems, the use of MNP-labelled mesenchymal stem cells (MSC) 
has been proposed due to their inherent tumour-tropic and migratory properties, thus 
enabling cell-based MNP vehicle for the targeted delivery into tumour (Roger et al., 
2010; Duchi et al., 2013; Gao et al., 2013; Huang and Hainfeld, 2013). However, a 
drawback to the use of MSC so far is that MSC have limited phagocytic capability, 
yielding poor intrinsic capacity to ingest extrinsically applied MNP (Yin et al., 
2016; Boutry et al., 2008). Therefore, a genetic engineering approach was utilized 
in this study, allowing MSC cells to intrinsically produce biogenic nanoparticles. 
 
7.1 SYNTHETIC CODON OPTIMISED mms6 GENE FOR MAMMALIAN 
EXPRESSION  
In the present work, I investigated the potential use of a magnetosome gene, mms6, 
as the candidate gene for genetically engineered-cells producing intrinsic biogenic 
nanoparticles. In MTB, mms6 encodes an iron binding protein which has a key role 
in initiating magnetite crystal nucleation within magnetosomes (Arakaki et al., 
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2003) and helps regulate the crystal morphology of magnetite during the formation of 
magnetosomes (Prozorov et al., 2007; Kashyap et al., 2014; Yamagishi et al., 2016). 
Having known the function of this gene, therefore, the ultimate aim of my project was 
to develop MSC able to self-express MNP by genetically modifying them with the 
mms6 gene.  
In Chapter 3, the main aims were to amplify the plasmid DNA containing synthetic 
codon-optimised mms6, which was called Mag02, using molecular cloning techniques 
and to demonstrate expression of Mag02 in AD-MSC after transfection. In particular, 
this chapter explains all the initial work performed in the 1st year of my PhD project. 
In this work, only one type of codon-optimised mms6 was used called Magister02 
(Mag02). The name Mag02 was used due to previous codon-optimised mms6, named 
Mag01, was designed and investigated in a previous study by Lisa Lungaro, former 
PhD student in the group. The Mag02 gene construct was designed by Dr. Christopher 
Boyd and was synthesized by GeneArt® Gene Synthesis service. In the previous work 
by Lisa Lungaro, the synthesised mms6 (Mag01) does not have a protein marker in the 
construct, thus a polyhistine-tagged (6x) was added in the Mag02 construct which 
aimed for easier protein detection by Western blot.  
Using molecular cloning techniques, I was able to amplify the plasmid which was 
important before starting the transfection experiment. To confirm this, using specific 
restriction enzyme digests in combination with DNA sequencing result, I was able to 
demonstrate that Mag02 plasmid was successfully cloned without mutation.  
 
7.2 EXPRESSION OF mms6 IN HUMAN ADIPOSE DERIVED-
MESENCHYMAL STEM CELLS 
For the transfection experiment, I explored a variety of transfection techniques in an 
attempt to improve the transfection efficiency. Initially, the experiments started with 
the X-tremeGENE™ HP DNA Transfection Reagent. This was the standard 
transfection reagent in our lab and had been previously optimised by Lisa Lungaro, 
showing successful transfection of bone marrow-derived MSC. Using this transfection 
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technique, I was able to demonstrate mms6 expression in AD-MSC at 10 days after 
transfection with Mag02 plasmid. This result was in agreement with the result from 
previous work by Lisa Lungaro, showing MSC and MG63 cells were able to express 
these MTB genes at 10 days after transfection with each of mmsF and mms6 genes. In 
addition, using the same technique, previous work by Elfick and co-workers (2017) 
also demonstrated expression of the mms6 in transfected MSC cells at 10, 15 and 21 
days post-transfection by RT-PCR and Sanger DNA sequencing of the PCR transcripts 
(Elfick et al., 2017). However, despite mRNA of Mag01 being successfully displayed 
in previous work, they did not provide evidence of Mms6 protein expression. In my 
work, it was necessary to demonstrate the evidence that a foreign protein like Mms6 
protein can be expressed in human AD-MSC.  
Previous work by Liu et al. (2016) indicates that a direct comparison between protein 
and mRNA abundances from the same location or from the same cell type may not be 
appropriate. This is mainly due to multiple processes beyond mRNA concentration 
that contribute to establishing the expression level of a protein including translation 
rates, translation rate modulation, modulation of a protein’s half-life or autophagy 
which may influence protein concentrations independent of transcript concentrations, 
protein synthesis delay and protein transport which disconnects proteins from the 
transcripts they were synthesized from (Liu et al., 2016).  Therefore, confirming Mms6 
protein expression was important for the two following reasons: 1) To confirm that the 
synthesis of biogenic nanoparticle in AD-MSC was mainly because of the expression 
of Mms6 protein which acts as an iron binding protein and not due to another unknown 
mechanism; 2) To establish if mRNA expression equates with levels of expression of 
protein. My results showed that the His-tagged Mms6 protein was absent following 
the transfection procedure despite positive mRNA expression being evident up to 10 
days after transfection. Indeed, it needs to be stated that the limitation of the 
experiment was that a specific Mms6 antibody for protein-based detection assay was 
not available commercially. It would have been great to use custom-designed Mms6 
antibody for direct detection of Mms6 expression. However, such option was not 
available and thus polyhistidine-tag method was preferred.  Nonetheless, such option 
should be considered in the future work. 
208 
 
In Chapter 4, the experiments conducted aimed to overcome the problems related to 
the absence of Mms6 protein expression discussed in Chapter 3.  It was thought that 
the absence of His-tagged Mms6 protein expression could be due to low transfection 
efficiency or could be due to an as yet unidentified problem possibly related to the 
codon-optimised mms6 construction. Therefore, the experiments in Chapter 4 aimed 
to demonstrate the mms6 mRNA and protein expression in AD-MSC using different 
codon-optimised mms6 and different technique of transfection. For this, additional 
codon-optimised mms6 were designed and investigated: MagWT, Mag01, Mag02 and 
Mag03. MagWT contains the original sequence mms6 gene of M. magneticum strain 
AMB-1 mms6 gene. Mag01 was kindly designed by Dr. Greg Kudla (Group leader of 
RNA synthetic biology group, MRC Institute of Genetics & Molecular Medicine, 
University of Edinburgh). Mag02 was designed by Dr. Chris Boyd (Group leader of 
gene therapy for cystic fibrosis research group, MRC Institute of Genetics & 
Molecular Medicine, University of Edinburgh). Mag03 was designed by GeneArt® 
Gene Synthesis service. 
Each of these constructs also included a polyhistidine-tag at the N terminus and a GFP-
tag at the C terminus of the mms6 DNA fragment. These double markers were essential 
to provide a quick and informative assessment of Mms6 protein expression following 
the transfection.  
Regarding the mms6 mRNA expression in AD-MSC, the end-point PCR result showed 
mRNA of mms6 was constantly expressed in AD-MSC up to 21 days after the 
transfection using X-tremeGENE™ DNA Transfection Reagent after the transfection 
with each of those 4 types of MAGISTER genes. However, Western blotting 
demonstrated that the His-tagged Mms6 protein expression was found to be absent in 
all samples with this transfection reagent. It was speculated that false positive results 
due to plasmid DNA contamination were obtained during end-point PRC experiment, 
hence Mms6 protein expression was absence on the western blot assay. In the later 
experiments, when HEK293T cells were used in combination with similar transfection 
methodology, His-tagged Mms6 protein expression was successfully detected. These 
results indicate that the expression of Mms6 protein is likely to be cell-dependent. In 
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this case, HEK293 cells are relatively easy to transfect cells, while MSC are widely 
known as difficult to transfect cells, unlike other primary cell types, (Baek et al., 2016). 
Indeed, common non-viral transfection methods used for mammalian cells, such as a 
cationic lipid-based reagent transfection system, still generally show low-to-moderate 
(less than 15%) gene transfer efficiency in transfecting MSC (Wang et al. 2014). 
Therefore, there was a need to improve the transfection strategy to be able to generate 
AD-MSC expressing mms6. 
 
7.3 NUCLEOFECTION IMPROVES THE EFFICIENCY OF AD-MSC 
TRANSFECTION. 
In the later experiments in Chapter 4, a physical-based transfection, nucleofection, was 
used. The GFP fluorescence expressed by AD-MSC as evaluated by both Flow 
cytometry and GFP imaging analysis confirmed the success of expression of His-GFP 
tag Mms6 protein in AD-MSC. This was also confirmed by Western blot analysis 
which shows the expression the His-GFP tag Mms6 protein in all cell samples 
nucleofected with MagWT, Mag01, Mag02 and Mag03 plasmid, resulting Mag01 and 
Mag03 expression higher than the other two, as indicated by a semi-quantitative 
protein quantification analysis on Western blot result.  
Flow cytometry analysis also showed that the nucleofection method was highly 
efficient as the method was able to generate 59.6±1.9 % of AD-MSC positively 
expressing His-GFP-tagged Mms6 protein at 2 days after transfection with Mag01 
plasmid. This was the highest percentage of transfection efficiency compared to the 
previously used method using X-tremeGENE™ transfection reagent with only 
15.55±3.9 % GFP-positive cells. This result is consistent with transfection efficiencies 
of 50 to 80% achieved using nucleofection method to transfect adult human MSC as 
reported by Haleem-Smith and co-workers (Haleem-Smith et al., 2005).  
However, a major drawback to the use of the nucleofection method was the reduction 
of cell viability. It was demonstrated the viability of AD-MSC nucleofected with 
Mag03 was significantly decreased to 66.2±2.5% against 100% cell viability of 
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control. This was expected as the disadvantage of using nucleofection method is the 
tendency for high level of damaged cells (Kaestner et al., 2015). It should be 
underlined that this cell viability problem alone technically made it difficult to use 
these transfected cells for in vitro MNHT experiments. Longer culture period may be 
needed to increase the cell number. However, it also means reduced protein expression 
overtime.  Therefore, it still remains a challenge to find a high-transfection method 
with less effect in cell viability for the transient expression of mms6 in AD-MSC. 
 
7.4 AD-MSC STABLY EXPRESSING mms6 AFTER LENTIVIRAL 
TRANSDUCTION 
In regard to the stable expression of mms6, a lentiviral vector carrying mms6 was 
designed. Using enzyme restriction digests, Mag01 gene fragment was successfully 
cloned into pSicoR-Ef1α-mCh-Puro lentiviral vector. Initially, it was aimed to clone 
Mag01 and Mag03 gene fragments into lentiviral vector as the expression of His-tag 
Mms6 protein was found to be higher in AD-MSC transfected with each of Mag01 and 
Mag03 compared to the other Magister plasmids, as shown by a semi-quantitative 
protein quantification analysis on western blot result. However, it was unfortunate that 
for unknown technical reason, I was unable to clone Mag03 into pSicoR-Ef1α-mCh-
Puro lentiviral vector, thus only Mag01 was used for the later experiments. Following 
the viral transduction of AD-MSC, puromycin antibiotic selection was conducted in 
order to generate colonies of AD-MSC expressing mms6. This was also confirmed by 
the constant expression of mCherry red fluorescence under fluorescence microscope. 
These cells were then expanded for the later experiments.  
In summary, my aims to demonstrate the mms6 mRNA and protein expression in AD-
MSC were largely successful and the experiments conducted in Chapter 3 and Chapter 
4 have improved understanding of the transfection approach for expressing MTB 
genes in adult human stem cells. 
For future studies it would be beneficial to investigate different techniques to optimally 
generate human stem cells stably expressing mms6. It will be interesting to use new 
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gene engineering tools such as zinc finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs), and CRISPR (clustered regularly interspaced short 
palindromic repeat)-Cas9(CRISPR-associated nuclease 9) system in order to improve 
the precision of genome editing, prevent mutations and maintain stable, long-term 
gene expression (Baek et al., 2016). Using these approaches, mms6 could be integrated 
into a specific site in MSC genome in a more accurate way than using chemical-based 
transfection or lentiviral-based transduction, allowing better understanding of gene 
and protein expression (Ding et al., 2016). 
 
7.5 THE mms6 EXPRESSION ON THE AD-MSC DOES NOT ALTER 
STEMNESS AND MULTIPOTENCY CAPABILITY. 
In Chapter 5, I aimed to investigate the effect of mms6 expression in lenti-mms6 
transduced AD-MSC stemness and differentiation potential following the lentiviral 
transduction. In addition, I also aimed to demonstrate the formation of nanoparticles 
inside the cells as well as the magnetic behaviour of AD-MSC expressing mms6. It 
was found that expression of mms6 gene by AD-MSC does not change cell stemness, 
and their capability to differentiate into the osteogenic and adipogenic lineage. 
However, due to technical problems, chondrogenesis differentiation was not shown in 
this study. It would be also interesting to compare these results with Ferucarbotran-
loaded or MNP-loaded AD-MSC in terms of their cell stemness and differentiation 
capability.  
Indeed, a previous study by Lima and co-workers demonstrated that MNP-loaded AD-
MSC have shown the potential to induce differentiation towards the osteogenic and 
chondrogenic lineages under the influence of an external magnetic field (Lima et al., 
2015). Ferucarbotran nanoparticles have also been reported to accelerate cell cycle 




7.6 AD-MSC EXPRESSING mms6 CONTAIN CLUSTERS OF 
NANOPARTICLES WITHIN MEMBRANE-ENCLOSED STRUCTURES 
The TEM result showed accumulation of membrane-bound, intracytoplasmic electron-
dense nanoparticles in Ferucarbotran-loaded AD-MSC. Similar electro-dense material 
was also found in AD-MSC expressing mms6, both virally transduced cells and 
nucleofected cells using Mag01 and Mag03 plasmid. However, unlike the highly 
ordered cubo-octahedral crystals of magnetite crystals of magnetosome in MTB, the 
nanoparticles produced by the AD-MSC expressing mms6 appeared unstructured. 
Nonetheless, my aim to demonstrate the formation of intracellular nanoparticle-like 
structure in AD-MSC were largely successful.  
This result was consistent with previous study by Elfick and co-workers which showed 
vesicles in mms6-transfected bone marrow-derived MSC filled with both dispersed and 
larger electron-dense material at day 10 to day 15 post-transfection (Elfick et al., 
2017). In addition, this was also in a good agreement with previous work by Zhang 
and co-workers, showing  gliosarcoma cell lines stably expressing mms6 contain 
clusters of nanoparticles within membrane-enclosed structures after 3 days incubation 
in ferric citrate doped medium (Zhang et al., 2014). 
 
7.7 FERROMAGNETIC BEHAVIOUR DISPLAYED BY AD-MSC 
EXPRESSING mms6 
In Chapter 5, the magnetic measurement based on ZFC-FC successfully showed the 
existence of room temperature ferromagnetism of AD-MSC expressing mms6 and 
superparamagnetic behaviour in Ferucarbotran-loaded AD-MSC. This result might be 
related to the previous study by Liu and co-workers demonstrating that magnetosomes 
have ferromagnetic behaviour. The study suggested that the different magnetic 
properties of magnetosomes and MNP may be largely due to their different size (Liu 
et al., 2012). The large sizes of magnetosomes results in a ferromagnetic behaviour at 
physiological temperature, while the SPION of sizes below 20 nm are 
superparamagnetic at this temperature (Arakaki et al., 2008; Alphandéry et al., 2010). 
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Although it should be stated that the expression of mms6 alone in AD-MSC would not 
be able to synthesise ferromagnetic magnetosome structure similar to the one in MTB, 
the ferromagnetic behaviour displayed by AD-MSC expressing mms6 could mean that 
the Mms6 protein binds iron and form bigger nanocrystal aggregates, instead of 
smaller superparamagnetic nanocrystal.  
For future experimentation, it would have been useful to use Atomic force 
microscopy/magnetic force microscopy (AFM/MFM) to analyse the magnetization of 
the cells, instead of using ZFC FC analysis alone.  Moreover, it will be interesting to 
quantify the amount of iron in cells by using mass spectrometry, an analytical 
technique that measures the mass of different molecules within a sample. This 
quantification works by ionizing the chemical species and sorting the ions based on 
their mass-to-charge ratio; the mass spectrum indicates the masses within a sample 
(Glish and Vachet, 2003). 
 
7.8 THE POTENTIAL USE OF AD-MSC EXPRESSING mms6 FOR MRI 
AND MNHT APPLICATION 
In Chapter 6, experiments were aimed to test the hypothesis that the nanoparticle 
produced inside AD-MSC expressing mms6 could generate a magnetic hyperthermia 
effect by applying AMF into the cells. Cell viability, cell apoptosis and HSP70 
expression were investigated as the parameter of magnetic hyperthermia effect. The 
experiments also aimed to demonstrate the potential use of AD-MSC expressing mms6 
as a contrast agent for MRI. 
To confirm the potential use of mms6 as a reporter gene for MRI, an in vitro MRI 
experiment successfully showed that MR contrast was detected in AD-MSC 
expressing mms6, indicating the promising use of mms6 as a reporter gene. This result 
was consistent with the previous report by Zhang and co-workers which showed mms6 
transfected gliosarcoma cells displaying MR changes in both in vitro and in vivo 
experiments (Zhang et al., 2014). However, due to limited time, this experiment was 
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only done once, thus more experiments are needed to improve the reliability and the 
reproducibility of the data.  
Using both 2-D monolayer and 3-D models, the in vitro AMF experiments revealed 
no observable difference in AMF application effect on cell viability of AD-MSC 
expressing mms6. In addition, similar negative results were also found on 
Ferucarbotran-loaded AD-MSC, despite these nanoparticles showing 
superparamagnetic behaviour as discussed in Chapter 5. The investigation on cell 
apoptosis and HSP70 expression of AD-MSC expressing mms6 following the AMF 
application also showed no observable difference. However, it was unfortunate that 
the cell apoptosis experiment was only performed once due to limited time and costs. 
Indeed, using TUNEL (terminal deoxynucleotidyl transferase mediated dUTP nick 
end labeling) analysis alone to detect cell apoptosis based on DNA fragmentation may 
not be enough to demonstrate cells undergoing apoptosis. Typical apoptosis hallmarks 
are: cell shrinkage, membrane blebbing, mitochondrial alteration, metabolic changes, 
nuclear condensation and genomic DNA fragmentation, activated caspases, and the 
eventual engulfment of the cell by phagosomes (Mukhopadhyay et al., 2014). 
Therefore, for the future experimentation, it would be useful to perform cell apoptosis 
detection techniques such as analysing the plasma membrane changes using 
AnnexinV, followed by fluorescence, confocal microscopy or, together with 
propidium iodide, by FACS (Gu et al., 2017); measuring the mitochondrial integrity 
using MitoTrackerRed, Rhodamine 123 followed by confocal microscopy or FACS 
(Gorojod et al., 2017); or analysis of caspase-3 activation (Wang et al., 2013; Zhang 
et al., 2013). 
Another important parameter assessed is the expression of heat shock proteins (HSP). 
HSPs represent one of the most conserved groups of proteins throughout evolution, 
and are  classified on the basis of their molecular weight and funtions, HSP are divided 
into five major families. HSP60, HSP70, HSP90 and HSP100 are the most studied 
members of the family. Each family is comprised of several members, with similar 
molecular weights, but different patterns of induction and expression (Fuller et al., 
1994; Dubey et al., 2015). It has been shown that HSP70 expression by hyperthermia 
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induced antitumour immunity in the T-9 rat glioma (Ito et al., 2003). Moreover, HSP70 
transcriptional activation analysis can be used as molecular thermometer to sense cells 
response to magnetic hyperthermia (Moros et al., 2015). For the future 
experimentation, it would have been beneficial to investigate the expression of few 
families of HSP at certain time point. Also, instead of using semi quantitative 
measurement based on western blot result performed in this study, other techniques 
such as qRT-PCR could be more accurate way to quantify the HSP expression (Moros 
et al., 2015).  
While the use of mms6 for cells innately producing intracellular nanoparticles has 
potential, the present study indicates continuing difficulty and reliability of actually 
demonstrating the use of such an approach for magnetic hyperthermia treatment. It 
was believed that the negligible magnetic hyperthermia effect associated with AMF 
treatment both on Ferucarbotran-loaded AD-MSC and AD-MSC expressing mms6 
could be related to low number of cells or small cell pellet size used in this study. The 
interpretation of this result is that the one million cells used in this experiment is not 
sufficient to achieve the AMF treatment scale for increasing the temperature. In 2002, 
Rabin declared that nanoscale heating effects are negligible, suggesting a single 
magnetic nanoparticle does not have a practical effect on hyperthermia. Using a simple 
diffusive heat transfer model, he predicted that the maximum temperature change 
incurred by an isolated cell is negligible, even if the cells are packed to capacity with 
AMF-treated magnetic nanoparticles. Furthermore, he integrated experimentally 
achievable intracellular nanoparticle concentrations and heating efficiencies (150 
mW/g Fe for iron oxide nanoparticles at 500 pg Fe/cell) to predict the achievable 
steady-state temperature increase of collections of such cells. He revealed that a high 
concentrated nanoparticle-containing cells, approximately 1 mm in diameter or 
containing no less than 200000 cells, would be crucial for therapeutic levels of 
hyperthermia to be achieved (Rabin, 2002). In agreement with this, Wilhelm and co-
workers showed more than 80% of the cells were killed after being submitted twice to 
AMF (31 mT; 700 kHz; 1 hour duration),  using 20 million cells of loose pellet. 
Interestingly, their study showed when magnetic cells coexist with non-magnetic ones, 
the same proportion of cytotoxicity was found on both populations following the AMF 
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application, suggesting the cytotoxic hyperthermia is a function of total iron particle 
content in the pellet (Wilhelm et al. 2007). In short, it is believed that macroscopic 
hyperthermia or extracellular hyperthermia is still far superior to intracellular 
hyperthermia in the thermal sense, assuming that the same number of nanoparticles 
are present in both situations. Therefore, future experimentation using a larger number 
of cells might be useful to test this hypothesis. Furthermore, several sessions of AMF 
may have more benefit than only performing one session of AMF application.  This 
has been suggested in a previous report which use magnetosome-loaded tumour 
exposed 12 to 15 of 30 min AMF applications to achieve full tumour disappearance 
(Alphandéry et al., 2017b) 
 
7.9 CONCLUSION 
In conclusion, the presented study, although it does not lead to a significant in-vitro 
magnetic hyperthermia effect, has significantly contributed to our knowledge on 
genetically modified AD-MSC expressing magnetic nanoparticles.  This approach is 
remains promising for MR imaging and could yet be optimised for magnetic 












8.1 MAGISTER PLASMID CONSTRUCT 
mms6 gene used in this study belongs to Magnetospirillum. Magneticum. The mms6 
DNA fragment was optimised for mammalian cell expression by using mms6 gene 
codon optimization and by adding a Kozak sequence at the N terminus of the mms6 
gene. This particular gene sequence was named MAGISTER (MAG) gene and. Two 
types of constructs were used:  
1) mms6 + single tag marker 
This construct has polyhistidine-tag at the N terminus of the mms6 DNA 
fragment. The construct was synthesized and cloned into pcDNA3.1 plasmid 
at KpnI/EcoRI restriction site by GeneArt® Gene Synthesis service. 











CATCATCATCACCATCAC : Polyhistidine Tag. 
GGTACC: KpnI Restriction Site 
GAATTC : EcoRI Retriction Site  
ATG : Start Codon 






2) mms6 + double tag marker 
This construct has polyhistidine-tag at the N terminus and GFP-tag at the C 
terminus of the mms6 DNA fragment. The construct was synthesized and 
cloned into pcDNA3.1 plasmid at NheI/HindIII restriction site by GeneArt® 
Gene Synthesis service. There were 4 different MAGISTER gene constructs 
with double tag markers, depending on different codon optimization of the 
mms6 gene, used in this study 
 
The nucleotide sequence of this construct is the following: 
 











































































































NheI:   GCTAGC 
Kozak sequence:  GCCGCCACC 
HisTag: CATCATCATCACCATCAC 


















Figure 8-2: pcDNA3.1(+) Vector containing His-GFP mms6 gene construct. The 











8.2 MAGISTER PLASMID PURIFICATION 
In order to evaluate whether the MAG plasmid containing His-GFP mms6 had been 
successfully amplified, restriction enzyme digestion by HindIII/NheI (for Mag gene 
with double tag marker) restriction enzymes was performed. Briefly, 1 µg plasmid 
DNA, five units of restriction enzyme and 5 µl of 10x CutSmart buffers were used in 
each reaction. The reactions were made up to a volume of 50 µl in distilled water and 
incubated at 37 °C for 2 hours. Enzymes were heated for 20 min at 85°C after 
digestion. The digestion products were then visualized by conducting electrophoresis 
on 2% (w/v) agarose gels with SYBRTM Safe DNA gel stain.  
Figure 8-3 showed DNA band at around 1200 bp, suggesting the presence of DNA 
fragment resulted from NheI and HindIII enzyme digestion, as indicated by Lane B, D, 
F, H. The expected size of the DNA digested with NheI/HindIII was 1181 bp. 
Therefore, this result confirmed the successful of MAGISTER plasmid cloning and 
purification. 
 
Figure 8-3: Agarose gel electrophoretograms demonstrating the plasmid DNA 
containing His-GFP mms6 gene fragment cut by NheI and HindIII restriction 
enzymes. Lane B, D, F, H = Control/Uncut; Lane A, C, E, G = plasmid containing His-GFP 
tag mms6 gene cut by NheI and HindIII. M = Marker 
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8.3 LENTI-mms6 PLASMID CONSTRUCT 
A lentiviral vector, pSicoR-Ef1a-mCh-Puro plasmid was used to construct lenti-mms6 
plasmid. The mms6 insert fragment was cut from pcDNA3.1 (+) plasmid containing 
codon optimized mms6 gene (Mag01). This Mag01 plasmid was kindly provided by 
Lisa Lungaro, former PhD student in the group.  
This mms6 insert sequence from pcDNA3.1 (+) is start from CAG enhancer region (or 
SpeI restriction enzyme site) to NotI restriction enzyme site. 
The insert sequence is ligated to pSicoR-Ef1a-mCh-Puro plasmid at XbaI (2626) and 
NotI (2982) restriction enzyme site. 

















Figure 8-4: PsicoR-Ef1a-mCh-Puro Vector map.  
 
 
Figure 8-5: PsicoR-Ef1a-mCh-Puro Vector containing codon optimised mms6 
(Mag01) gene construct. 
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Figure 8-6 DNA shows DNA sequencing analysis of the PsicoR-Ef1a-mCh-Puro 
vector containing codon optimised mms6 (Mag01). The sequencing results were 
aligned to match the original sequence using the Basic Local Alignment Search Tool 
(BLAST).   
 
 
Figure 8-6: DNA sequencing analysis of plasmid DNA containing Mag02 
obtained from Miniprep. Detailed side by side alignment information for the DNA 
sequence result for sample (query) and known Mag01 gene sequence (subject). The sample 







8.4 LENTI-mms6 TRANSDUCTION EFFICIENCY TEST ON HT1080 
HUMAN FIBROBLAST CELLS. 
 
 
Figure 8-7: Lenti-mms6 transduced efficiency test on HT1080 human fibroblast. 
Cells were plated at 2 x 105 cells/well and lentivirus added at a multiplicity of infection of 1, 











8.5  FLOW CYTOMETRY ANALYSIS OF MAG01-NUCLEOFECTED AD-
MSC 
 
Figure 8-8: Representative image for Flow cytometry analysis of Mag01-
transfected AD-MSC at 2 days after nucleofection.  P1 gate set for total cell 
population. P2 gate set for live cells. P4 gate set for GFP positive cells by using untransfected 
control cells to set the gate excluding GFP-negative population. Percentage of GFP-positive 
expression are indicated by the red arrow in the panel. The result shows 58.2% GFP-positive 




Figure 8-9: Representative image for Flow cytometry analysis of Mag01-
transfected AD-MSC at 2 days after transfection using Lipofectamine 3000.  P1 
gate set for total cell population. P2 gate set for live cells. P4 gate set for GFP positive cells 
by using untransfected control cells to set the gate excluding GFP-negative population. 
Percentage of GFP-positive expression are indicated by the red arrow in the panel. The result 





Figure 8-10: Representative image for Flow cytometry analysis of Mag01-
transfected AD-MSC at 2 days after transfection using XtremeGENE HP.  P1 gate 
set for total cell population. P2 gate set for live cells. P4 gate set for GFP positive cells by 
using untransfected control cells to set the gate excluding GFP-negative population. 
Percentage of GFP-positive expression are indicated by the red arrow in the panel. The result 








Figure 8-11: Representative image for Flow cytometry analysis of Mag01-
transfected AD-MSC at 2 days after transfection using FugeneHD.  P1 gate set for 
total cell population. P2 gate set for live cells. P4 gate set for GFP positive cells by using 
untransfected control cells to set the gate excluding GFP-negative population. Percentage of 
GFP-positive expression are indicated by the red arrow in the panel. The result shows 58.2% 







8.6 magneTHerm V1.5 SYSTEM 
8.6.1 magneTHerm V1.5 Setup 
The physical principle that underlies the magneTherm system device function is that a 
current applied through a conductor determines the creation of a circular magnetic field 




where B is the magnetic field, µ0 the permeability of the free space, I is the current in 
the wire, and r the radius from the wire. 
If the conductor is a coil (as for the magneTherm system), the magnetic field strength 
is enhanced, and a strong field is created at the centre of the coil, where all the magnetic 
field generated by each turn of the coil pass. The physical concept that drives the 
experiments is that MNPs subjected to an AC magnetic field: 
1) lose energy as a consequence of their magnetisation reversal process, producing 
heat; 
2) tend to vibrate, causing the cell membrane breaking 






Figure 8-12: Nanotherics magneTherm system device used in the experiments. 
Components of the system are: A) MagneTherm system (top down view). Red arrow shows 
water jacket and sample location B) MagneTherm system, C) Function generator, D) DC 











8.6.2 magneTHerm V1.5 System Calculation Document 
Three different capacitors used in the magneThermTM: a 200 nF capacitance; a 22 nF 
capitance; and a 6.2 nF capitance to achieve the desired frequency range for the 9-turn 
coil. The function generator was used to generate a square waveform at three different 





A: area, square meters 
C: capitance 
I: inductance 
N: number of turns 
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